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Introduction 
The heart is an adaptive organ for pumping blood, responding to changing needs by 
modifying contractile strength and beating rate. The cardiomyocyte is the principal 
cell of the heart; it coordinates and performs contraction and has the capability to 
sense a large number of hormonal, neural, electrical and mechanical inputs. In 
addition, cardiomyocytes are also target for an extraordinary number of metabolic 
changes, because of the critical need to regulate ATP concentrations.  
The human heart uses between 3.5 and 5 kg of ATP every day to keep pumping [1]. 
Although constant ATP provision is required for cardiac contraction and all 
associated essential processes, such as calcium uptake by the sarcoplasmic 
reticulum, most of the ATP produced by the heart is dissipated. Minimal amounts of 
ATP are used for: active transport by the sodium-potassium pump, the actual 
generation of the action potential, and the conduction of the cardiac impulse. Even 
lower amounts of ATP are needed to phosphorylate proteins or to form cyclic AMP, 
for the futile cycles of glycogen and triacylglycerol turnover, for mitochondrial 
calcium uptake and release, and protein synthesis. Thus, the actual energy liberated 
by ATP hydrolysis is largely converted to heat, and approximately 25% of the ATP 
is actually converted into mechanical work [1].  
To produce ATP, the heart requires a continuous supply of both oxygen and 
specific fuels to meet increases in energy need (e.g., increased workload). Glucose 
and lactate are the predominant carbohydrates utilized, and long-chain fatty acids 
(LCFA) are the key lipids oxidized [2, 3]. However, both at rest and during 
increased workload, LCFA (60-70%) oxidation is the principal route for ATP 
synthesis with glucose (20-30%) being used to a lesser extent [3-5]. While in the 
healthy heart there is a distinctive and very finely tuned balance between the 
utilization of these metabolic substrates, in chronic cardiac disease this balance is 
altered. In some diseases (e.g., cardiac hypertrophy and failure) [6-8] glucose 
utilization is markedly increased, while in other pathologies (e.g., diabetic 
cardiomyopathy) [9-11] LCFA utilization is greatly favoured. Recent studies 
support the concept that changes in cardiac metabolism may play a causal role in 
the development of cardiac diseases. Optimizing myocardial energy metabolism 
and thereby manipulating the balance of energy utilization could be of therapeutic 
benefit [12]. Therefore, understanding the regulation of cardiac metabolism in the 
healthy heart could be promising to help identify therapeutic targets to rectify a 
disruption of the cardiac substrate balance occurring in chronic cardiac diseases. 
This thesis describes new insights in the mechanism of cellular substrate uptake and 
its regulation by signal transduction pathways, and discusses their significance for 
myocardial energy homeostasis. This introduction aims to present the reader with 
background information to comprehend the studies performed in this thesis. 
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Substrate uptake and their transporters 
It is known that both LCFA and glucose are mainly supplied from extracellular 
sources to the heart (and also to skeletal muscle), because the heart possesses a 
limited storage capacity for LCFA and glucose [13]. Hence, sarcolemmal transport 
might be an important step in the metabolism of substrate uptake [12], and could 
provide another key point regulatory side next to the regulation of mitochondrial 
oxidation according to the Randle cycle [14]. The uptake of both LCFA and glucose 
appears to be dependent on a substrate gradient across the plasma membrane, which 
in turn, is dependent on the metabolic rate of the respective tissue. The heart, having 
a relatively high metabolic rate, has a steep inwardly direct gradient for LCFA and 
glucose. Upon their uptake, both substrates are rapidly covalently linked to high-
energy moieties, resulting in their trapping and maintenance of the substrate 
gradient. Before uptake these substrates need to pass the selectively permeable lipid 
bilayer of cardiomyocytes. Because of its hydrophilic nature, glucose is unable to 
pass the lipid bilayer of the plasma membrane by passive diffusion. Therefore, 
glucose transport across the plasma membrane is largely a protein-mediated process 
[15, 16]. The molecular process of LCFA transport is more controversial due to the 
biophysical properties of LCFA. The hydrophobic properties of LCFA do not rule 
out the possibility of passive diffusion [17, 18], however, evidence for protein-
mediated LCFA transport across the plasma membrane is accumulating [19, 20]. In 
the earlier days, this evidence was provided by the saturation kinetics of LCFA 
uptake, sensitivity to inhibitors of protein-mediated transport, and sensitivity to 
competitive inhibition [20, 21]. More recently, evidence for protein-mediated 
LCFA transport has been provided from experimental work in transfected cell lines, 
and from studies with genetically manipulated animals [22, 23]. The integrated 
view is that both mechanisms contribute to LCFA uptake, but at least in the heart, 
the bulk of LCFA uptake is regulated by protein-mediated transport. In addition, 
distinct LCFA binding and LCFA transport proteins have been identified and were 
found to be crucial for cardiac LCFA uptake [20, 21]. The potential physiological 
importance of protein-mediated transmembrane transport is that it would represent a 
site of control, allowing changes in the presence and/or activity of these membrane 
proteins to regulate not only glucose uptake, as has been discovered in the early 
eighties, but similarly also regulate cellular LCFA uptake [12]. 
 
Protein-mediated long-chain fatty acid uptake 
The membrane-associated proteins involved in cardiac LCFA uptake are putative 
fatty acid translocase/CD36 (CD36), plasma membrane fatty acid-binding protein 
(FABPpm), and the isoforms of the fatty acid-transport protein family (FATP1, 
FATP4 and FATP6) [20]. These proteins function in trapping of LCFA from 
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extracellular donors, whereafter LCFA cross the cell membrane either in un-ionized 
form by a flip-flop mechanism through the lipid bilayer (passive diffusion) or 
through a channel formed from (homo- or heterotrimeric) complexes of these 
membrane-associated proteins (facilitated diffusion). However, the membrane 
topology of the various membrane proteins is still unclear so that the exact nature 
whereby each of these proteins acts on LCFA uptake is not yet known [24-26] (Fig. 
1.1).  
 
Figure 1.1 Schematic representation of the mechanism of LCFA uptake into cardiomyocytes 
The proposed mechanisms for transmembrane transport of long-chain fatty acids (LCFA) are illustrated 
by numbers 1-5. Because of their hydrophobic nature LCFA could cross the membrane by passive 
diffusion (1). However, the majority of LCFA uptake is dependent on the presence of fatty acid 
translocase/CD36 (CD36). It is not yet clear whether CD36 binds LCFA at the cell surface alone (2), or 
that it operates in conjunction with the plasma membrane fatty acid-binding protein (FABPpm) (3) to 
increase the transport of LCFA across the sarcolemma. CD36 might also serve in trapping LCFA close 
to the plasma membrane to supply fatty acid-transport protein 1 and/or 6 (FATP 1 and FATP6) (4) with 
LCFA which in turn transfer this substrate directly across the plasma membrane, or FATP1/6 itself (5) 
is sufficient to increase LCFA influx.  
 
 
CD36  
An 88-kDa adipocyte membrane protein was identified by covalent labeling with N-
sulfosuccinimidyl esters of LCFA, which irreversibly inhibited LCFA transport by 
75% [30, 31]. Subsequently, Abumrad et al. [32] cloned fatty acid translocase 
(FAT), the sequence of which was 85% homologous with that of glycoprotein IV 
(CD36). This 88-kDa integral membrane protein known as FAT/CD36 or CD36 
[32], is a heavily glycosylated integral membrane protein with two transmembrane 
domains, two short cytoplasmic tails and an extracellular domain. This structure 
makes it likely that CD36 operates mainly through trapping of LCFA to the plasma 
membrane. Consequently, accumulation of LCFA close to the cell surface will 
create a local diffusional gradient across the plasma membrane, or alternatively 
facilitates the flip-flop of LCFA across the bilayer [33-35].  
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CD36, when expressed in cells normally lacking this protein, can bind LCFA with 
high affinity which resulted in increased rates of LCFA uptake [36, 37]. Specific 
inhibition of CD36 with sulfo-N-succinimidyl esters of LCFA, e.g., sulfo-N-
succinimidyl oleate (SSO) or sulfo-N-succinimidyl palmitate (SSP), provided 
pharmacological evidence for the notion that CD36 is responsible for the majority 
of LCFA uptake [30, 38, 39]. Many other studies have documented that CD36 is a 
key LCFA transporter in metabolically important tissues. CD36 is mainly expressed 
in tissues that prefer LCFA utilization, e.g., heart, red skeletal muscle, and 
adipocytes. In CD36 null mice the basal uptake rates of fatty analogs were 
significantly reduced in heart (50-80%), skeletal muscle (40-75%), and adipose 
tissue (60-70%) [40]. Reduced LCFA uptake in CD36 null mice also lowered the 
rates of LCFA oxidation and LCFA incorporation into intramyocellular 
triacylglycerols in muscle and heart [40-42]. Muscle-specific overexpression of 
CD36 has shown that LCFA oxidation was increased in this tissue, but only during 
muscle contraction, not at rest [43].  
 
FABPpm 
Plasma membrane-associated fatty acid-binding protein (FABPpm) was identified 
in the heart by Stremmel [44]. Analysis of its amino acid sequences showed 
FABPpm to be identical to mitochondrial aspartate aminotransferase (mAspAt) 
[45]. Apparently, FABPpm/mAspAt is a protein with distinct functions at different 
subcellular sites. FABPpm is a 43-kDa peripheral membrane protein anchored with 
its hydrophobic tail to the outer leaflet of the plasma membrane [45]. Since 
FABPpm is a peripheral membrane protein, this protein is not expected to operate 
as a classical channel for LCFA, but rather it could be involved in the trapping of 
LCFA close to the cell surface. This LCFA trapping could be sufficient for 
facilitation of LCFA transport, because of the generation of locally steep outward-
to-inward LCFA gradients. Additionally, FABPpm could cooperate with (an) other 
protein(s) to facilitate the transport of LCFA across the plasma membrane.  
Similar to CD36, FABPpm can bind LCFA with high affinity, and a higher 
expression of FABPpm results in increased LCFA uptake rates [46, 47]. In addition, 
LCFA uptake rates were inhibited by antibodies directed against FABPpm [48]. It 
remains to be established whether FABPpm alone is effective for increasing LCFA 
transport rates or that FABPpm may function in conjunction with other LCFA 
transporters, particularly CD36, as these proteins co-immunoprecipitate [27]. Based 
on kinetic evidence, it has been suggested that both FABPpm and CD36 function as 
two components of one LCFA transport system, in which FABPpm serves as a 
receptor for LCFA, and then interacts with CD36, which, on its turn, mediates the 
transmembrane passage of LCFA [20, 27, 48, 49]. 
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FATP1-6 
A family of fatty acid-transport proteins (FATPs) has been implicated in facilitating 
LCFA as well [50]. FATPs are integral membrane proteins with several 
transmembrane domains [51]. It has been shown that these LCFA transporters 
additionally possess long-chain acyl-CoA synthase activity, which could be 
beneficial for so called vectorial LCFA uptake. Thus, the extra enzymatic activity 
would cause rapid trapping of the substrate without decline of the outward-to-
inward LCFA gradient [52]. Six members of the FATP family (FATP1-6) have 
been identified and are expressed in a tissue-specific manner [28, 53, 54]. FATP1 
and FATP4 are expressed in adipose tissue, heart and skeletal muscle while FATP6 
appears to be exclusively expressed in the heart. Since FATP1 and FATP6 are 
associated with the sarcolemma and colocalize with CD36, the proposed models 
either envision that CD36 and FATPs act together [28, 29], possibly by transferring 
LCFA from CD36 to FATPs at the plasma membrane, or alternatively FATPs 
transfer LCFA directly across the plasma membrane [55]. 
Genetically manipulated mice with cardiac-specific overexpression of FATP1 
demonstrated a fourfold increase in LCFA uptake [10]. This was associated with a 
twofold increase in cardiomyocyte lipid accumulation and LCFA metabolism, as 
well as cardiac dysfunction with pathophysiological findings similar to those in 
diabetic cardiomyopathy [10]. FATP6 is principally expressed in the heart where it 
is the predominant FATP family member [28]. Stably expressing human FATP6 in 
a cell line enhanced uptake of LCFA and indicates that the FATP6 isoform is more 
important than FATP1 for LCFA uptake [28]. However, there is some debate as to 
the whether FATP6 has a transport role in the heart [56].  
 
Glucose transporter-mediated glucose uptake  
A family of specific glucose transporter (GLUT1-12) proteins has been identified 
and these transporters were found to show a tissue specific distribution. In the heart, 
skeletal muscle and adipose tissue two glucose transport proteins are present, 
namely GLUT1 and GLUT4, of which GLUT4 is most abundant. GLUT1 is mainly 
present at the sarcolemma, and is largely responsible for basal glucose uptake [57, 
58]. However, GLUT4 is located in intracellular storage compartments from where 
it can be recruited to the plasma membrane upon insulin stimulation and elevated 
contractile activity. At the cell surface, GLUT4 functions in achieving altered rates 
of glucose uptake [15, 59].  
GLUT4 is critical for postprandial glucose disposal, and results from several 
knockout and transgenic mouse models support the hypothesis that GLUT4 plays a 
key role in whole-body glucose homeostasis. For example, in the diabetic db/db 
mouse model, overexpression of the human GLUT4 gene protected these animals 
from insulin resistance and diabetes [60]. Interestingly, the global GLUT4 
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homozygous knockout mouse showed a less severe phenotype with respect to 
glucose homeostasis than heterozygous GLUT4+/í animals, most likely due to 
compensatory mechanisms in the homozygous condition [61, 62]. In addition, the 
GLUT4 knockout animals showed many severe defects, including decreased life 
spans and growth retardation, as well as cardiac and adipose tissue abnormalities, 
further complicating interpretations regarding glucose homeostasis. The 
heterozygous GLUT4+/í mice, however, are insulin resistant and predisposed to 
developing diabetes [61, 62]. Interestingly, in the hearts of db/db mice and of 
GLUT4 knockout mice, defects in glucose homeostasis lead to an enhanced LCFA 
oxidation [63-65]. This shows that the heart possesses an enormous metabolic 
flexibility, namely that the heart is able to switch to another substrate depending on 
its availability.  
 
Regulation of substrate uptake by signaling pathways  
As was first identified for GLUT4, also LCFA transporters have been found to be 
present in intracellular compartments as well as at the sarcolemma. The 
sarcolemmal pool forms the functional pool of these transporters, whereas the 
intracellular pools are used as the storage depot. Regulation of substrate transport 
can occur via the translocation of transporter proteins from these intracellular 
depots to the sarcolemma. At the cell surface, these transporters function in 
achieving altered rates of LCFA and glucose uptake [12, 20].  
In the heart, the two main physiological stimuli to enhance substrate uptake are 
insulin and contraction. Insulin and contraction induce transporter translocation 
concomitant with substrate uptake acutely, i.e., within minutes [66, 67]. Although 
both stimuli enhance the abundance of sarcolemmal LCFA and glucose transporters 
simultaneously, their signaling pathways appear to be distinct. Several key players, 
mainly protein kinase B (PKB)/Akt and AMP-activated protein kinase (AMPK) are 
potential candidates to be involved in the insulin and contraction signaling 
pathways, respectively. These signaling events ultimately result in the activation of 
the so-called trafficking machinery which is responsible for migration of cargo from 
one compartment to the other, and vice versa. Regulation of this transport needs to 
be unidirectional and extremely specific to ensure that vesicles containing cargo 
(e.g., CD36 and/or GLUT4) destined for the plasma membrane do not fuse 
randomly with membranes from other organelles [68]. The studies in this thesis 
focus on the signaling and trafficking mechanisms involved in stimulation of 
substrate uptake by (i) insulin, and by (ii) contraction. For this, these pathways will 
be discussed in more detail in the next paragraphs.  
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Insulin signaling pathway 
Insulin is known as a regulatory hormone for whole-body and cellular glucose 
homeostasis. Circulating insulin stimulates glucose uptake in the heart and skeletal 
muscle by the recruitment of intracellularly stored GLUT4 to the sarcolemma [67]. 
It has been established that insulin is also capable of increasing LCFA uptake in 
these muscle tissues [67]. This effect of insulin was attributable to the translocation 
of CD36 from storage compartments to the sarcolemma (Table 1.1), in a similar 
manner as has been observed for GLUT4. Since the eighties, the insulin-derived 
signaling pathways have been subject to intensive investigations, and includes 
insulin binding to, and activation of its receptor followed by docking of insulin 
receptor substrates and activation of the regulatory subunit p85 of 
phosphatidylinositol-3-kinase (PI3K) [69, 70] as depicted in Fig. 1.2. Blocking 
PI3K with its inhibitors (wortmannin and LY-294002) prevented both the insulin-
induced GLUT4-mediated glucose uptake and CD36-mediated LCFA uptake in 
cardiomyocytes [67]. This suggests that glucose and LCFA uptake are similarly 
regulated by PI3K activity. Downstream, PI3K catalyses the formation of 
phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3), which, in turn, leads to the 
activation of atypical protein kinase C (aPKC)-Ȝ/ȗ and of PKB/Akt. Thereafter, 
PKB/Akt and the PKCs contribute in parallel to insulin-induced GLUT4 
translocation [71-74]. Whether similar downstream targets of PI3K are required for 
CD36-mediated LCFA uptake by insulin remains largely unidentified [67], but 
PKB/Akt is likely involved [75]. The direct downstream target of PKB/Akt in 
insulin-stimulated GLUT4 translocation has been identified in a screen for putative 
substrates possessing the PKB/Akt regulatory motif [76]. Of these, the Rab- 
GTPase-activating protein (GAP) Akt substrate of 160-kDa (AS160) participates in 
GLUT4 translocation to the plasma membrane [77, 78], presumably through its 
recently identified targets Rab2, Rab8, Rab10 and/or Rab 14 [79]. Hence, AS160 is 
an interesting player in insulin-induced GLUT4 translocation, in that it connects 
signaling pathways to trafficking pathways. Additionally, a PI3K-independent 
pathway involving c-Cbl associated protein (CAP), Cbl and the GTPase TC10 
could regulate GLUT4 translocation [80], as observed in adipocytes [81]. The 
importance of this pathway in heart and muscle is still a matter of debate. 
Insulin-regulated GLUT4 trafficking can be divided into two discrete steps: 1) 
movement of GLUT4-containing vesicles close to the plasma membrane; and 2) 
docking and fusion of these vesicles with the plasma membrane. The first step 
likely involves an interaction of GLUT4 storage vesicles with the cytoskeleton. 
Several recent studies have shown a role for microtubule-associated motor proteins 
[82, 83] as well as an actin-associated myosin in GLUT4 trafficking to the plasma 
membrane [84]. The nature of the insulin-regulated association of GLUT4 storage 
vesicles with these structures remains to be defined. The second step includes the  
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Figure 1.2 The Insulin signaling pathway involved in substrate uptake into cardiomyocytes 
Insulin-stimulated activation of phosphatidylinositol-3-kinase (PI3K) and subsequently protein kinase B 
(PKB)/Akt as well as the atypical protein kinase C (PKC)-Ȝ and -ȗ, are required for glucose transporter 
4 (GLUT4) mobilization from recycling endosomes to the sarcolemma. A recently identified 
downstream target of PKB/Akt is AS160. Phosphorylated AS160 results in a reposition of Munc18c on 
target soluble N-ethylmaleimide-sensitive factor attachment protein receptors (tSNARE) proteins 
leading to a more active conformation, allowing vesicle SNARE (vSNARE) protein binding and 
subsequent docking and fusion of GLUT4. Also insulin-dependent translocation of fatty acid 
translocase/CD36 (CD36) is dependent on activation of PKB/Akt, however, downstream events are 
unknown. Increased abundance of GLUT4 and CD36 at sarcolemma elevates the glucose and long-
chain fatty acid (LCFA) uptake rates into cardiomyocytes, respectively. 
 
 
fusion and docking of GLUT4 containing vesicles with the plasma membrane. 
Several vesicle soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (vSNARE), including vesicle-associated membrane protein 2 (VAMP2), 
which is located on the GLUT4 storage vesicles, play an important role in 
exocytosis of these vesicles [85, 86]. VAMP2 helps to guide the vesicles to the 
plasma membrane docking site, which consists of the target SNAREs (tSNARE) 
syntaxin4 and 23-kDA synaptosomal-associated protein (SNAP23) [87]. SNAREs 
can form a core complex, a major regulatory feature in the formation of this is the 
ability of syntaxin to flip between two different conformations [88]. Several 
syntaxin-binding proteins have been identified as possible regulators of this 
conformational switch. Some of these are members of the Sec1p/Munc18 (SM) 
family of proteins [89]. The structure of the Munc18/syntaxin complex 
demonstrates that the SM protein cradles syntaxin in its inactive closed 
conformation in the absence of insulin, thus rendering docking and fusion as a 
major rate-determining step in GLUT4’s presentation at the cell surface. Insulin, 
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through activation of Akt, results in the phosphorylation of AS160, which disables 
its GAP activity and results in GTP loading of its cognate Rab protein [76, 78]. The 
GTP-loaded Rab may subsequently bind to Munc18c resulting in a reposition of 
Munc18c on syntaxin4 [90]. Syntaxin4 can then flip into a more active 
conformation, allowing GLUT4 storage vesicles to dock and fuse with the plasma 
membrane [91]. Taken altogether, increasing numbers of trafficking proteins are 
being implicated in insulin-induced GLUT4 translocation. However, the search for 
CD36 trafficking proteins has not yet started. In this respect it would be interesting 
to examine whether GLUT4 trafficking and CD36 trafficking after insulin-
stimulation depends on the same trafficking machinery. In case different trafficking 
proteins might be involved in CD36 translocation compared to GLUT4 
translocation, these proteins might present novel targets to modulate cardiac 
substrate preference. 
 
Contraction signaling pathway 
The continuous contractile function of the heart muscle requires that 
cardiomyocytes produce large amounts of ATP. This high ATP demand is met 
primarily by the utilization of LCFA and glucose. AMPK has been established as a 
key player involved in cardiac energy homeostasis. Generally, AMPK activation 
results in activation of catabolic pathways (such as LCFA and glucose oxidation) 
and de-activation of anabolic pathways (such as LCFA and glucose storage) [92]. In 
the heart, AMPK is assumed to be involved in the translocation of CD36 and 
GLUT4 based on an association of AMPK activation by contraction and a 
corresponding increase in LCFA and glucose uptake, respectively [66]. Because of 
these metabolic consequences of AMPK, up- and downstream targets of AMPK are 
also likely candidates that may regulate substrate transport in the heart (Fig. 1.3). 
AMPK is a heterotrimeric protein consisting of a catalytic Į subunit and two 
regulatory subunits ȕ and Ȗ. Different isoforms of each subunit have been identified. 
Both AMPKĮ1 and AMPKĮ2 are expressed in the heart, of which Į2 is the 
predominant subunit [93]. Activation of the AMPK complex occurs mainly via 
AMP by three independent mechanisms: (i) promotion of phosphorylation of 
Thr172 within the Į subunit by upstream kinases, (ii) allosteric activation of the 
phosphorylated enzyme, and (iii) inhibition of dephosphorylation of Thr172 by 
protein phosphatases [94]. Indeed under conditions that favour a rapid increase in 
intracellular AMP, such as during increased contractile activity [95] or during a 
period of ischemia [96, 97], AMPK becomes activated in the heart.  
Upstream kinases [LKB1 and calmodulin-dependent protein kinase kinase Į and ȕ 
(CaMKK)] [92, 98] and downstream targets of AMPK [acetyl-CoA carboxylase 
(ACC) and AS160] [99, 100] have been suggested to be involved in regulating 
substrate uptake and oxidation. In vivo, the upstream kinases LKB1 and CaMKKȕ  
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Figure 1.3 The contraction signaling pathway involved in substrate uptake into cardiomyocytes  
Increased contractile activity results in a temporary increase in the AMP/ATP ratio, which induces a 
conformational change within AMP-activated protein kinase (AMPK) to make it accessible for 
phosphorylation by LKB1. Downstream of AMPK, AS160 is involved in glucose transporter 4 
(GLUT4)-mediated glucose uptake, the role of AS160 in fatty acid translocase/CD36 (CD36)-mediated 
long-chain fatty acids (LCFA) uptake is not yet known. AMPK also activates another downstream 
target, acetyl-CoA carboxylase (ACC), which results in a de-inhibition of LCFA influx into the 
mitochondria and subsequent elevate LCFA oxidation (ȕ-ox). Treatment of cardiomyocytes with 
oligomycin (Oli) or 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) results in activation of 
AMPK and mimics the metabolic effects of contraction. Separately, dipyridamole (DPY) activates an 
unknown protein kinase downstream of AMPK specifically leading to elevated CD36-mediated LCFA 
uptake rate. 
 
 
each are regulated differently. In muscle tissue, CaMKKȕ is activated by an 
increase in intracellular Ca2+ [98]. In contrast, LKB1 is constitutively active [101], 
but it can only activate AMPK during conditions at which intracellular AMP is 
elevated. Namely, AMP-binding to AMPK induces a conformational change within 
the AMPK complex so that Thr172 becomes accessible to phosphorylation by 
LKB1 [102]. Whether CaMKKȕ regulates contraction-stimulated glucose uptake in 
muscle via AMPK activation remains controversial [102, 103]. However, in LKB1 
knockout mice, contraction-stimulated glucose uptake by muscle was reduced 
[104], as was LCFA oxidation [105]. With respect to regulation of LCFA oxidation, 
AMPK-mediated phosphorylation of ACC at Ser79 is a crucial event. Ser79 
phosphorylation is inhibitory to this enzyme, which leads to a reduction of 
intracellular malonyl-CoA and the de-inhibition of carnitine palmitoyltransferase-I, 
thereby increasing mitochondrial LCFA oxidation [106]. An interesting novel target 
of AMPK is the Rab GTPase-activating protein AS160, which is involved in 
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contraction-stimulated glucose uptake into skeletal muscle [100] in an AMPKĮ2 
dependent manner [107, 108]. Collectively, these studies have implicated upstream 
AMPK kinases and downstream targets of AMPK in the regulation of glucose 
uptake into skeletal muscle. It has been established that AMPK is involved in 
cardiac substrate uptake, however, no studies have yet been undertaken to 
investigate whether the upstream kinases, LKB1 and CaMKK, and downstream 
target, AS160, are involved in the regulation of cardiac substrate uptake. It has been 
suggested that in insulin-induced GLUT4 translocation AS160 is involved in the 
activation of the trafficking machinery. Therefore, it could be speculated that 
AS160 is also involved in the contraction-induced trafficking of GLUT4 and 
presumably CD36, however, this process is completely unknown. Again, AS160 
could provide the link between signaling and trafficking in contraction-induced 
substrate uptake, as has been shown for insulin-induced substrate uptake (see 
previous section). Whether the contraction-dedicated trafficking machinery 
involved in GLUT4 translocation or CD36 translocation encompasses the same 
trafficking protein types/isoforms involved insulin-induced GLUT4 or CD36 
translocation, needs further investigation. 
Pharmacological agents are commonly used to activate AMPK, including 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR) [109, 110] and the F1F0-
ATPase inhibitor oligomycin [66, 111]. At appropriate concentrations these agents 
stimulate LCFA and glucose uptake into cardiomyocytes, by inducing the 
translocation of LCFA (Table 1.1) and glucose transporters to the sarcolemma 
suggesting that indeed AMPK is activated by these pharmacological agents [66, 
112-114]. Importantly, the effects of AICAR and oligomycin on LCFA and glucose 
uptake in cardiomyocytes are not additive to that of contraction, suggesting that the 
signaling pathways activated by these agents converge with the contraction 
signaling pathway to induce CD36 and GLUT4 translocation [66]. Another 
contraction-mimetic agent is dipyridamole, because, just like oligomycin and 
AICAR, it stimulates LCFA uptake into cardiomyocytes in a non-additive manner 
to contraction [115]. In contrast to oligomycin and AICAR, dipyridamole does not 
activate AMPK nor does it stimulate glucose uptake, suggesting that this compound 
acts on a component in the contraction pathway to CD36 translocation downstream 
of AMPK [115]. This indicates a hypothetical branch point in signaling to 
separately regulate CD36 and GLUT4 translocation. 
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Table 1.1 Effects of physiological and pharmacological stimuli on LCFA transporter 
abundance at the sarcolemma  
 
              Stimulus                                           LCFA transporter 
CD36 FABPpm  FATP1 FATP4 FATP6 
 
             Insulin        +     -     -     n.k.     n.k. 
             Contraction         +     n.k.     n.k.     n.k.     n.k. 
              AICAR       +     +     -     n.k.     n.k. 
             Oligomycin       +     n.k.     n.k.     n.k.     n.k. 
 
The main regulatory mechanism of long-chain fatty acid (LCFA) uptake is the abundance of LCFA 
transporters at the sarcolemma at the expense of intracellular storage compartments. Fatty acid 
translocase/CD36 (CD36) relocates towards the sarcolemma, as seen upon insulin treatment and during 
contraction, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) treatment, and oligomycin 
treatment. The plasma membrane fatty acid-binding protein (FABPpm) translocates by AICAR but not 
by insulin stimulation. For fatty acid-transport protein 1, 4 and 6 (FATP1, FATP4 and FATP6) this 
mechanism has not yet been determined, not known (n.k).  
 
 
Aim of this thesis 
The heart is capable of utilizing a variety of metabolic substrates and is able to 
rapidly adapt its substrate utilization in the face of changes in substrate need and 
supply. For example, during exercise the metabolic state is characterized by 
elevated circulation of lipids, from lipolysis in adipose tissue [5, 116, 117], which 
competes with glucose at the heart [4]. However, in diabetes and obesity elevated 
circulating LCFA and triacylglycerols can lead to cardiac lipid accumulation and 
excessive LCFA metabolism. Recent studies suggest that the alterations in cardiac 
LCFA metabolism that occur in diabetes and obesity may play a causal role in the 
development of cardiomyopathies [118, 119]. In contrast, the development of 
pathologic cardiac hypertrophy and cardiac failure is characterized by a gradual 
decrease in LCFA utilization, partly compensated for by increased glucose 
utilization [2, 7, 120] (Fig. 1.4). These observations led to the notion that a 
disruption of the cardiac substrate balance and cardiac pathology appear invariably 
linked [12]. The pathways involved in LCFA and glucose metabolism are subject to 
a complex regulation that is not completely understood. Hence, it is of crucial 
importance to gain insight in the mechanism of LCFA and glucose metabolism in 
the healthy heart. Understanding these pathways could be of importance in finding 
targets to rectify cardiac substrate balance in situation in which altered metabolism 
contributes to the severity of cardiac abnormalities. The studies described in this 
thesis, therefore, explore the role of transporter proteins and signal transduction 
pathways in the regulation of LCFA and glucose uptake in the heart.  
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Figure 1.4 Cardiac long-chain fatty acid and glucose utilization in health and disease 
Schematic presentation of the concept of balance of fuels for the heart, illustrating that an optimal 
cardiac function appears related to a certain set point of the balance between the relative contribution of 
long-chain fatty acids and glucose to total energy production, and that a shift from this set point, either 
towards increased utilization of long-chain fatty acid or glucose, is associated with cardiac disease, e.g., 
diabetic cardiomyopathy or hypertrophy and heart failure, respectively.  
 
 
Experimental model: isolated mouse cardiomyocytes in 
suspension 
Cardiomyocytes, the predominant muscle cell of the heart, have served as a well-
established model for studying cardiac substrate metabolism [121]. We used freshly 
isolated cardiomyocytes to perform the measurements presented in the studies of 
this thesis. The standard procedure for the isolation of cardiomyocytes is a 
retrograde Langendorff perfusion with collagenase, where after cells are kept in 
suspension. Single-cell suspensions are easily accessible by pharmacologically 
active compounds and different interventions are possible within cardiomyocytes 
from one heart. At the same time the extracellular environment is well-controlled 
and vascular factors and the endothelial barrier are eliminated. Moreover, the 
transport of substrates across the sarcolemma can be studied independently of the 
influence of other types of cells and transport barriers. Although cardiomyocytes 
contract constantly in vivo, in suspension the trigger for controlled contractions is 
not present resulting in a decline in metabolic rate. The availability of an 
experimental system that induces contractions at 200V with a frequency of 4Hz in 
cardiomyocytes in suspension makes it possible to investigate the signaling 
processes and metabolic effects that are induced by contraction. Moreover, in 
cardiomyocytes the contraction signaling pathway can be pharmacologically 
activated, for instance by oligomycin, AICAR and dipyridamole.  
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Isolated cardiomyocytes were used to measure metabolic parameters, e.g., LCFA 
and glucose uptake and oxidation. Until now the regulation of metabolism in 
isolated cardiomyocytes has been mainly studied by using pharmacological 
inhibitors. The disadvantages of pharmacological approaches are the possible side-
effect, of which only some are known. Given the current focus on mouse genetics, 
isolated cardiomyocytes from mouse hearts offer significant advantages. However, 
isolation of cardiac myocytes from mouse heart proved to be quite difficult, notably 
in comparison to rat cardiomyocytes. This especially applies for metabolic studies 
demanding relatively high input of cellular material, and may explain the low 
number of publications on metabolism in isolated cardiomyocytes from genetically 
manipulated mice. However, in case that the technical problems in the isolation 
procedure due to the small size of the heart can be overcome, and the 
cardiomyocyte yield is sufficient to conduct metabolic experiments, there are 
considerable benefits related to this cardiac model system. Namely, genetically 
manipulated mice with altered expression of relevant signaling and trafficking 
genes with putative roles in stimulus-induced translocation of LCFA transporters 
(most notably CD36) will provide direct evidence for their role in the substrate 
preference of the heart under healthy and pathological conditions. This thesis 
describes several studies in which genetically manipulated mouse models were 
investigated to further unravel the molecular mechanism underlying the regulation 
of cardiac energy metabolism.  
 
Outline of thesis 
The routinely used model system in this thesis to study the regulation of cardiac 
substrate uptake is isolated mouse cardiomyocytes. Chapters 2-7 describe several 
relevant physiological factors and pharmacological agents to stimulate cardiac 
substrate uptake, and the signaling cascades involved in these events. Specifically: 
In chapter 2 different approaches are described and compared to study the 
metabolic effects induced by contraction signaling in cardiomyocytes.   
Chapter 3 describes the role of CD36 in LCFA uptake in response to metabolic 
challenges by using isolated cardiomyocytes from CD36 knockout mice.  
Moreover, CD36 knockout cardiomyocytes were used to deliver the ultimate 
evidence concerning the presumed specificity for the CD36 inhibitor SSO. 
In order to unravel the contraction transduction pathway involved in the 
translocation of CD36 and GLUT4 concomitant with LCFA and glucose uptake, 
respectively, different genetically manipulated mouse models were investigated, 
e.g., AMPKĮ2 kinase-dead, AMPKĮ2 knockout and LKB1 knockout mice. Chapter 
4 reports the regulation of CD36-mediated LCFA and GLUT4-mediated glucose 
uptake by the LKB1 - AMPK axis.  
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AICAR can be used for AMPK activation although this agent exerts several 
unspecific effects. The role of CD36 in AICAR-induced LCFA uptake was studied 
in cardiomyocytes from CD36 knockout mice as described in chapter 5. 
Furthermore, the AICAR-induced change in abundance of FABPpm, FATP1 and 
FATP6 at the sarcolemma was determined.  
Chapter 6 presents the role of Munc18c in cardiac substrate uptake. Mun18c is 
known to be involved in insulin-stimulated GLUT4 translocation in skeletal muscle, 
but, its role in the heart is not yet known. Insulin and oligomycin-stimulated glucose 
and LCFA uptake rates were determined in cardiomyocytes from Munc18c-/+ mice.  
In Chapter 7 the main results of the studies presented in this thesis are summarized, 
new insights will be discussed, and placed in a broader perspective.  
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Abstract 
Mechanical, electrical and pharmacological tools can be used to study cardiac 
metabolism in in vivo/ex vivo models such as the working heart and isolated 
cardiomyocytes preparations, to maintain metabolic demand of the heart that is 
indicative of the metabolic demand seen in vivo. The pharmacological 
mitochondrial F1F0-ATPase inhibitor oligomycin has proven a valuable tool to 
increase long-chain fatty acid (LCFA) and glucose utilization in these models. 
Therefore, changes in cardiac energy metabolism induced by increased workload in 
working heart preparations and in electrically stimulated cardiomyocytes can be 
mimicked by oligomycin. The conclusion that oligomycin mimics the effects of 
cellular contraction is based on crucial metabolic parameters of contraction that are 
also observed during oligomycin stimulation: (i) increase of the AMP/ATP ratio; 
(ii) activation of the signaling pathway, including AMP-activated protein kinase, 
acetyl-CoA carboxylase, 6-phosphofructo-2-kinase, protein kinase D and cardiac 
troponin-I; and (iii) translocation of fatty acid translocase/CD36 and GLUT4 to the 
sarcolemma to increase LCFA and glucose uptake, respectively. These findings 
indicate that increased workload in the working heart preparation, electrical 
stimulation of isolated cardiomyocytes, and oligomycin treatment of 
cardiomyocytes mutually share a common regulatory mechanism finally leading to 
increased ATP production. Taken together, oligomycin represents a powerful tool 
to study the consequence of metabolic challenges in the heart.  
Thesis_Habets_v2.pdf   30 30-9-2008   13:39:31
  Oligomycin as tool to mimic contraction signaling to metabolism in cardiomyocytes | 31 
 
Introduction 
Most of the heart is made up of contractile muscle cells, also known as myocytes or, 
more specifically, cardiomyocytes. The continuous contractile function of the heart 
muscle requires that the myocytes produce large amounts of ATP. This high ATP 
demand is met primarily by the utilization of the predominant substrates of the 
heart, i.e., fatty acids and carbohydrates [1, 2]. Because measurement of cardiac 
metabolic parameters in vivo are difficult and often indirect, in vitro/ex vivo 
techniques for measuring energy metabolism in the heart have been developed [3, 
4]. The working heart and isolated cardiomyocytes preparations are models most 
widely used for investigating energy metabolism in a variety of physiological and 
pathological states. These models permit simultaneous measurements of metabolic 
rates and avoid confounding systemic factors (e.g., uncontrolled endocrine, 
metabolic and workload changes), while isolated cardiomyocytes preparations also 
eliminate cardiovascular factors and the endothelial barrier. A key factor controlling 
flux through the various metabolic pathways is the work being performed by the 
heart. Rates of ATP production by the heart depend on ATP utilization rates [5]. As 
cardiac work decreases, ATP utilization rates decrease and this directly or indirectly 
results in a feedback inhibition on all of the pathways involved in ATP production. 
As a result, flux through glycolysis, glucose oxidation, lactate oxidation, fatty acid 
oxidation, tricarboxylic acid cycle activity, and electron transport chain activity is 
critically dependent on the work performed by the heart. It is therefore desirable to 
use experimental models in which the heart is functioning at physiologically 
relevant workloads. This is neither a problem with in vivo studies nor with isolated 
working heart preparations, but can be an important factor in many in vitro/ex vivo 
studies. For instance, isolated cardiomyocytes consume oxygen at a rate that is 
approximately 10% of that of the intact working heart, as a result of which it seems 
likely that the metabolic demand is reduced [6, 7]. Indeed, because of this quiescent 
nature oxidative metabolism in isolated cardiomyocytes can be 50-100 times lower 
than rates in intact working hearts [8, 9]. For the proper investigation of the 
regulation of cardiac metabolism, especially its changes during the transition 
between distinct levels of ATP production, the hearts should be performing relevant 
levels of cardiac work or the metabolic rates should be similarly high.  
A number of techniques have been developed to stimulate cardiac energy 
metabolism for in vitro/ex vivo approaches. An experimental setup which can be 
used in a variety of small animals is the isolated working heart preparation [3]. The 
preparation is a left ventricular ejecting heart, in which both preload and afterload 
are controlled. Increased workload in working heart preparations can be induced by 
simultaneous adrenergic stimulation, parasympathic blockade, or aortic constriction 
[10-12]. To study cardiac contraction in isolated cardiomyocytes, an approach was 
developed to electrically stimulate cardiomyocytes in suspension [7]. The applied 
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frequency can be varied, thereby increasing the rate of oxygen consumption up to 
approximately 50% of that in vivo. This system can be properly used to stimulate 
isolated rat cardiomyocytes in a controlled manner with 100V up to 250V and up to 
5Hz, cardiomyocytes optimally contract at 4Hz/200V. However, this system has not 
yet been adapted for the stimulation of mouse cardiomyocytes because myocytes 
isolated from this specie appear relatively fragile.  
Various pharmacological tools also stimulate cardiac metabolism in both in vitro/ex 
vivo approaches in a wide range of species. Mitochondrial inhibitors that reduce 
oxidative phosphorylation, like oligomycin, rotenone, 2,4-dinitrophenol and 
sodiumazide are widely used for this purpose [13-15]. It has been established that 
oligomycin is the best mimeticum to stimulate cardiac metabolism under 
physiological conditions because only oligomycin increases both long-chain fatty 
acid (LCFA) and glucose utilization [16]. In response to oligomycin the myocardial 
metabolic rates increase comparably to electrically-stimulated cardiomyocytes [14]. 
Also in the working heart [17] and in several cells lines (with and without a 
contractile apparatus) [18] oligomycin mimics the physiological metabolic events of 
the heart.  
This review will summarize the current state of knowledge regarding the use of 
oligomycin as a tool to increase energy metabolism in the heart. First, the 
characteristics of oligomycin and its inhibitory action on mitochondria are 
described. Second, evidence is presented that oligomycin elevates cardiac substrate 
utilization comparable to cellular contractions and increased workload. The effects 
of oligomycin on selected metabolic parameters, e.g., glucose and LCFA uptake 
and oxidation, will be discussed. Finally, examples are given of the application of 
oligomycin in studies on the regulation of cardiac energy metabolism.  
 
Characterization and inhibitory mechanism of oligomycin  
Oligomycins, a family of natural antibiotics, were discovered by Smith et al. [19] in 
the early fifties and isolated from Streptomyces diastatochromogenes. The original 
complex was separated into three components, designated A, B and C [20]. The 
slight chemical differences between oligomycins A, B and C (Fig. 2.1A) do not 
affect the ability of these compounds to inhibit oxidative phosphorylation [21]. A 
combination of the three components, of which oligomycin A is the major 
component (comprising ~65%), is commonly used as an inhibitor of oxidative 
phosphorylation.  
Oligomycin is characterized as an inhibitor of the ATP synthase [22, 23] (Fig. 
2.1B). ATP synthase, also called complex V, is the final enzyme in the oxidative 
phosphorylation pathway. Under oxidative conditions, the role of this enzyme is to 
catalyze the formation of ATP from ADP and inorganic phosphate using energy 
from a proton motive force across the membrane to drive the reaction. The ATP 
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synthase is composed of two structurally and functionally distinct domains, a 
transmembrane domain known as F0 and an intracellular globular domain, called F1, 
linked together by a central and peripheral stalk [24]. F1 is the catalytic domain 
comprising the ATPase activity while F0 mediates the transmembrane proton 
transport and energy transfer to and from F1. Thus, when F1 is bound to F0, the 
whole complex catalyzes ATP synthesis and hydrolysis, and in both cases these 
reactions are coupled to proton transport across the membrane through F0 [25]. 
Oligomycin binds to the F0 subunit [23, 26, 27] that blocks proton transport leading 
to inhibition of ATP synthesis. The inhibitory effect of oligomycin on complex V 
has been investigated in isolated bovine heart mitochondria. In these mitochondria 
complex V was inhibited for 90% by oligomycin with an IC50 value of 8 nM [28].  
 
Cellular effects of oligomycin in the heart 
For the regulation of many cellular processes a maintained level of ATP is required. 
This applies that high amounts of ATP are needed for the regulation of calcium flux 
and contractile function during increased workload or contraction. Oligomycin has 
been used in many cardiac studies to investigate the role of the F1F0-ATPase 
complex or to prevent mitochondrial ATP synthesis by using low concentrations (< 
1 μM). High concentrations of oligomycin have other effects on cellular function 
(e.g., heart function, oxygen consumption, Ca2+ influx and apoptosis) than only 
inhibition of ATP synthesis (> 15-50 μM, depending on incubation conditions), as 
described below. However, many of these impaired cellular processes are an 
indirect result of low ATP content induced by oligomycin. 
The heart is an adaptive organ, responding to changing needs by modifying 
contractile strength and beating rate. Perfusion of isolated rat hearts for 2 min with 
10 μM oligomycin did not change heart rate, but decreased cardiac function and 
increased coronary flow [29]. It has been suggested that decrease of cardiac 
function is the result of this marked decrease of ATP levels by 31%. Oligomycin-
stimulated coronary flow suggests that there is a feedback mechanism to maintain 
the cardiac ATP content.  It can be speculated that enhanced coronary flow results 
in elevated substrate supply to the heart for ATP production.  
To maintain its function, the heart requires a constant supply of oxygen. High 
cardiac contractile performance leads to higher oxygen consumption in isolated 
cardiomyocytes [6] and in working heart preparations [12]. The workload related 
oxygen consumption is necessary for aerobic metabolic rates in the heart [3]. 
Oxygen consumption resulting from oxidation of cardiac substrates is increased 
after acute and prolonged workload stimulation [12]. Therefore, when cardiac 
substrate utilization is measured, oligomycin should not disrupt oxygen 
consumption. Indeed, to inhibit the oxygen consumption by 50% an oligomycin 
concentration five times higher than for ATPase inhibition has to be used [30]. In 
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conclusion, when used at low concentrations, oligomycin can be applied to 
stimulate cardiac energy metabolism without disruption of oxygen levels.  
Besides the substrates for ATP production, also myoplasmic Ca2+ is required during 
contraction. It is known that only high concentrations of oligomycin do interrupt 
calcium flux. The concentrations of oligomycin required to inhibit Ca2+ influx and 
efflux were nearly 50-fold higher than the concentrations that blocked 
mitochondrial ATP production [31].  
Because oligomycin is leading to ATP depletion, this could affect the yield of cells 
during treatment with this compound. However, short incubation of oligomycin of 
maximally 30 minutes does not decrease the viability of isolated rat and mouse 
cardiomyocytes [14]. In contrast, incubations of cultured neonatal rat 
cardiomyocytes with 1 μM oligomycin for 7 hours showed increased apoptosis 
[32]. Perhaps the inhibitory effect of oligomycin on ATP production is too strong to 
use it for long incubations. For instance, incubation of cells for 24 hours with 20 
μM or 40 μM oligomycin reduced the cellular ATP content by 80% and 90%, 
respectively [33]. 
As described above, high concentrations of oligomycin can display other effects 
than only inhibition of the F1F0-ATPase complex. This could complicate 
measurements of energy substrate metabolism in the heart. As a result, 
measurements of energy metabolism in working heart preparations and 
cardiomyocyte preparations should be performed with relatively low concentrations 
of oligomycin. A concentration of 1-15 μM of oligomycin is preferred, depending 
on the incubation conditions and experimental setup.  
 
Effects of oligomycin on myocardial adenosine 
nucleotide concentrations 
Increased workload results in elevated intracellular concentrations of AMP at the 
expense of that of ATP. These changes are mimicked by oligomycin via inhibition 
of the mitochondrial ATPase which is leading to a drop in intracellular ATP 
concentration and a subsequent increased AMP/ATP ratio. In this section we will 
discuss the effect of oligomycin on the AMP/ATP ratio in different models, like the 
isolated working heart preparations, isolated cardiomyocytes preparations from rat 
or mouse hearts, and cell lines.  
The metabolic status of the model studied could influence the effects of oligomycin. 
Perfusion of rat hearts with 5 μM oligomycin for 10 minutes evokes an 44-fold 
increase of the cardiac AMP/ATP ratio [17]. Another study also showed that 
perfusion of rat hearts with 10 μM oligomycin for 2 minutes reduces ATP 
concentration by 31% [29]. The impact of oligomycin on high-energy phosphate 
concentrations is greater in working heart preparations compared to isolated  
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Figure 2.1 The structure of oligomycin, its inhibitory mechanism, and its effect on intracellular 
nucleoside phosphates in cardiomyocytes  
Oligomycin occurs in three different isoforms, which vary in the composition of four residues (panel 
A). Oligomycin inhibits the ATP synthase present on the inner mitochondrial membrane by blocking its 
proton channel necessary for oxidative phosphorylation of ADP to ATP (panel B). Isolated 
cardiomyocytes from rats incubated for 15 min in the absence (Ctrl) or presence of electrical 
stimulation at 200V/4Hz (4Hz) or 30 μM oligomycin (Oli) stimulation showed changes in intracellular 
levels of ATP, AMP, and the AMP/ATP ratio (panel C). Data are means ± SD of three to six 
experiments carried out with different cardiomyocyte preparations. *Significantly different from Ctrl 
(P<0.05). 
 
 
cardiomyocyte preparations. Stimulation of rat cardiomyocytes with 30 μM 
oligomycin for 15 min decreases the ATP concentration by 24%, leading to an 
elevation of cardiomyocytic AMP/ATP ratio by 2.5-fold [14] (Fig. 2.1C). In mouse 
cardiomyocytes, oligomycin (1 μM for 20 min) induced a 47% drop in the ATP 
content resulting in a 6.3-fold increase of AMP/ATP ratio. The difference in 
changes of high-energy phosphate concentration between species, i.e., rat and 
mouse, could be explained by difference in mitochondrial volume leading to higher 
oxidative metabolism. As mammals become smaller in body size, the volume that 
mitochondria occupy within the myocytes increases, as does the surface area of the 
inner mitochondrial membrane within the mitochondria itself [34-36].  
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As in isolated working hearts and in cardiomyocyte preparations, oligomycin has 
also been used in different cell lines. Treatment of Dmel2 (Drosophila embryonic 
cell line) cells with oligomycin (100 nM for 1 hour) caused very large increases in 
the cellular AMP/ATP ratio and ADP/ATP ratio (40-fold and 14-fold, respectively) 
[37]. Also in H4IIE (rat hepatoma cell line) cells 10 nM oligomycin increased the 
ADP/ATP ratio by 2-fold [18]. However, in CHO (Chinese hamster ovary 
fibroblasts) cells oligomycin stimulation ranging from 1 to 5 mM did not 
significantly change the cellular ADP/ATP ratio [18]. The fact that CHO cells were 
resistant to inhibition of mitochondrial ATP synthesis shows that these cells must 
be capable of generating sufficient amounts of ATP by glycolysis only [18] rather 
than by oxidative metabolism [38]. In summary, oligomycin can be applied to 
change high-energy nucleotide concentrations in perfused hearts and isolated 
cardiomyocytes, although the effect on cell lines depends on the quantity of aerobic 
versus anaerobic metabolism of the cell.  
Similar changes in the high-energy phosphate concentrations, as induced by 
oligomycin, have been observed after physiological manipulation (like cellular 
contractions and increased workload) [12]. This suggests that the onset of a higher 
metabolic demand induced by oligomycin is comparable with physiological 
situations, like contractions, in the heart. For example, in rat cardiomyocytes the use 
of oligomycin has been fully adapted to the metabolic alterations of electrical 
stimulation of cardiomyocytes. The ATP content in cardiomyocytes was reduced by 
24.2% with oligomycin and by 17.4% with 4Hz contractions while the AMP levels 
were elevated by 50% and 36.1%, respectively (Fig. 2.1C). This results in an 
oligomycin-stimulated increase of the AMP/ATP ratio by 2.5-fold, whereas 4Hz 
contractions evokes a 1.9-fold increase (Fig. 2.1C). Although the mechanism of the 
applied tools is different (oligomycin inhibits ATP production while 4Hz 
stimulation enhances the ATP consumption) the result in the AMP/ATP ratio is 
comparable. The changes in adenosine nucleotide phosphates show that the heart 
highly regulates processes to maintain the ATP content. In the next section we will 
discuss whether the reduced ATP content induced by oligomycin is leads to the 
activation of metabolic processes that produces ATP in the heart, i.e., cardiac 
substrate utilization. 
 
Effect of oligomycin on myocardial substrate uptake and 
oxidation  
The major substrates for the heart are fatty acid and carbohydrate. Long-chain fatty 
acids (LCFA) are the key lipids oxidized; glucose and lactate are the carbohydrates 
primary utilized. However, LCFA oxidation is the principal route for ATP synthesis 
with glucose being used to a minor extent both at rest and during exercise [1, 39]. In 
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order to investigate whether oligomycin mimics the metabolic effects of increased 
contractions, such as during exercise, we treated isolated cardiomyocytes derived 
from rat and mouse with oligomycin and determined LCFA and glucose uptake and 
oxidation. Indeed, oligomycin dose-dependently elevates the uptake rates of LCFA 
and glucose. When LCFA uptake was studied as a function of the oligomycin 
concentration, LCFA uptake was found to be maximally stimulated at 5-25 μM in 
rat cardiomyocytes (Fig. 2.2A) and 1-5 μM in mouse cardiomyocytes (Fig. 2.2B). 
However, in both rat and mouse cardiomyocytes glucose uptake was already 
maximally stimulated at a lower concentration of oligomycin, namely 1 μM and 
0.2-1 μM, respectively. This suggests that the glucose uptake rates are stimulated 
by a more sensitive mechanism than LCFA uptake rates. Interestingly, although that 
the basal glucose uptake rates and rat or mouse cardiomyocytes differ, the relative 
impact of oligomycin is comparable (Fig. 2.2A).  
Subsequently, the metabolic effects of oligomycin were compared with electrically-
stimulated rat cardiomyocytes. LCFA and glucose uptake increased with the pulse 
frequency up to 4Hz. Contractile activity elevates LCFA and glucose uptake by 1.5-
fold and 2.0-fold, respectively, which is, however, lower than the stimulating effect 
of oligomycin on LCFA and glucose uptake (2.1-fold and 2.6-fold stimulation, 
respectively; Fig. 2.2C and 2.2D). Thus, when considering these two stimuli, there 
is a positive correlation between the AMP/ATP ratio and the uptake of LCFA and 
glucose. This suggests that both stimuli activate a common mechanism. This 
conclusion is strengthened by the observation that elevated LCFA uptake induced 
by oligomycin is ineffective in contracting cardiomyocytes (Fig. 2.2C).  
Moreover, intracellular lipid metabolism (oxidation and esterification) was 
determined for both stimuli in rat cardiomyocytes. Again the effect of oligomycin 
(3.7-fold increase) on LCFA oxidation is larger compared to 4Hz contractions (2.8-
fold increase). In addition, both stimuli do not change the esterification of LCFA 
into the lipid storage compartments [14]. Not only LCFA oxidation was stimulated 
by oligomycin but also glycolysis was increased in perfused rat heart as has also 
been observed during increased workload [40, 41]. Studies with working heart 
preparations in which LCFA and glucose were simultaneously measured showed 
opposite results regarding the preferred substrate during increased workload. Some 
studies demonstrated a selective increase in glucose utilization [42, 43], in contrast, 
other studies demonstrated a selective increase in LCFA utilization [44, 45] or a 
parallel increase in LCFA and glucose oxidation during increased workload [1, 12, 
46, 47]. When working hearts were perfused with high palmitate levels, LCFA 
oxidation was increased at the expense of carbohydrates, as observed in oligomycin 
and electrically-stimulated cardiomyocytes [1, 12]. Because during exercise the 
blood supplies the heart with high levels of lipids [48, 49] these measurements are 
regarded more representative for the situation in vivo [39]. To summarize, in 
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response to oligomycin, electrostimulation or increased workload, all of which 
cause the ATP concentration in the heart to decrease, a simultaneous LCFA 
oxidation and glucose oxidation accounts for ATP production, with LCFA 
oxidation being the main source of ATP. 
 
 
Palmitate
Deoxyglucose
Rat cardiomyocytes
0 1
0
10
20
30
40
50
0.0
2.5
5.0
7.5
10.0
5 15 25 125
*
* *
*
* * * *
A
Oligomycin concentration (PM)
P
al
m
ita
te
 u
pt
ak
e
(n
m
ol
/g
 w
w
 p
er
 m
in
) Deoxyglucose uptake
(nm
ol/g w
w
 per m
in)
Mouse cardiomyocytes
0 1
0
10
20
30
40
50
0.0
2.5
5.0
7.5
10.0
5 15 25 125
*
* * *
* *
* *
*
B
Oligomycin concentration (PM)
P
al
m
ita
te
 u
pt
ak
e
(n
m
ol
/g
 w
w
 p
er
 m
in
) Deoxyglucose uptake
(nm
ol/g w
w
 per m
in)
 
Ctrl 2Hz 4Hz Oli Oli + 4Hz
0
10
20
30
40
50
60
* *
* *
C
Pa
lm
ita
te
 u
pt
ak
e
(n
m
ol
/g
 w
w
 p
er
 m
in
)
     Ctrl 2Hz 4Hz Oli
0
1
2
3
4
*
*
*
D
D
eo
xy
gl
uc
os
e 
up
ta
ke
(n
m
ol
/g
 w
w
 p
er
 m
in
)
 
 
Figure 2.2 Frequency-dependent and dose-dependent effect of electrical stimulation and of 
oligomycin treatment, respectively, on substrate uptake in cardiomyocytes 
Isolated cardiomyocytes from rat (panel A) and mouse (panel B) were incubated for 20 min with various 
concentrations of oligomycin (0.2-125 μM). Subsequently, 14C-palmitate (left axis) and 3H-deoxyglucose 
(right axis) uptake were measured. The effects of 15 min treatment of rat cardiomyocytes in the absence 
(Ctrl) or presence of 30 μM oligomycin (Oli) on 14C-palmitate (panel C) and 3H-deoxyglucose (panel D) 
were compared with electrostimulation at 2Hz, and 4Hz. Data are means ± SD of 4 experiments carried 
out with different cardiomyocyte preparations. *Significantly different from Ctrl (P<0.05).  
 
 
Application of oligomycin in studies on the regulation of 
cardiac energy metabolism 
Cardiac metabolism is regulated by a complex process which has been unraveled 
only partly. Oligomycin has been used successfully in different studies to identify 
important key players in the regulation of cardiac substrate transport (e.g., glucose 
and LCFA) and signal transduction pathways involved in substrate uptake and 
metabolism. These examples are reviewed below.  
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Glucose uptake into cardiomyocytes has long been recognized to occur via a protein 
mediated process involving the glucose transporters 1 and 4 (GLUT1 and GLUT4). 
It is well documented that upon stimulation by insulin, GLUT4 is recruited from an 
intracellular membrane compartment to the sarcolemma concomitant with an 
increase in glucose uptake. In addition, increased sarcolemmal GLUT4 can be 
achieved by a drop in oxygen supply (anoxia/ischemia), by mitochondrial 
inhibitors, or by increased mechanical activity of the heart [15, 50, 51]. The 
observation that each factor induces a drop in cardiac ATP concentration, suggests 
that they share a common signaling pathway. Since oligomycin depletes the ATP 
content it seems likely that oligomycin also induces GLUT4-mediated glucose 
uptake. Indeed,  the oligomycin-induced glucose uptake is associated with increased 
sarcolemmal GLUT4 [14, 52] (Fig. 2.3A). Subsequently, in several studies it has 
been observed that oligomycin stimulates glucose uptake in both rat [14, 52-54] and 
mouse [55] cardiomyocytes. Interestingly, it has been observed that the effects of 
oligomycin and cellular contractions on the trafficking cycle of GLUT4 are distinct. 
Oligomycin slows endocytosis of GLUT4 mediated transport while in contracting 
cardiomyocytes exocytosis of GLUT4 transport is stimulated [52]. Although the 
GLUT4-trafficking steps modulated by contraction and oligomycin are different, 
the result is the same: increased sarcolemmal GLUT4 concomitant with increased 
glucose uptake [14, 52]. Thus, oligomycin can be used to stimulate GLUT4-
mediated glucose uptake in the heart but oligomycin is less appropriate to mimic 
contraction events in trafficking processes. 
Oligomycin has been successfully used to delineate the regulation of LCFA uptake. 
LCFA uptake is mainly protein dependent, with sarcolemmal fatty acid 
translocase/CD36 (CD36) mediated uptake accounting for 70% of the total LCFA 
uptake rate. Like for GLUT4-mediated glucose uptake, the LCFA uptake rate 
increases with higher amounts of CD36 present at the sarcolemma [4]. The 
translocation of CD36 from intracellular compartments to the plasma membrane 
can be stimulated acutely by different stimuli like insulin and cellular contractions. 
CD36 is especially important during situations of higher metabolic demands in 
muscle tissue [56]. Just as insulin and contraction also oligomycin treatment results 
in increased LCFA uptake. The involvement of CD36 in oligomycin-induced LCFA 
uptake has been confirmed in both rat and mouse cardiomyocytes in different 
experimental setups. As observed during contractions, in oligomycin-stimulated rat 
cardiomyocytes both rates of LCFA uptake and amounts of sarcolemmal CD36 
were increased (Fig. 2.3A). In addition, the oligomycin-induced increase in LCFA 
uptake could be completely inhibited with sulfo-N-succinimidyl oleate (SSO), a 
specific inhibitor of CD36 [14]. This suggests that oligomycin-induced LCFA 
uptake into cardiomyocytes is CD36 dependent. The use of cardiomyocytes from 
CD36 knockout mice strengthens this finding. In cardiomyocytes from CD36  
Thesis_Habets_v2.pdf   39 30-9-2008   13:39:31
 40 | Chapter 2 
 
0.0
0.5
1.0
1.5
2.0
*
* *
LDM    PM        LDM    PM
CD36                 GLUT4
*Ctrl
Oli
A
Tr
an
sp
or
te
rs
 in
 s
ub
ce
llu
la
r
ca
rd
io
m
yo
cy
te
 fr
ac
tio
ns
(re
la
tiv
e 
ab
un
da
nc
e)
Tr
an
sp
or
te
rs
 in
 s
ub
ce
llu
la
r
ca
rd
io
m
yo
cy
te
 fr
ac
tio
ns
(re
la
tiv
e 
ab
un
da
nc
e)
Ctrl         Oli        4Hz
p-AMPK
Thr172
63 kDa
p-ACC
Ser 79
280kDa
p-PKD
Ser 916
115 kDa
p-cTnI
Ser 23/24
28 kDa
>
>
>
>
B
 
 
Figure 2.3 The effects of oligomycin and contraction on sarcolemmal transporter abundance 
and on signal transduction  
Cardiomyocytes were incubated for 15 min with 30 μM oligomycin (Oli) whereafter the cells were 
subjected to subcellular fractionation. The low-density microsomal (LDM) and plasma membrane (PM) 
fractions were subjected to electrophoresis and Western Blotting (panel A) to detect glucose transporter 
4 (GLUT4) at 45 kDa and fatty acid translocase/CD36 (CD36) at 88 kDa. Cardiomyocytes were treated 
with 1 ȝM oligomycin (Oli), or with 4Hz electrostimulation (4Hz) during 15 min (panel B). For 
assessment of phosphorylation of protein kinase D (PKD)-Ser916 (n=9), cardiac troponin-I (cTnI)-
Ser23/24 (n=5), AMP-activated protein kinase (AMPK)-Thr172 (n=10) and acetyl-CoA carboxylase 
(ACC)-Ser79 (n=10), cardiomyocytes were pelleted, dissolved in sample buffer, and thereafter which 
Western Blotting was performed with phosphospecific antibodies. Gels were loaded with equal 
quantities of protein for each cell lysate (20 ȝg per lane). Signals were quantified by densitometry. 
Transporter content is expressed as multiple of control (Ctrl) in the corresponding fraction. Data are 
means ± SD of at least four experiments carried out with different cardiomyocyte preparations. 
Representative Western Blots are shown. *Significantly different from Ctrl (P<0.05). 
 
 
knockout mice the oligomycin-stimulated LCFA uptake was largely reduced [55] 
(see chapter 3). Taken together, these findings show that oligomycin can be applied 
to study myocardial CD36-mediated LCFA uptake. 
As for the regulation of protein-mediated substrate uptake into the heart, 
oligomycin was crucial to study the signal transduction cascade involved in 
stimulated cardiac metabolism. AMP-activated protein kinase (AMPK), especially 
AMPKĮ2 which is the predominant subunit in the heart [57], has been established 
as a key player involved the activation of catabolic pathways (such as LCFA and 
glucose oxidation) and de-activation of anabolic pathways (such as LCFA and 
glucose storage). The first evidence that AMPK was involved in the regulation of 
LCFA uptake came from studies with isolated cardiomyocytes from rats that had 
been stimulated with oligomycin. Activation of AMPK was assessed by 
determining its ability to phosphorylate acetyl-CoA carboxylase (ACC), one of the 
major substrates of AMPK [58]. The phosphorylation of ACC by AMPK decreases 
its activity and results in a drop in the intracellular malonyl-CoA concentration and 
Thesis_Habets_v2.pdf   40 30-9-2008   13:39:32
  Oligomycin as tool to mimic contraction signaling to metabolism in cardiomyocytes | 41 
 
de-inhibition of mitochondrial LCFA oxidation [59]. Recently, we showed in 
cardiomyocytes from AMPK kinase-dead and AMPKĮ2 knockout mice that the 
effects of oligomycin on LCFA and glucose uptake were AMPK dependent (see 
chapter 4). Furthermore, the effects of oligomycin on the activation of AMPK 
signaling are comparable with that of electrostimulation. With both manipulations 
(oligomycin and electrostimulation) the rise in the AMP/ATP ratio was found to be 
sufficient to activate AMPK [14], but oligomycin (12.2-fold increase) is more 
potent than 4 Hz contractions (5.8-fold increase; Fig. 2.3B). In line with this, 4 Hz 
contractions substantially (5.0-fold) increased the phosphorylation of ACC. This 
increase is also of a lesser magnitude than that of oligomycin (8.7-fold). 6-
phosphofructo-2-kinase (PFK-2) another AMPK downstream kinase, is responsible 
for the synthesis of fructose 2,6-biphosphate, a potent stimulator of glycolysis [60, 
61]. Oligomycin elevates PFK-2 phosphorylation and activity in perfused hearts 
[17, 61] and monocytes [41]. There is some controversy whether PFK-2 in the heart 
can be activated by AMPK or by a wortmannin-sensitive mechanism. In the heart 
PFK-2 can be activated AMPK-dependent by oligomycin [17], but AMPK-
independent by increased workload [40]. To summarize, in isolated 
cardiomyocytes, treated with oligomycin or electrostimulation, AMPK is a crucial 
kinase in the regulation of substrate utilization, however, in working heart 
preparations and in vivo studies there is some controversy about the effect on 
AMPK activation in response to increased workload [40, 62-64].  
Recently, two protein kinases upstream of AMPK have been identified, namely 
LKB1 and Ca2+-calmodulin-dependent protein kinase kinase-ȕ (CaMKKȕ) [65-67]. 
CaMKKȕ activity is enhanced by an intracellular rise of calcium concentration, as 
observed after treating cells with Ca2+ ionophores [68] and during contractions of 
skeletal muscle [69]. In the heart CaMKKȕ was able to strongly activate AMPK 
[70]. Since low concentrations of oligomycin do not affect the Ca2+ levels [31], the 
role of Ca2+-mediated CaMKKȕ activity after oligomycin stimulation could be 
excluded. In contrast to CaMKKȕ, which is activated by an increase in intracellular 
Ca2+, LKB1 is constitutively active [71]. LKB1 is necessary for AMPK activation 
but has no regulatory role as its activity is not increased during contraction. In 
skeletal muscle the contraction-induced AMPK activity was greatly reduced in 
LKB1 knockout mice [72]. In LKB1 knockout mice the cardiomyocytic response of 
oligomycin-stimulated AMPK and ACC phosphorylation was markedly reduced 
(see chapter 4). In addition, the uptake rates of LCFA and glucose were totally 
inhibited in oligomycin-stimulated cardiomyocytes from these mice. In summary, 
oligomycin activates a similar signal transduction cascade as observed during 
increased workload and contraction, namely, the LKB1-AMPK axis as well as the 
downstream targets, i.e., ACC and PFK-2. 
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Table 2.1 Effects of 4Hz stimulation and of oligomycin on contraction signaling and 
transporter-mediated substrate uptake in cardiomyocytes.  
 
Intervention   Activation of   CD36-mediated GLUT4-mediated 
  AMPK/ACC      PKD      CaMKK LCFA uptake glucose uptake  
 
4Hz / contraction            +              +  +            +               + 
Oligomycin            +              +  -            +               + 
 
 
Electrical stimulation (4Hz) and oligomycin treatment have similar effects on protein-mediated 
substrate uptake in cardiomyocytes. The signal transduction pathway activated by 4Hz 
electrostimulation includes AMP-activated protein kinase (AMPK) / acetyl-CoA carboxylase (ACC), 
protein kinase D (PKD) and Ca2+-calmodulin-dependent protein kinase kinase (CaMKK) whereas 
oligomycin activates AMPK/ACC and PKD but not CaMKK in cardiomyocytes. Subsequently, 
activation of the contraction signaling pathway by 4Hz stimulation and oligomycin simultaneously 
increased long-chain fatty acid (LCFA) and glucose uptake. This is mediated by the translocation of 
fatty acid translocase/CD36 (CD36) and the glucose transport protein 4 (GLUT4), respectively, from 
intracellular storage compartments to the plasma membrane. 
 
 
Recently, we identified another protein kinase that is activated upon contraction, 
protein kinase D (PKD) [70]. Contractions of cardiomyocytes increased PKD 
phosphorylation to 5.1-fold, a similar order of magnitude compared to oligomycin 
stimulation (Fig. 2.3B). Since PKD is closely related to that of the CaMKK [73] it 
seems possible that contractions increase the activity of this protein. It has been 
observed that oligomycin and 4Hz-electrostimulation similarly increase PKD 
activity and, upon this, autophosphorylation of Ser916 [70]. The role of CaMKKȕ 
and AMPK seems to be less important since in vitro phosphorylation assays: (i) 
inhibitors of CaMKK did not inhibit oligomycin-induced PKD phosphorylation, 
and (ii) studies with cardiomyocytes from AMPKĮ2 knockout mice had no impact 
on PKD activity. This suggests that contraction and oligomycin also activate a 
pathway independent of AMPK which involves PKD. One possibility to explain 
contraction-induced PKD activation could be via reactive oxygen species (ROS) as 
a by-product of oxidative phosphorylation, which are elevated during contraction 
and upon oligomycin treatment [74, 75]. Indeed, ROS has found to be capable of 
inducing PKD activation [76], and ROS could also induce glucose uptake [77-79]. 
Moreover, by using inhibitors of PKD it has been shown that oligomycin-induced 
PKD activity could increase glucose uptake [70]. In a yeast 2-hybrid screen, 
troponin-I has been identified as substrate of PKD [80, 81]. Troponin-I is a 
contractile protein, it allows fast relaxation ensuring that heart muscle does not 
contract maximally [82, 83]. Subsequently, troponin-I phosphorylation was noticed 
in both contracting  and oligomycin-stimulated cardiomyocytes [70] (Fig. 2.3B).  
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Concluding remarks 
The molecular mechanisms regulating cardiac metabolism under different 
conditions are hard to study in vivo. Therefore, different approaches have been 
developed to investigate metabolic demands of the heart in vitro/ex vivo that is 
indicative of the metabolic demands seen in vivo. The pharmacological agent 
oligomycin has been established as a tool to increase cardiac energy metabolism in 
working heart and cardiomyocyte preparations. In previous studies with isolated 
cardiomyocytes comparable results have been observed on cardiac metabolism after 
oligomycin treatment and contraction stimulation, especially with regard to LCFA 
and glucose utilization (see Table 2.1). Subsequently, oligomycin has been used to 
unravel important key players in the regulation of LCFA and glucose uptake. It has 
been observed that AMPK is centrally involved in the CD36-mediated LCFA 
uptake and GLUT4-mediated glucose uptake. Recently, it has been shown that 
oligomycin could activate PKB [54] and PKD [70] concomitant with substrate 
uptake. Thus, oligomycin is a useful tool to unravel molecular processes and key 
players involved in metabolic events induced by contraction. However, oligomycin 
also has side-effects related to its main effect on cellular depletion. Importantly, 
these side-effects are seen at high oligomycin concentrations (> 25 μM) and/or 
during prolonged treatment (> 1 h). A low concentration of oligomycin only inhibits 
the ATPase and will not interfere with the cellular process of interest. Therefore, the 
optimal concentration of oligomycin should be determined before using oligomycin 
as tool. In conclusion, oligomycin is a powerful tool to study physiological relevant 
levels of cardiac work and subsequently identify key players involved in cardiac 
metabolism.  
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Abstract  
CD36, also named fatty acid translocase/CD36, has been identified as a putative 
membrane transporter for long-chain fatty acids (LCFA). In the heart, contraction- 
induced AMP-activated protein kinase (AMPK) signaling regulates cellular LCFA 
uptake through translocation of CD36 and possibly of other LCFA transporters 
from intracellular storage compartments to the sarcolemma. In this study isolated 
cardiomyocytes from WT and CD36 knockout mice were used to investigate to 
what extent basal and AMPK-mediated LCFA uptake are CD36-dependent. Basal 
LCFA uptake was not altered in CD36 knockout cardiomyocytes, most likely 
resulting from a (1.8-fold) compensatory upregulation of fatty acid-transport protein 
1. The stimulatory effect of contraction-mimetic stimuli, oligomycin (2.5-fold) and 
dipyridamole (1.6-fold), on LCFA uptake into WT cardiomyocytes was almost 
completely lost in CD36 knockout cardiomyocytes, despite that AMPK signaling 
was fully intact. CD36 is almost entirely responsible for AMPK-mediated 
stimulation of LCFA uptake into cardiomyocytes, indicating a pivotal role for 
CD36 in mediating changes in cardiac LCFA fluxes. 
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Introduction 
Long-chain fatty acid (LCFA) and glucose are the predominant substrates for the 
heart, and contribute, under normal circumstances, for approximately 70% and 
20%, respectively, to cardiac energy production [1, 2]. Cardiac LCFA uptake in 
rodents is largely mediated by protein-mediated transport, with a minor (< 20%) 
part attributable to passive diffusion [3]. Three proteins have been identified as 
functioning in transmembrane transport of LCFA and each is expressed in the 
cardiac muscle: fatty acid translocase/CD36 (CD36), plasma membrane fatty acid-
binding protein (FABPpm), and fatty acid-transport protein (FATP) [4]. Transgenic 
mice would present an ideal model to investigate the contribution of each individual 
transporter to the cardiac LCFA flux.  
The first studies with CD36 transgenic mice were performed by Febbraio et al. in 
1999 [5]. CD36 knockout (CD36 KO) mice showed a significant increase in fasting 
plasma levels of cholesterol, (nonesterified) LCFA, and triacylglycerol, suggesting 
a functionally important role for CD36 in whole body lipid metabolism [5]. Tail 
vein injections of CD36 KO mice with radio-iodinated LCFA derivatives (BMIPP, 
IPPA) revealed that LCFA uptake into adipose tissue, skeletal muscle, and heart 
was reduced, and was associated with lower LCFA esterification into 
triacylglycerols in each tissue [6]. In addition, experiments with perfused hearts 
indicated that cardiac LCFA oxidation was markedly decreased in CD36 KO mice. 
This depressed cardiac LCFA oxidation was accompanied by a compensatory 
increase in glucose oxidation [7], highlighting the metabolic flexibility of the heart. 
Conversely, muscle-specific overexpression of CD36 elicits higher LCFA oxidation 
rates in skeletal muscle in response to contraction, but not during rest [8]. Only 
during an extra demand for energy, increased CD36 expression results in increased 
utilization of LCFA. Altogether, these studies with transgenic mouse models 
suggest that CD36-mediated LCFA uptake into heart and muscle is closely linked to 
changes in LCFA metabolism [9]. However, possible compensatory alterations in 
the expression of other LCFA transporters in these mice have not yet been 
evaluated, so that the quantitative involvement of CD36 in cardiac LCFA uptake 
remains unknown.  
CD36 is not only a facilitator for LCFA uptake but also appears to be involved in 
the acute regulation of LCFA uptake. This regulation occurs by stimulus-induced 
reversible CD36 translocation from intracellular storage compartments to the 
sarcolemma [10]. These stimuli include cellular contractions and the hormone 
insulin, both of which have been found to induce glucose uptake through 
translocation of the glucose transporter 4 (GLUT4) [11, 12]. Just like insulin-
induced GLUT4 translocation, insulin-induced CD36 translocation, but not 
contraction-induced CD36 translocation was found to be dependent on activation of 
phosphatidylinositol-3-kinase [11]. Recently, studies have started to disclose the 
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contraction signaling cascade involved in translocation of CD36 and GLUT4 in rat 
cardiomyocytes. This cascade is elicited by elevation of intracellular levels of AMP, 
leading to activation of AMP-activated protein kinase (AMPK) and, subsequently, 
downstream kinases, eventually resulting in the concomitant translocation of both 
CD36 and GLUT4 [13]. Interestingly, several pharmacological agents, among 
which oligomycin and dipyridamole, were also found to stimulate LCFA uptake 
through CD36 translocation [13, 14]. Both oligomycin, a mitochondrial F1F0-
ATPase inhibitor, and dipyridamole, a phosphodiesterase V/VI inhibitor, stimulated 
LCFA uptake in a non-additive manner to contractions, indicating that these agents 
activate the same signaling cascade as contractions. Indeed, oligomycin was found 
to potently activate AMPK. The stimulatory action of dipyridamole on LCFA 
uptake was unrelated to inhibition of phosphodiesterase activity, since zaprinast, 
another phosphodiesterase V/VI inhibitor, and isobutyl-methylxanthine, a general 
phosphodiesterase inhibitor, had no effect on LCFA uptake [15]. In fact, 
dipyridamole was able to translocate CD36 without influencing subcellular GLUT4 
localization, indicating that it activates a signaling compound downstream of 
AMPK [14]. 
Besides regulating LCFA uptake, AMPK signaling is also involved in regulation of 
LCFA oxidation via control of the phosphorylation state of acetyl-CoA carboxylase 
(ACC), intracellular malonyl-CoA levels and of inhibition of carnitine 
palmitoyltransferases-I (CPT-I) [16]. The simultaneous recruitment of CD36 and 
activation of CPT-I by AMPK signaling serves to channel the extra LCFA taken up 
specifically into oxidative metabolism to increase ATP production needed for 
increased cardiac workload. 
In order to properly assess the quantitative contribution of CD36 to initial LCFA 
uptake rate both in the absence and presence of AMPK stimulation we used freshly 
isolated cardiomyocytes as a model system for allowing to study LCFA uptake 
under carefully controlled conditions. Measurements of LCFA uptake and, for 
comparison, glucose uptake were performed in cardiomyocytes from both CD36 
wild-type (WT) mice and CD36 KO mice under quiescent conditions and upon 
addition of oligomycin or dipyridamole. Sulfo-N-succinimidyl palmitate (SSP) 
which specifically inhibits CD36 [17] was used to determine the involvement of 
CD36 in LCFA uptake in WT mice. 
 
Materials and methods 
Materials  
[1-14C]palmitic acid and 2-deoxy-D-[1-3H]glucose were obtained from Amersham 
Life Science (Little Chalfont, U.K.). BSA (fraction V, essentially fatty acid free), 
DMSO, phloretin, oligomycin, and dipyridamole were obtained from Sigma (St. 
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Louis, MO). Liberase blendzyme 1 was purchased from Roche Diagnostics 
(Indianapolis, IN). SSP is routinely synthesized in our laboratory, as has been 
previously described [18]. The antibody directed against phosphorylated ACC was 
from Upstate (Dundee, UK), and anti-phospho-AMPK from Cell Signalling 
(Danvers, MA). Antibodies directed against CD36 and GLUT4 were obtained from 
Chemicon International Inc. (Temecula, USA), and FATP1 and FATP4 from Santa 
Cruz Biotechnology Inc. (Santa Cruz, USA). Anti-FABPpm was a gift from Dr. J. 
Calles-Escandon, Wake Forest University School of Medicine & Baptist Medical 
Center, Winston-Salem NC. 
 
Animals 
CD36 KO mice were generated by targeted homologous recombination and crossed 
back eight times to the C57Bl/6 background [5]. CD36 KO and WT mice were bred 
at TNO Quality of Life, Leiden, the Netherlands. The Experimental Animal 
Committee of Maastricht University gave approval for all experiments involving 
animals. 
 
Isolation of mouse cardiomyocytes 
Adult mouse cardiomyocytes (mice 11-14 months of age) were isolated using a 
Langendorff perfusion system according to the procedure described by Severson et 
al. [19]. The main differences in cardiomyocyte isolation between mouse and rat 
include the type of collagenase used (Liberase blendzyme 1 versus Worthington 
collagenase type II) and the flow rate  (constantly at 2.5 ml/min versus 
progressively increasing from 6 ml/min at the beginning till 11 ml/min at the end of 
the perfusion period) [19, 20]. For all the experiments the viability of 
cardiomyocytes was 60-80% (data not shown). 
 
Substrate uptake by cardiomyocytes 
Cell suspensions were incubated with 1% dimethyl sulfoxide (DMSO) or 500 
μmol/l SSP in bicarbonate medium (120 mM NaCl, 5.4 mM KCl, 1.2 mM MgSO4, 
1.2 mM NaH2PO4, 20 mM NaHCO3, pH 7.5) supplemented with 100 μM CaCl2 and 
0.2% bovine serum albumin (BSA) during the recovery period of 30 minutes at 
room temperature, and subsequently washed and resuspended in bicarbonate 
medium supplemented with 100 μM CaCl2 and 2.0% BSA. Thereafter, cell 
suspensions (2.0 ml; 5-9 mg wet mass/ml) were pre-incubated in capped 20-ml 
incubation vials with or without 15 μmol/l oligomycin or 100 μmol/l dipyridamole 
for 20 min at 37°C under continuous shaking. At the applied concentrations of 
oligomycin and dipyridamole, LCFA uptake rates were found to be maximally 
stimulated (data not shown). Oligomycin (15 μmol/l) increased the cellular 
AMPK-mediated increase in myocardial LCFA uptake critically depends on CD36
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AMP/ATP ratio by > 2-fold, thereby increasing AMPK activity without inhibiting 
oxygen consumption [13]. To study palmitate and deoxyglucose uptake, 0.5 ml of a 
mixture of  [1-14C]palmitate/BSA complex  and [1-3H]deoxyglucose was added at 
the start of the incubations so that the final concentration of both palmitate and 
deoxyglucose amounted to 100 μmol/l with a corresponding palmitate/BSA ratio of 
0.3 [21]. Cellular uptake of palmitate (3-min incubation) and deoxyglucose (3-min 
incubation) was determined upon washing the cells three times for 2 min at 150 g in 
an ice-cold stop solution containing 0.2 mmol/l phloretin. 
 
Western Blotting 
The relative amounts of the substrate transporters CD36, FABPpm, FATP1, 
FATP4, and GLUT4 were determined in cardiomyocyte pellets obtained after a 
pulse spin in a microcentrifuge, and subsequently dissolved in sample buffer 
containing 62.5 mmol/l Tris-HCl (pH 6.8), 2 mmol/l EDTA, 20 mmol/l 
dithiothreitol, 7.5% (wt/vol) SDS, and 50% sucrose. Upon SDS-ployacrylamide gel 
electrophoresis, we applied a mouse monoclonal anti-CD36 antibody 1258, a rabbit 
polyclonal anti-FABPpm antiserum, a goat polyclonal anti-FATP1 antiserum, anti-
FATP4 antiserum, and a sheep polyclonal anti-GLUT4 antiserum, respectively for 
the detection of these transporters according to manufacturer’s instructions.  
Upon pulse centrifugation of cardiomyocytes and dissolution of the pellet in sample 
buffer, activation of AMPK and ACC was measured with antibodies against 
phospho-AMPKĮ (Thr172) and phospho-ACC (Ser79), according to the 
manufacturer’s instructions. 
 
Data presentation and statistics 
All data are present as means ± S.E.M. for the indicated number of cardiomyocyte 
preparations. Statistical difference between means was analyzed by the paired 
Student’s t test. P values  0.05 were considered significant. 
 
Results and Discussion 
Prior studies addressing cardiac LCFA uptake in CD36 transgenic mice have only 
used semi-quantitative methods in assessing a role for CD36 in this process [6, 8]. 
Our approach with freshly isolated cardiomyocytes in suspension provides accurate 
quantitative information about the initial LCFA uptake rate under controlled 
conditions. In addition with single-cell suspension of cardiomyocytes 
pharmacological agents such as the contraction-mimicking agents oligomycin and 
dipyridamole have easy access to their intracellular target allowing to study the 
dynamics of LCFA uptake, particularly in response to changes in energy demand 
that occur during alterations in myocytes contraction. 
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Involvement of CD36 in basal cardiac LCFA uptake 
Palmitate uptake into cardiomyocytes was studied at defined conditions at which 
the uptake rate is linear with time and linear with the exogenous concentration so as 
to allow the measurement of unidirectional influx in the absence of saturation of 
transporters [20]. Under basal conditions there is no difference in LCFA uptake 
between WT and CD36 KO cardiomyocytes (Fig. 3.1A). Remarkably, LCFA 
uptake into WT cardiomyocytes was decreased by 39% in the presence of SSP, 
while LCFA uptake into CD36 KO cardiomyocytes was unaffected by SSP (Fig. 
3.1A). Several conclusions can be drawn from these observations. First, the lack of 
an effect of SSP on LCFA uptake into CD36 KO cardiomyocytes strongly confirms 
that SSP solely inhibits the CD36 component in the LCFA uptake process, and does 
not affect the activity of other transporters and/or passive diffusional uptake. 
Second, CD36 mediates 39% of basal LCFA uptake into mouse cardiomyocytes, 
which is comparable to the CD36 component in basal LCFA uptake into 
cardiomyocytes from rat (50%) [21]. Third, in CD36 KO cardiomyocytes there 
must be full compensation at the level of sarcolemmal transporters to maintain 
LCFA uptake. Therefore, we have measured in WT and CD36 KO cardiomyocytes 
expression levels of other LCFA transporters (Fig. 3.2). It appears that expression 
levels of FABPpm and FAPT4 were not different in WT and CD36 KO 
cardiomyocytes. However, FATP1 was 1.8-fold (P<0.05) upregulated in CD36 KO 
cardiomyocytes, which could adequately explain the unaltered rate of basal 
cardiomyocytic LCFA uptake in the absence of CD36. 
 
Involvement of CD36 in AMPK-mediated cardiac LCFA uptake 
Two contraction-like pharmacological stimuli (oligomycin and dipyridamole) were 
used to study contraction-induced LCFA uptake into CD36 KO cardiomyocytes. 
We established previously that both agents stimulate AMPK signaling: oligomycin 
acts upstream of AMPK [13], and dipyridamole acts downstream of AMPK [14]. 
Accordingly, oligomycin potently stimulated phosphorylation of both AMPK and 
the AMPK target ACC in WT cardiomyocytes (Fig. 3.3A and 3.3B). Oligomycin 
had a similar effect on phosphorylation of both proteins in CD36 KO 
cardiomyocytes, indicating that AMPK-mediated signaling is fully intact in CD36 
KO cardiomyocytes. Dipyridamole, which appears to act on a still unidentified 
protein kinase downstream of AMPK, did not significantly alter the 
phosphorylation states of AMPK-Thr172 and ACC-Ser79 either in WT or CD36 
KO cardiomyocytes (Fig. 3.3A and 3.3B). 
Just like in rat cardiomyocytes [13, 14], oligomycin (2.5-fold) and dipyridamole 
(1.6-fold) markedly stimulated LCFA uptake into WT cardiomyocytes (Fig. 3.1B). 
However, in CD36 KO cardiomyocytes, oligomycin-induced LCFA uptake was 
reduced by 79% to a residual (but significant) level of 1.3-fold above basal.  
AMPK-mediated increase in myocardial LCFA uptake critically depends on CD36
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Figure 3.1 Effects of inhibition of CD36 and AMPK-mediated stimulation on substrate uptake 
by cardiomyocytes from WT and CD36 KO mice  
WT (Ƒ) and CD36 KO cardiomyocytes (Ŷ) were incubated in the absence (Ctrl) or presence of 500 
μmol/l sulfo-N-succinimidyl palmitate (SSP; pre-incubation during the 30 min recovery period), 
centrifuged, washed and resuspended, whereafter uptake rates of palmitate (panel A) and deoxyglucose 
(panel C) were measured. To mimic contraction signaling, cardiomyocytes from WT mice (Ƒ) and 
CD36 KO mice (Ŷ) were incubated for 20 min in the absence (Ctrl) or presence of 15 μmol/l 
oligomycin (Oli) or 100 μmol/l dipyridamole (DPY) which was again followed by measurement of 
palmitate (panel B) and deoxyglucose (panel D) uptake. Values are means ± S.E.M. for 4-7 animals per 
group. *Significantly different from Ctrl (P<0.05). 
 
 
Interestingly, we have recently shown in rat cardiomyocytes that the AMPK 
activation by the adenosine analog 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) results in translocation of both CD36 and FABPpm from 
an intracellular compartment to the sarcolemma [22]. Therefore, this small 1.3-fold 
increase in oligomycin-stimulated LCFA uptake into CD36 KO cardiomyocytes is 
most likely due to translocation of FABPpm. Just like genetic ablation of CD36, 
blocking CD36 with SSP in WT cardiomyocytes completely inhibited oligomycin-
stimulated LCFA uptake (oligomycin: 44.7 ± 2.4 i.e., 2.5-fold basal versus 
oligomycin + SSP: 14.2 ± 0.2 i.e., 0.8-fold basal; n=4, P<0.05), allowing us to 
estimate the contribution of CD36 to LCFA uptake into fully stimulated 
cardiomyocytes (i.e., optimal AMPK activation) to amount to 68%. 
The stimulatory effect of dipyridamole (1.6-fold) on LCFA uptake into WT 
cardiomyocytes was completely absent in CD36 KO cardiomyocytes (Fig. 3.1B).  
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Figure 3.2 Expression of substrate transporters in cardiomyocytes from WT and CD36 KO 
mice 
Protein expression of fatty acid translocase/CD36 (CD36; 88 kDa), plasma membrane fatty acid-
binding protein (FABPpm; 43 kDa), fatty acid-transport protein 1 (FATP1; 63 kDa), FATP4 (70 kDa), 
and glucose transporter 4 (GLUT4; 45 kDa) in cardiomyocytes from WT mice (Ƒ) and CD36 KO mice 
(Ŷ) was determined by Western Blotting followed by densitometry (relative abundance WT set at 1). 
From each sample, 20 μg of myocytes wet mass was taken for electrophoresis. Western Blotting with 
antibodies against caveolin-3 and ȕ-actin further confirmed no differences in protein amount per lane 
(data not shown). Values are means ± S.E.M for 6-10 animals per group. Representative Blots are 
shown. *Significantly different from WT (P<0.05). 
 
 
Together, these findings strongly indicate that AMPK-mediated increase in LCFA 
uptake into the heart is critically dependent on the presence of CD36. 
 
Regulation of glucose uptake in CD36 KO hearts 
Similar to LCFA uptake, the rate of glucose uptake is not different between WT and  
CD36 KO cardiomyocytes under basal conditions (Fig. 3.1C). In line with this, the 
expression of GLUT4 is also not altered in CD36 KO cardiomyocytes (Fig. 3.2). 
SSP has no effect on glucose uptake (Fig. 3.1C), underlining that its inhibitory 
action is restricted to the LCFA uptake process. Oligomycin stimulated glucose 
uptake into CD36 KO (2.9-fold) and WT cardiomyocytes (2.2-fold) to a similar 
extent, while dipyridamole similarly inhibited glucose uptake into both WT (-89%) 
and CD36 KO cardiomyocytes (-87%; Fig. 3.1D). The inhibition of glucose uptake 
by dipyridamole is likely due to a direct interaction of dipyridamole with GLUT4 
[23]. The selective inhibition of oligomycin-stimulated LCFA uptake, but not 
glucose uptake, into CD36 KO cardiomyocytes clearly illustrates that trafficking 
processes are not affected by CD36 ablation, and that AMPK-mediated GLUT4 
translocation remains unaltered in CD36 KO cardiomyocytes. However, this study 
may seem in contrast to results obtained in a working heart model (continuous 
AMPK activation) [7]. In working hearts from CD36 KO mice, glucose oxidation  
AMPK-mediated increase in myocardial LCFA uptake critically depends on CD36
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Figure 3.3 Effects of AMPK-mediated stimulation on the contraction signaling cascade in 
cardiomyocytes from WT and CD36 KO mice  
Cardiomyocytes from WT mice (Ƒ) and CD36 KO mice (Ŷ) were incubated for 20 min in the absence 
(Ctrl) or presence of 15 ȝmol/l oligomycin (Oli) or 100 ȝmol/l dipyridamole (DPY). Phosphorylation of 
AMP-activated protein kinase (AMPK)-Thr172 (panel A) and of acetyl-CoA carboxylase (ACC)-Ser79 
(panel B) was determined by Western Blotting followed by densitometry (relative abundance Ctrl set at 
1). From each sample, 20 μg of myocytes wet mass was taken for electrophoresis. Western Blotting 
with antibodies against caveolin-3 and ȕ-actin further confirmed no differences in protein amount per 
lane (data not shown). Values are means ± S.E.M. for 5-7 animals per group. Representative Blots are 
shown. *Significantly different from Ctrl (P<0.05). 
 
 
was 3-fold upregulated relative to WT hearts to compensate for the drop in 
palmitate oxidation. In fact, we do not think that there is a conflict between our 
study and the study using the working heart model, because the present study only 
excludes that the compensatory increase in glucose oxidation observed in CD36 KO 
working hearts can be explained at the level of glucose transporters and their 
recycling. This leaves open other compensatory mechanisms such as improved 
channeling of glucose metabolites into mitochondria and/or decreased storage of 
glucose into glycogen. 
 
Concluding remarks 
The major conclusions that can be drawn from these observations on cardiac 
substrate uptake in CD36 KO mice are: (i) CD36 contributes significantly to 
facilitating basal LCFA uptake, and its ablation results in compensatory 
upregulation of the myocardial expression of FATP1; (ii) CD36 is almost entirely 
responsible for the AMPK-mediated increase in LCFA uptake which increase is not 
compensated in cardiomyocytes from CD36 KO mice at the level of other LCFA 
transporters. The low rate of LCFA uptake in the working CD36 KO heart will 
likely contribute to the development of cardiac hypertrophy, as is seen in aged 
CD36 KO mice (M. Febbraio, unpublished observation) and human subjects lacking 
this major cardiac LCFA transporter [24]. 
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Abstract 
Enhanced contractile activity increases cardiac long-chain fatty acids (LCFA) and 
glucose uptake via translocation of the substrate transporters fatty acid 
translocase/CD36 and glucose transporter 4 to the sarcolemma, respectively. AMP-
activated protein kinase (AMPK) is proposed to be involved in these translocation 
processes. Furthermore, no studies have been performed on the role of LKB1, a 
kinase with AMPKK activity, on regulation of cardiac LCFA uptake. Using 
different genetically engineered mouse models (AMPKĮ2 kinase-dead, AMPKĮ2 
knockout and LKB1 knockout mice), we tested whether LKB1 and AMPK are 
required for stimulation of LCFA and glucose utilization upon treatment of 
cardiomyocytes with compounds that mimic the metabolic effects of contraction. In 
cardiomyocytes from AMPKĮ2 kinase-dead mice, the stimulating effects of 
oligomycin and AICAR on LCFA and deoxyglucose uptake and LCFA oxidation 
were almost completely lost. Moreover, in cardiomyocytes from AMPKĮ2 and 
LKB1 knockout mice, oligomycin-induced LCFA and glucose uptake were 
completely abolished. However, the stimulatory effect of dipyridamole, another 
compound inducing CD36 translocation in a contraction-mimetic manner, on LCFA 
uptake and oxidation was preserved in cardiomyocytes from AMPKĮ2 kinase-dead 
mice. In conclusion, in the heart there is a signaling axis consisting of LKB1 and 
AMPKĮ2 which activation results in enhanced LCFA and glucose utilization. In 
addition, an unknown dipyridamole-activated pathway, can stimulate cardiac LCFA 
utilization by activating signaling downstream of AMPK. 
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Introduction 
Long-chain fatty acid (LCFA; 60-70%) and glucose (20-30%) are the primary 
substrates for cardiac ATP production [1, 2]. Glucose uptake into cardiomyocytes 
has long been recognized to occur via a protein mediated process involving glucose 
transporter 4 (GLUT4; >70%) and glucose transporter 1 (GLUT1; <30%)  [3]. 
More recently, it has been shown that LCFA uptake is also protein-dependent [4], 
with fatty acid translocase/CD36 (CD36) accounting for 70% of the LCFA uptake 
rate [5, 6]. In isolated cardiomyocytes, contraction induces the translocation of both 
CD36 and GLUT4, within minutes, from an intracellular membrane compartment to 
the sarcolemma [7, 8]. Thus, substrate provision into cardiomyocytes can be rapidly 
upregulated in concert with increased energetic demands. 
As to the signaling pathways involved in contraction-induced translocation of CD36 
and GLUT4 in the heart, there are a number of possible routes, since contraction 
activates a great variety of protein kinases [9, 10]. An important candidate kinase is 
AMP-activated protein kinase (AMPK), because it is rapidly activated by 
contraction and it orchestrates a variety of metabolic actions in heart and skeletal 
muscle [11]. AMPK is a heterotrimeric protein consisting of a catalytic Į subunit 
and two regulatory subunits ȕ and Ȗ. Two isoforms of the Į subunit have been 
identified, i.e., AMPKĮ1 and AMPKĮ2; and also for the other subunits, different 
isoforms are described. Both AMPKĮ1 and AMPKĮ2 are expressed in the heart, of 
which AMPKĮ2 is the predominant subunit [12]. 
Previously, the importance of AMPK activity in glucose utilization by skeletal 
muscle and heart was explored in different genetically manipulated mice. The 
increase in glucose uptake during ischemia [13] and reperfusion [14] was reduced 
in hearts from mice expressing a AMPKĮ2 kinase-dead subunit (AMPK KD) and in 
hearts from AMPKĮ2 knockout (AMPKĮ2 KO) mice [15]. Not only glucose uptake 
but also LCFA oxidation was impaired during perfusion in AMPK KD hearts [14]. 
In skeletal muscle from muscle-specific AMPKĮ2 KD mice [16, 17], AMPKĮ2 KO 
mice  [18] and AMPKȖ3 KO mice [19], 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR)-induced glucose uptake was completely blocked. 
However, contraction-induced glucose uptake into skeletal muscle was not affected 
[17-19] or only partly reduced [16, 20] in these mouse models. Hence, these 
conflicting results cast doubt on the role of AMPK in contraction-induced glucose 
uptake in muscle tissues. 
A number of protein kinases have been proposed to function in contraction 
signaling upstream of AMPK, including LKB1 and calmodulin-dependent protein 
kinase kinase (CaMKK) [11, 21]. In vivo, the upstream kinases LKB1 and 
CaMKKȕ are each regulated differently. In muscle tissue, CaMKKȕ is activated by 
an increase in intracellular Ca2+ [21]. In contrast, LKB1 is constitutively active [22], 
but it can only activate AMPK during conditions at which intracellular AMP is 
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elevated. Namely, AMP-binding to AMPK induces a conformational change within 
the AMPK complex so that Thr172 becomes accessible to phosphorylation by 
LKB1 [23]. Whether CaMKKȕ regulates contraction-stimulated glucose uptake in 
muscle via AMPK activation remains controversial [20, 24]. However, in LKB1 
knockout mice (LKB1 KO), contraction and AICAR-stimulated glucose uptake by 
muscle were reduced [25], as was LCFA oxidation [26]. However, no studies have 
been undertaken to assess the role of LKB1 in regulation of cardiac substrate uptake 
by contraction. 
Pharmacological agents are commonly used to activate AMPK, including AICAR 
[27, 28] and the F1F0-ATPase inhibitor oligomycin [7, 29]. At appropriate 
concentrations these agents stimulate LCFA and glucose uptake into 
cardiomyocytes, by inducing the translocation of CD36 and GLUT4 to the 
sarcolemma, respectively [6, 7, 30, 31]. Importantly, the effects of AICAR and 
oligomycin on LCFA and glucose uptake in cardiomyocytes are not additive to that 
of contraction, suggesting that the signaling pathways activated by these agents 
converge with the contraction signaling pathway to induce CD36 and GLUT4 
translocation. Dipyridamole is another compound that induces CD36 translocation 
in a contraction-mimetic manner, because, just like oligomycin and AICAR, it 
stimulates LCFA uptake into cardiomyocytes in a non-additive manner to 
contraction [32]. In contrast to oligomycin and AICAR, dipyridamole does not 
activate AMPK nor does it stimulate glucose uptake, suggesting that this compound 
acts on a component in the contraction pathway to CD36 translocation downstream 
of AMPK, resulting in a selective increase in LCFA uptake [6, 32].  
Until now, the involvement of AMPK in the regulation of LCFA and glucose 
uptake in the heart has only been deduced from an association between AMPK 
activation by different stimuli, i.e., 4Hz-electrostimulation, biguanide molecules, 
oligomycin and AICAR, and their stimulating action on LCFA and glucose uptake 
into cardiomyocytes [7, 31]. Mice deficient for AMPK or its upstream kinases are 
excellently suited to provide definitive proof for a key role of AMPK in cardiac 
substrate uptake. Of the available mouse models, AMPK KD mice would be most 
suited because in this model both AMPKĮ1 and Į2 activities are reduced [14]. On 
the other hand, in AMPKĮ2 KO mice, Į1 activity is maintained in the heart [33] or 
even increased in skeletal muscle [18], and therefore might allow some residual 
AMPK activation. Furthermore, in cardiomyocytes from LKB1 KO mice, other 
putative AMPKK’s, such as CaMKKȕ, could provide an alternative route to 
activate AMPK in response to contraction. Therefore, we started with 
cardiomyocytes from AMPK KD mice on characterizing AMPK signaling and 
energy metabolism, especially on the responses of these processes towards 
oligomycin, AICAR and dipyridamole. Upon establishment of the overall role of 
AMPK in contraction-induced substrate uptake in AMPK KD mice, we attempted 
Thesis_Habets_v2.pdf   66 30-9-2008   13:39:34
  Crucial role for LKB1 to AMPKĮ2 axis in transporter-mediated cardiac substrate uptake | 67 
 
to answer the questions which Į-isoform of AMPK and which upstream kinase are 
involved. For this purpose, we used AMPKĮ2 KO mice and LKB1 KO mice, and 
studied the effects of oligomycin on glucose and LCFA uptake into cardiomyocytes 
isolated from these mice. Our studies demonstrate that activation of a signaling axis 
involving LKB1 and AMPKD2 results in stimulation of LCFA and glucose uptake 
into cardiomyocytes treated with agents that induce CD36 and GLUT4 
translocation, respectively, in a contraction-mimetic manner. Interestingly, there is a 
signaling pathway activated by dipyridamole which converges with AMPK 
signaling downstream of AMPK, specifically leading to increased LCFA uptake 
and oxidation. 
 
Materials and methods 
Materials 
 [1-14C]palmitic acid, 2-deoxy-D-[1-3H]glucose, [Ȗ-32P] ATP and protein G 
sepharose 4 were obtained from GE Healthcare (Piscataway, NJ, USA). BSA 
(fraction V, essentially fatty acid free), laminin, phloretin, DMSO, oligomycin, 
AICAR and dipyridamole were obtained from Sigma (St. Louis, MO). Liberase 
blendzyme 1 and protease inhibitor cocktail tablets were purchased from Roche 
Diagnostics (Indianapolis, IN). Sulfo-NHS-LC-biotin and immobilized streptavidin 
were from Perbio Science (Etten-Leur, the Netherlands).The antibody directed 
against phosphorylated acetyl-CoA carboxylase (ACC) was from Upstate (Dundee, 
UK), and anti-phospho-AMPK from Cell Signalling (Danvers, MA). Antibodies 
directed against CD36 and GLUT4 were obtained from Chemicon International Inc. 
(Temecula, USA). The antibodies directed against AMPKĮ1 and AMPKĮ2, and the 
SAMS peptide were a gift from Prof. Grahame Hardie (University of Dundee, UK). 
 
Animals 
The following genetically manipulated mouse models were bred separately and 
studied: i) muscle-specific AMPKĮ2 kinase-dead [16] and wild-type (WT) mice 
from the University of Copenhagen, Denmark; ii) AMPKĮ2 knockout [34] and WT 
mice from the Université Paris Descartes, France; and iii) muscle-specific 
LKB1floxed/floxed Cre recombinase+/- [25] and WT mice from the Université 
catholique de Louvain, Belgium. All these mouse models have a C57Bl/6 
background. The Experimental Animal Committee of Maastricht University gave 
approval for all experiments involving animals. 
 
Isolation and pre-incubation of mouse cardiomyocytes 
Adult mouse cardiomyocytes (male mice 2-3 months of age) were isolated using a 
Langendorff perfusion system according to the procedure described by Severson et 
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al. [35], which has been described previously [6]. For all the experiments the 
viability of cardiomyocytes was 60-80% (data not shown). 
Cell suspensions (2.0 ml; 5-10 mg wet mass/ml) were pre-incubated in capped 20-
ml incubation vials either with 0.35% dimethyl sulfoxide (DMSO; Ctrl), 1 μmol/l 
oligomycin, 2 mmol/l AICAR or 100 μmol/l dipyridamole for 20 min at 37°C under 
continuous shaking. At the applied concentrations of oligomycin, AICAR and 
dipyridamole, LCFA uptake rates were found to be maximally stimulated (data not 
shown). 
 
Preparation of cardiomyocyte lysates 
Pellets of cardiomyocytes were obtained by a pulse centrifugation of pre-incubated 
cell suspensions whereafter supernatants were removed. Cardiomyocytes were 
incubated for 1 h with ice-cold lysis buffer containing 50 mmol/l Tris·HCl, pH 7.5, 
1 mmol/l EGTA, 1 mmol/l EDTA, 1% Triton X-100, 1 mmol/l sodium 
orthovanadate, 50 mmol/l sodium fluoride, 5 mmol/l sodium pyrophosphate, 0.27 
mol/l sucrose, 0.1% 2-mercaptoethanol, and Complete protease inhibitor cocktail 
(Roche, 1 tablet per 50 ml). Homogenates were centrifuged at 13,000 g for 10 min 
at 4°C, supernatants were removed, and aliquots were frozen in liquid nitrogen. 
 
Expression of AMPKĮ1, AMPKĮ2, p-AMPK, p-ACC, CD36 and 
GLUT4 in cardiomyocytes 
Cardiomyocyte lysates (20 μg protein) containing sample buffer (62.5 mmol/l Tris-
HCl (pH 6.8), 2 mmol/l EDTA, 20 mmol/l dithiothreitol, 7.5% (wt/vol) SDS, and 
50% sucrose) were subjected to SDS-polyacrylamide gel electrophoresis, followed 
by Western blotting for the detection of total AMPKĮ1 and AMPKĮ2, 
phosphorylation of AMPK and ACC by applying antibodies against AMPKĮ1, 
AMPKĮ2, phospho-AMPKĮ (Thr172) and phospho-ACC (Ser79), according to the 
manufacturer’s instructions. 
These sample buffer-containing cardiomyocyte lysates (20 μg protein) were also 
used for the detection of the relative amounts of the substrate transporters CD36 and 
GLUT4 upon electrophoresis and Western Blotting. Mouse monoclonal anti-CD36 
antibody 1258 and sheep polyclonal anti-GLUT4 antiserum, respectively, were used 
for the detection of these transporters according to manufacturer’s instructions. 
 
AMPKĮ1 and AMPKĮ2 activity in cardiomyocytes 
Cardiomyocyte lysates (75 μg protein) were incubated at 4°C for 1 h on a rotating 
wheel with 40 μl of protein G-sepharose covalently conjugated to 1 μg of AMPKĮ1 
or AMPKĮ2 antibody. The sepharose beads were washed twice with lysis buffer 
containing 0.5 mol/l NaCl and twice with wash buffer (50 mmol/l Tris·HCl, pH 7.5, 
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0.1 mmol/l EGTA, and 0.1% 2-mercaptoethanol). Phospho-incorporation into the 
SAMS peptide was then measured in a total assay volume of 50 μl consisting of 50 
mmol/l Tris·HCl, pH 7.5, 0.1 mmol/l EGTA, 0.1% 2-mercaptoethanol, 10 mmol/l 
magnesium acetate, 0.2 mmol/l SAMS peptide, 0.2 mmol/l AMP, 0.2 mmol/l ATP 
and 2μCi [32P]ATP. The assays were carried out at 30°C and after 20 min, 25 μl of 
the reaction mixture was spotted onto p81 membranes. The papers were washed 
four times for 15 min with 1% phosphoric acid, once with acetone and dried. The 
radioactivity was measured by scintillation counting. 
 
Phosphocreatine, creatine and adenosine phosphate contents in 
cardiomyocytes 
Pellets of cardiomyocytes were obtained by a pulse centrifugation of pre-incubated 
cell suspensions whereafter supernatants were removed. Cell pellets were freeze 
dried followed by extraction with 1.3 M perchloric acid and neutralization with 1 M 
KHCO3. Thereafter, the cellular contents of phosphocreatine, creatine, ATP, ADP 
and AMP were determined by high-performance liquid chromatography as 
described previously [36]. 
 
Palmitate and deoxyglucose uptake into cardiomyocytes 
To study palmitate and deoxyglucose uptake, 0.5 ml of a mixture of  [1-
14C]palmitate/BSA complex  and [1-3H]deoxyglucose was added to pre-incubated 
cell suspensions at the start of the incubations with a final concentration of 100 
μmol/l palmitate and 100 μmol/l deoxyglucose with a corresponding palmitate/BSA 
ratio of 0.3 [5]. Cellular uptake of 14C-palmitate (3-min incubation) and 3H-
deoxyglucose (3-min incubation) was determined upon washing the cells two times 
for 2 min at 45 g in an ice-cold stop solution containing 0.2 mmol/l phloretin. The 
radioactivity of the cell pellets was measured by scintillation counting. 
 
Palmitate oxidation in cardiomyocytes 
To study palmitate oxidation, 0.5 ml of a mixture of  [1-14C]palmitate/BSA 
complex  was added to pre-incubated cell suspensions at the start of the incubations 
with a final concentration of 100 μmol/l palmitate with a corresponding 
palmitate/BSA ratio of 0.3 [5]. The oxidation of palmitate (20-min incubation) into 
CO2 was determined after addition of perchloric acid (final concentration 0.5 M) to 
cell suspensions. Production of 14CO2 was measured after base trapping [37]. 
 
Sarcolemmal CD36 and GLUT4 content of cardiomyocytes 
Directly after isolation, cell suspensions of cardiomyocytes were plated in laminin-
coated (20 μg/ml) 35 mm culture plates. After 1 h the cells were incubated with 
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0.35% DMSO (Ctrl) or 1 μmol/l oligomycin for 20 min at 37°C. As previously 
described [38], cells were biotinylated with the cell-permeable reagent sulfo-NHS-
LC-biotin in bicarbonate medium at a final concentration of 1 mg/ml for 45 min at 
4°C. Cells were treated with ice-cold glycine in bicarbonate medium (100mM). 
After a brief wash with ice-cold bicarbonate medium, cells were lysed by scraping 
in 250 μl lysis buffer. The lysates were incubated on ice for 1 h, and centrifuges for 
10 min at 13,000 g at 4°C. A 15 μl supernatant sample was used as total lystate 
sample for Western Blotting, and 150 μl was then incubated overnight with 
streptavidin beads. Samples were briefly centrifuged, and the beads were washed 
twice with lysis buffer. The biotinylated proteins were eluted by incubation of the 
streptavidin beads for 5 min at 95°C in sample buffer. Samples were subjected to 
SDS-polyacrylamide gel electrophoresis, followed by Western Blotting for the 
detection of CD36 and GLUT4, as previously described. 
 
Data presentation and statistics 
All data are presented as means ± S.E.M. for the indicated number of 
cardiomyocyte preparations. Statistical difference between means was analyzed by 
the paired Student’s t test. P values  0.05 were considered significant. 
 
Results 
AMPK dynamics in WT and AMPK KD cardiomyocytes: 
confirmation of the AMPK KD phenotype 
Total expression of AMPKĮ1 and AMPKĮ2 were not significantly different 
between WT and AMPK KD cardiomyocytes treated without or with oligomycin, 
AICAR or dipyridamole (Fig. 4.1A). AMPK-Thr172 phosphorylation in quiescent 
cardiomyocytes (referred to as basal/control) was not significantly altered in AMPK 
KD cardiomyocytes (Fig. 4.1A). Oligomycin markedly increased the 
phosphorylation of AMPK, i.e., by 5.0-fold (± 0.6; n=5, P<0.05) in wild-type (WT) 
cardiomyocytes, which increase was modestly reduced (to 3.4-fold ± 0.5; n=5, 
P<0.05) in oligomycin-treated AMPK KD cardiomyocytes. Hence, the mutant Į 
subunit in AMPK KD cardiomyocytes retains the ability to be phosphorylated at 
Thr172, as observed in the presence of oligomycin, albeit to a lesser extent. AICAR 
treatment resulted in a modest (1.5-fold ± 0.2; n=5, P<0.05) increase in AMPK-
Thr172 phosphorylation in WT cardiomyocytes, which was reduced to 1.3-fold (± 
0.1; n=5, P<0.05) in AMPK KD cardiomyocytes (Fig. 4.1A). In contrast, 
dipyridamole had no effect on AMPK-Thr172 phosphorylation, neither in WT nor 
in AMPK KD cardiomyocytes. 
With respect to AMPK’s major target ACC, treatment of WT cardiomyocytes with 
oligomycin (6.4-fold ± 0.9; n=5, P<0.05) or AICAR (5.5-fold ± 1.1; n=5, P<0.05)  
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Figure 4.1 Influence of contraction-mimetic stimuli on phosphorylation of AMPK, ACC, and on 
AMPKĮ1 and Į2 expression and activity in cardiomyocytes from WT and AMPK KD mice  
WT (Ƒ) and AMPK KD cardiomyocytes (Ŷ) were incubated for 20 min in the absence (Ctrl) or 
presence of 1 μmol/l oligomycin (Oli), 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR) or 100 μmol/l dipyridamole (DPY), whereafter AMPKĮ1, AMPKĮ2, phospho-AMPK 
(Thr172), phospho-acetyl-CoA carboxylase (ACC; Ser79) (panel A), and the activity of AMPKĮ1 
(panel  B) and AMPKĮ2 (panel C) were determined. A representative Western Blot is presented out of 
5 experiments with different cardiomyocyte preparations. Data are means ± S.E.M. for 5-6 experiments 
carried out with different cardiomyocyte preparations. *Significantly different from Ctrl (P<0.05); 
^significantly different from WT (P<0.05). 
 
 
but not dipyridamole, increased its phosphorylation at Ser79, in agreement with our 
previous observations in rat cardiomyocytes [7, 32]. Under all conditions, Ser79 
phosphorylation of ACC was decreased in AMPK KD cardiomyocytes (Fig. 4.1A). 
Under basal conditions, this decrease was total, whereas during oligomycin (-81% ± 
1, n=5; P<0.05) or AICAR treatment (-88% ± 6; n=5, P<0.05) this decrease was 
near-total. These observations confirm the phenotype of the AMPK KD 
cardiomyocytes in that AMPK’s activity towards ACC is greatly reduced. The 
discrepancy between the modest AMPK-Thr172 phosphorylation and the potent 
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ACC-Ser79 phosphorylation upon AICAR treatment of WT cardiomyocytes (Fig. 
4.1A) may suggest that AMPK-independent mechanisms could contribute to 
AICAR-induced ACC-Ser79 phosphorylation. However, the large reduction in 
AICAR-induced ACC phosphorylation in AMPK KD cardiomyocytes indicates that 
AMPK is mainly responsible for ACC phosphorylation upon AICAR treatment.  
Phosphorylation of ACC by AMPK is the resultant of combined Į1 and Į2 activity. 
AMPKĮ1 activity was reduced during basal conditions in AMPK KD 
cardiomyocytes by 46% compared to WT cardiomyocytes (Fig. 4.1B). Treatment 
with oligomycin increased AMPKĮ1 activity by 5.1-fold in WT cardiomyocytes. In 
AMPK KD cardiomyocytes, oligomycin-induced AMPKĮ1 activity was reduced by 
67%, but still 1.7-fold above basal AMPKĮ1 activity in WT cardiomyocytes. 
AICAR and dipyridamole did not change AMPKĮ1 activity, neither in WT nor in 
AMPK KD cardiomyocytes compared to the basal state (Fig. 4.1B). Hence, these 
measurements confirmed that overexpression of the kinase-dead AMPKĮ2 mutant 
markedly reduced the AMPKĮ1 activity [14], as observed under basal conditions 
and after oligomycin treatment of cardiomyocytes.  
During basal conditions, AMPKĮ2 activity was reduced by 46% in AMPK KD 
cardiomyocytes (Fig. 4.1C). Oligomycin increased AMPKĮ2 activity by 10.8-fold 
in WT cardiomyocytes. This increase was almost completely blunted in AMPK KD 
cardiomyocytes, so that AMPKĮ2 activity upon oligomycin treatment was lower 
than in WT cardiomyocytes under basal conditions. AICAR treatment increased 
AMPKĮ2 activity by 2.3-fold in WT cardiomyocytes, which effect was completely 
blunted in AMPK KD cardiomyocytes. Dipyridamole did not change AMPKĮ2 
activity in WT nor in AMPK KD cardiomyocytes (Fig. 4.1C).  
Integrating the findings concerning activation of both Į-isoforms in cardiomyocytes 
demonstrates that oligomycin treatment induces both Į1 and Į2 activity of AMPK, 
whereas AICAR only induces AMPKĮ2 activity. Furthermore, all the oligomycin 
and AICAR-induced signaling responses involving AMPK were largely absent in 
AMPK KD cardiomyocytes. 
 
Expression of CD36 and GLUT4 in WT and AMPK KD 
cardiomyocytes 
Expression of CD36 and GLUT4 were not significantly different between WT and 
AMPK KD cardiomyocytes (Fig. 4.2), indicating that the cardiac transport capacity 
for LCFA and glucose is not altered due to the dominant-negative overexpression of 
mutant AMPKĮ2. 
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Figure 4.2 Total GLUT4 and CD36 expression in cardiomyocytes from WT and AMPK KD 
mice 
Protein expression of fatty acid translocase/CD36 (CD36; 88 kDa) and glucose transporter 4 (GLUT4; 
45 kDa) were detected by Western Blotting in lysates of different WT and AMPK KD cardiomyocyte 
preparations (n=5). A representative Western Blot is presented.  
 
 
Contents of phosphocreatine, creatine and adenosine phosphates 
in WT and AMPK KD cardiomyocytes 
Basal phosphocreatine content in cardiomyocytes was not significantly different 
between WT and AMPK KD mice (Table 4.1). Treatment with oligomycin, AICAR 
or dipyridamole did not significantly change the phosphocreatine contents neither in 
WT nor in AMPK KD cardiomyocytes. During basal conditions and after treatment 
with AICAR and dipyridamole, creatine levels were similar in WT and AMPK KD 
cardiomyocytes. Treatment of cardiomyocytes with oligomycin significantly 
increased the creatine content in both mouse groups at the expense of 
phosphocreatine.  
The intracellular contents of ATP, ADP AMP were not significant different 
between WT and AMPK KD cardiomyocytes under control conditions or treated 
with AICAR or dipyridamole. Oligomycin treatment significantly decreased the 
ATP content and concomitantly increased the AMP and ADP content in WT and 
AMPK KD cardiomyocytes, in agreement with the inhibiting action of this 
compound on the F1F0-ATPase. These effects were slightly larger in AMPK KD 
cardiomyocytes (Table 4.1), indicating modest problems with ATP homeostasis in 
the hearts of these transgenic animals under increased metabolic demands. ZMP 
levels were not detectable in cardiomyocytes during basal, oligomycin and 
dipyridamole treatments, and were increased after AICAR stimulation similarly in 
WT and AMPK KD cardiomyocytes (data not shown).Taken together, the energy 
reserve of AMPK KD cardiomyocytes is in almost all instances not different from 
that of WT cardiomyocytes under basal conditions, as well as in the presence of 
contraction-mimetic stimuli. Hence, the viability of these cells is not affected by the 
inactivation of AMPK. Moreover, energy demanding processes, such as CD36 and 
GLUT4 translocation to the sarcolemma, presenting the underlying events for 
increased LCFA and glucose uptake in the presence of the applied stimuli, remain 
operable in AMPK KD cardiomyocytes.  
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Table 4.1 Influence of contraction-mimetic stimuli on intracellular contents of high-energy 
phosphates in cardiomyocytes from WT and AMPK KD mice 
 
Parameter      WT  AMPK KD 
 
PCr 
Ctrl  116.2 ± 16.8 171.3 ± 29.2 
Oli     78.5 ± 9.70 107.8 ± 9.77 
AICAR  109.5 ± 34.7 128.0 ± 26.3 
DPY  116.7 ± 13.0   173.5 ± 35.6 
 
Cr 
Ctrl      3.0 ± 0.6     3.7 ± 0.7 
Oli    22.2 ± 3.2*   17.4 ± 2.7* 
AICAR         6.6 ± 0.6     5.1 ± 0.3 
DPY      5.1 ± 1.1     4.4 ± 0.6 
 
ATP 
Ctrl    18.5 ± 2.0   17.4 ± 2.5 
Oli       7.7 ± 1.5*     5.0 ± 0.4*^ 
AICAR    18.8 ± 6.4      17.2 ± 2.6 
DPY    15.3 ± 1.7     15.3 ± 4.3 
 
ADP 
Ctrl      3.2 ± 0.4     3.5 ± 0.6 
Oli      7.3 ± 1.5*     5.5 ± 0.8*^ 
AICAR          3.2 ± 1.0     3.7 ± 0.4 
DPY      3.2 ± 0.7     4.0 ± 0.6 
 
AMP 
Ctrl      0.5 ± 0.1     0.5 ± 0.1 
Oli      1.5 ± 0.3*     2.8 ± 0.5*^ 
AICAR         0.5 ± 0.1     0.5 ± 0.1 
DPY      0.7 ± 0.1     0.6 ± 0.1 
 
 
WT and AMPK KD cardiomyocytes were incubated for 20 min in the absence (Ctrl) or presence of 1 
μmol/l Oligomycin (Oli), 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) or 100 
μmol/l dipyridamole (DPY), after which intracellular levels of phosphocreatine (PCr), creatine (Cr), 
ATP, ADP and AMP were determined. Values (ȝmol/g dry mass) are means ± S.E.M. from 5 
experiments carried out with different cardiomyocyte preparations. *Significantly different from Ctrl 
(P<0.05) ; ^significantly different from WT (P<0.05). 
 
Even in oligomycin-treated AMPK KD cardiomyocytes, which display a modestly 
larger drop in ATP content compared with their WT counterparts, this further 
reduction in ATP is not limiting for CD36 and GLUT4 translocation, because we 
also observed stimulation of substrate uptake in WT cardiomyocytes treated with 5 
ȝM oligomycin, reducing the ATP content to below 5 ȝmol/g dry mass (data not 
shown). In case of impaired metabolic responses (see below) in AMPK KD 
cardiomyocytes upon treatment with oligomycin, AICAR or dipyridamole, these 
impairments cannot be attributed to the inability of these cells to mobilize CD36 
and GLUT4. 
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CD36-mediated palmitate and GLUT4-mediated deoxyglucose 
uptake into WT and AMPK KD cardiomyocytes 
In WT cardiomyocytes, treatment with oligomycin, AICAR or dipyridamole 
enhanced LCFA uptake by 1.6-fold, 1.6-fold or 1.5-fold, respectively (Fig. 4.3A). 
Deoxyglucose uptake into WT cardiomyocytes was enhanced by 3.2-fold or 1.8-
fold, respectively, whereas dipyridamole treatment lowered deoxyglucose uptake (-
48%; Fig. 4.3A). The effects of AICAR or dipyridamole on LCFA uptake and that 
of AICAR on deoxyglucose uptake were non-additive to those of oligomycin (Fig. 
4.3A), indicating that all three pharmacological stimuli use the same mechanism to 
stimulate the uptake of both substrates into WT cardiomyocytes. 
In order to investigate if this mechanism includes a translocation of CD36 and 
GLUT4 from intracellular stores to the sarcolemma, as established in rat 
cardiomyocytes using subcellular fractionation [7], we used a cell surface 
biotinylation assay. Oligomycin treatment resulted in an increase in sarcolemmal 
contents of CD36 and GLUT4, amounting to 1.9- and 3.3-fold, respectively, 
whereas the total cellular content of both transporters did not change as a result of 
this treatment (Fig. 4.3B). These increases in cell surface substrate transporter 
content closely paralleled the oligomycin-induced increases in substrate uptake 
(Fig. 4.3A), indicating that CD36 and GLUT4 translocation are responsible for 
stimulation of LCFA and deoxyglucose uptake upon treatment of cardiomyocytes 
with this compound. In combination of the non-additive effects of the three stimuli 
on substrate uptake, it is concluded that, besides oligomycin, also AICAR induces 
CD36 and GLUT4 translocation, and that dipyridamole selectively induces the 
translocation of CD36. 
Palmitate uptake into quiescent cardiomyocytes was not significantly different 
between WT and AMPK KD cardiomyocytes (Fig. 4.3C). In addition, basal 
deoxyglucose uptake was similar between WT and AMPK KD cardiomyocytes 
(Fig. 4.3D). Together, these observations indicate that AMPK activity is not 
required for substrate uptake into quiescent cardiomyocytes. Treatment of WT 
cardiomyocytes with oligomycin and AICAR increased palmitate uptake by 1.9-
fold and 1.6-fold, respectively, and deoxyglucose uptake by 2.6-fold and 1.6-fold, 
respectively, all of which effects were completely inhibited in AMPK KD 
cardiomyocytes (Fig. 4.3C and 4.3D). Dipyridamole significantly increased 
palmitate uptake into both WT and AMPK KD cardiomyocytes by 1.7-fold and 1.6-
fold, respectively (Fig. 4.3C). In contrast, dipyridamole reduced deoxyglucose 
uptake into WT cardiomyocytes (-50%) and AMPK KD cardiomyocytes (-52%; 
Fig. 4.3D), in agreement with earlier observations in cardiomyocytes from rat [32] 
and mouse [6]. 
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Figure 4.3 Influence of contraction-mimetic stimuli on CD36 and GLUT4-mediated palmitate 
and deoxyglucose uptake, respectively, and on palmitate oxidation in cardiomyocytes from 
WT and AMPK KD mice  
Panel A: Different cardiomyocytes preparations (n=4) were incubated for 20 min in the absence (Ctrl) 
or presence of  1 μmol/l oligomycin (Oli) 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR), 100 μmol/l dipyridamole (DPY), or in the combinations indicated, whereafter uptake rates of 
14C-palmitate (Ƒ) and 3H-deoxyglucose (Ŷ) were measured. Panel B: Different cardiomyocytes 
preparations (n=5) were incubated for 20 min in the absence (Ctrl) or presence of 1 μmol/l oligomycin 
(Oli), whereafter biotin-labeled (cell surface) fatty acid translocase/CD36 (CD36) and total cellular 
CD36 (upper panel) and biotin-labeled (cell surface) glucose transporter 4 (GLUT4) and total cellular 
GLUT4 were determined. A representative Western Blot is displayed. Panels C, D and E: WT (Ƒ) and 
AMPK KD cardiomyocytes (Ŷ) were incubated for 20 min in the absence (Ctrl) or presence of 1 μmol/l 
Oli, 2 mmol/l AICAR or 100 μmol/l DPY whereafter uptake rates of 14C-palmitate (panel C) and 3H-
deoxyglucose (panel D), as well as rates of 14C-palmitate oxidation (measured as 14CO2 production; 
panel E) were measured. With respect to measurement of substrate uptake (panels C and D), data are 
means ± S.E.M. for 6-8 experiments carried out with different cardiomyocyte preparations, and with 
respect to measurement of palmitate oxidation, data are means ± S.E.M. for 5 experiments. 
*Significantly different from Ctrl (P<0.05); ^significantly different from WT (P<0.05). 
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Taken together, these results indicate that AMPK activity regulates oligomycin and 
AICAR-induced CD36 translocation/palmitate uptake and GLUT4 
translocation/deoxyglucose uptake. However, AMPK is not involved in the 
substrate-uptake effects of dipyridamole. 
 
Palmitate oxidation in WT and AMPK KD cardiomyocytes 
Rates of basal palmitate oxidation were similar in AMPK KD cardiomyocytes and 
WT cardiomyocytes (Fig. 4.3E). Upon oligomycin or AICAR treatment, palmitate 
oxidation was significantly increased in WT cardiomyocytes by 4.5-fold and 1.6-
fold, respectively, and in AMPK KD cardiomyocytes these effects were reduced by 
49% or completely blunted, respectively. Dipyridamole-induced palmitate oxidation 
was increased by 6.3-fold in WT cardiomyocytes and by 6.7-fold in AMPK KD 
cardiomyocytes (Fig. 4.3E). Hence, AMPK regulates AICAR-induced palmitate 
oxidation entirely, and oligomycin-induced palmitate oxidation largely, but is not 
involved in dipyridamole-induced palmitate oxidation. 
 
AMPK activation in WT versus AMPK KD, AMPKĮ2 KO and LKB1 
KO cardiomyocytes treated with oligomycin 
In case of each of the three genetically manipulated mouse models, cardiomyocytes 
from WT littermates were taken as control. In cardiomyocytes from all three control 
mouse strains, oligomycin treatment induced a >5-fold increase in AMPK-Thr172 
and ACC-79 phosphorylation (Fig. 4.4A), in agreement with data from Fig. 4.1. As 
also displayed in Fig. 4.1, oligomycin-induced Thr172 phosphorylation of the KD 
mutant of AMPK was only modestly (32%) decreased compared to WT. In contrast, 
in AMPKĮ2 KO and LKB1 KO cardiomyocytes oligomycin-induced Thr172 
phosphorylation was markedly reduced or completely abolished, respectively (Fig. 
4.4A). When regarding oligomycin-induced ACC-Ser79 phosphorylation in 
cardiomyocytes from the three genetically manipulated models, this is largely 
reduced in AMPK KD (by 81 % ± 1; n=4) and AMPKĮ2 KO (by 71% ± 12; n=4) 
cardiomyocytes, and almost completely absent in LKB1 KO cardiomyocytes. 
Hence, in AMPKĮ2 KO cardiomyocytes AMPK activation is largely reduced but 
not completely absent due to the residual presence of AMPKĮ1, and in LKB1 KO 
cardiomyocytes AMPK signaling is almost entirely blunted. 
 
Palmitate and deoxyglucose uptake into WT versus AMPK KD, 
AMPKĮ2 KO and LKB1 KO cardiomyocytes after oligomycin 
stimulation 
In all three mouse models (AMPK KD, AMPKĮ2 KO and LKB1 KO), basal 
palmitate and deoxyglucose uptake rates into cardiomyocytes from genetically  
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Figure 4.4 Influence of oligomycin on phosphorylation of AMPK and ACC in cardiomyocytes 
and on palmitate and deoxyglucose uptake into cardiomyocytes from WT, AMPK KD, 
AMPKĮ2 KO and LKB1 KO mice 
Cardiomyocytes from WT (Ƒ) and genetically manipulated mice (Ŷ) were incubated for 20 min in the 
absence (Ctrl) or presence of 1 μmol/l oligomycin (Oli), whereafter phospho-AMPK (Thr172), 
phospho-acetyl-CoA carboxylase (ACC; Ser79; panel A), and uptake rates of 14C-palmitate (panel B) 
and 3H-deoxyglucose (panel C) were determined. A representative Western Blot is presented out of 4-5 
experiments with cardiomyocytes from each of the genetically manipulated mice models and their WT 
littermates. Note that the upper band in the p-AMPK Blot likely represents albumin, which is present 
abundantly in the cardiomyocyte lysates. Albumin, like AMPK, has a molecular mass of ~60 kDa. Data 
are means ± S.E.M. for 3-8 experiments carried out with different cardiomyocyte preparations. 
*Significantly different from Ctrl (P<0.05); ^significantly different from WT (P<0.05). 
 
 
manipulated mice did not differ from the uptake rates into cardiomyocytes from 
WT mice (Fig. 4.4B and 4.4C). Oligomycin treatment resulted in similar increases 
in palmitate uptake into cardiomyocytes from WT littermates from each of the three 
genetically manipulated models, amounting to 1.9-fold, 1.4-fold and 1.6-fold, 
respectively (Fig. 4.4B). Also the oligomycin-induced increases in deoxyglucose 
uptake into WT cardiomyocytes from all three models were in a similar range, i.e., 
by 2.6-fold, 3.0-fold and 2.6-fold respectively (Fig. 4.4C). Both oligomycin-
induced palmitate and deoxyglucose uptake into cardiomyocytes were completely 
abrogated in cardiomyocytes from all three genetically manipulated mouse models. 
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Discussion 
Until now, the evidence for the involvement of AMPK in contraction-induced 
LCFA and glucose uptake into the heart was only based on association between 
AMPK activation by different stimuli and their stimulating action on LCFA uptake 
into cardiomyocytes [7], while there is no information about the involvement of 
LKB1. Using mouse models deficient for AMPK and LKB1, we sought to obtain 
direct evidence whether, or not, the LKB1 - AMPK signaling axis is involved in 
regulation of cardiac substrate uptake by oligomycin, AICAR or dipyridamole, i.e., 
agents that induce CD36 translocation in a contraction-mimetic manner. Using 
these genetically engineered mouse models, the following novel findings have been 
made. (i) Oligomycin and AICAR-stimulated LCFA uptake and oxidation, and 
glucose uptake into cardiomyocytes are almost completely dependent on AMPK. 
(ii) Oligomycin-stimulated LCFA and glucose uptake into cardiomyocytes is 
dependent on the presence of LKB1 and AMPKĮ2. (iii) In contrast, AMPK is not 
involved in dipyridamole-stimulated LCFA uptake and oxidation by 
cardiomyocytes. Collectively, our findings reveal that cardiac substrate utilization 
induced by contraction-mimetic stimuli is dependent on signaling through LKB1 
and AMPKĮ2. In addition, an unknown pathway, independent of AMPKĮ2, can 
stimulate LCFA but not glucose utilization. 
 
Involvement of AMPK in induction of LCFA and glucose uptake 
and LCFA oxidation by oligomycin or AICAR 
Based on their ability to induce CD36 and GLUT4 translocation in a contraction-
mimetic manner, oligomycin and AICAR were used to investigate the involvement 
of AMPK in contraction-induced substrate utilization in the heart. In wild-type 
cardiomyocytes, oligomycin and AICAR displayed differential actions towards 
activation of each of the Į-isoforms of AMPK. Both oligomycin and AICAR induce 
the activation of AMPKĮ2, but only oligomycin additionally induces Į1 activation. 
Because both compounds stimulate uptake of LCFA and glucose and LCFA 
oxidation, Į2 activation seems to be sufficient for these metabolic effects (Fig. 4.5). 
Moreover, the degree of Į2 activation is proportional with the degree of stimulation 
of glucose uptake and LCFA oxidation, with oligomycin having the larger effect in 
comparison to AICAR. For LCFA uptake this is less obvious, but in earlier studies 
oligomycin-induced LCFA uptake into cardiomyocytes was markedly larger than 
that induced by AICAR [7]. 
AMPK KD and AMPKĮ2 KO mice were used to investigate the overall and 
isoform-specific involvement of AMPK in regulation of cardiac substrate 
utilization. First, we confirmed that in AMPK KD cardiomyocytes 
oligomycin/AICAR-induced activation of both Į1 and Į2 isoforms was at least 
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Figure 4.5 Hypothetical scheme of the involvement of AMPKĮ1/Į2 and LKB1 in stimulation of 
LCFA and glucose uptake and LCFA oxidation by contraction and contraction-mimetic agents  
Under basal conditions, the majority of the glucose transporter 4 (GLUT4) and ~50% of fatty acid 
translocase/CD36 (CD36) is present in intracellular stores (recycling endosomes) with the remaining 
portion of both transporters at the sarcolemma. The onset of contraction results in elevation of 
intracellular AMP and cyclic-AMP (c-AMP) levels. Elevation of AMP stimulates LKB1-mediated 
phosphorylation of the AMPK isoforms Į1 and Į2. Elevation of c-AMP results in activation of protein 
kinase A (PKA). Both activated AMPKĮ1/Į2 and PKA directly phosphorylate acetyl-CoA carboxylase 
(ACC), resulting in increased mitochondrial ȕ-oxidation (ȕ-ox) of long-chain fatty acids (LCFA). 
AMPKĮ2, but not Į1 or PKA, is also involved in contraction-induced uptake of LCFA and glucose, 
specifically, AMP-induced LKB1-mediated activation of AMPKĮ2 results in vesicle-mediated 
translocation of CD36 and GLUT4 from the recycling endosomes to the sarcolemma. Treatment of 
cardiomyocytes with oligomycin (Oli) results in elevation of AMP and subsequent AMPKĮ1/Į2 
activation, and finally in CD36 and GLUT4 translocation from contraction-responsive recycling 
endosomal subcompartments, as well as stimulation of ȕ-ox. Treatment of cardiomyocytes with 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR) results in activation of AMPKĮ2, and 
thereafter in CD36 and GLUT4 translocation from contraction-responsive recycling endosomes, as well 
as stimulation of ȕ-ox. Treatment of cardiomyocytes with dipyridamole (DPY) results in elevation of c-
AMP and subsequent activation of PKA and ACC, and finally in increased ȕ-ox. Separately, 
dipyridamole activates an unknown protein kinase (hypothetical target of dipyridamole; TOD) 
downstream of AMPKĮ2 at the signaling branch specifically leading to CD36 translocation from 
contraction-responsive recycling endosomes. 
 
 
greatly reduced, and that in both AMPK KD and AMPKĮ2 KO cardiomyocytes 
oligomycin/AICAR-induced overall AMPK activation was completely absent. 
When considering cardiac substrate utilization, almost all effects of oligomycin and 
AICAR on LCFA uptake and oxidation and glucose uptake in AMPK KD 
cardiomyocytes were blunted, indicating that Į1 and/or Į2 activation are necessary 
in these processes. The only metabolic response that was not completely absent in 
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AMPK KD cardiomyocytes is oligomycin-induced LCFA oxidation, which could 
be explained by the residual Į1 activation/ACC phosphorylation in the presence of 
oligomycin. This residual Į1 activation was not sufficient to sustain oligomycin-
induced LCFA and glucose uptake. This finding, in combination with the 
observation that Į2 activation is sufficient to allow AICAR-induced LCFA and 
glucose uptake, suggests that solely Į2 activation is involved in the enhanced 
uptake of both LCFA and glucose into the heart. This notion is confirmed by the 
observation that in AMPKĮ2 KO cardiomyocytes oligomycin-induced LCFA and 
glucose uptake are entirely blunted. Together, the combined data obtained with 
cardiomyocytes from AMPK KD and AMPKĮ2 KO mice demonstrate that (i) Į2, 
but not Į1 activation results in stimulation of cardiac LCFA and glucose uptake 
through translocation of CD36 and GLUT4 translocation, respectively, and that (ii) 
both Į1 and Į2 activity are involved in stimulation of LCFA oxidation, with Į2 
having the largest contribution. 
 
LKB1 is the upstream kinase involved in AMPK-mediated 
myocardial LCFA and glucose uptake 
LKB1 has been proven to be the main kinase upstream of AMPK in the heart [39]. 
The involvement of LKB1 in AMPK-dependent substrate utilization in the heart has 
not been investigated. The present study, in which we observed that the stimulatory 
effects of oligomycin on LCFA and glucose uptake were lost in LKB1 KO 
cardiomyocytes, shows for the first time the full dependence of oligomycin-induced 
LCFA and glucose uptake into cardiomyocytes on LKB1 activity. Hence, the LKB1 
- AMPKĮ2 axis is necessary for stimulation of LCFA and glucose uptake into the 
heart upon stimulation with agents that induce the translocation of both CD36 and 
GLUT4 in a non-additive manner to contraction.  
 
Dipyridamole-stimulated LCFA uptake and oxidation in 
cardiomyocytes is independent of AMPK 
Upon establishment that the phosphodiesterase inhibitor dipyridamole stimulated 
LCFA uptake into cardiomyocytes [40], we discovered that the underlying 
mechanism involved a translocation of CD36 to the sarcolemma. Surprisingly, the 
similarly effects of dipyridamole on LCFA uptake and CD36 translocation were 
unrelated to elevation of intracellular cyclic AMP/GMP since other 
phosphodiesterase inhibitors failed to increase LCFA uptake [41]. In addition, 
dipyridamole was identified to stimulate LCFA uptake in a non-additive manner to 
contraction. However, in contrast to oligomycin and AICAR, dipyridamole 
treatment did not induce AMPK activation, eluding to the notion that this 
compound interacts with the AMPK signal transduction pathway downstream of 
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AMPK [6, 32]. Accordingly, in the present study we found no effect of 
dipyridamole on AMPK-Thr172 and ACC-Ser79 phosphorylation, nor on Į1 and Į2 
activity. Moreover, we have previously shown that dipyridamole’s ability to induce 
CD36 translocation was not accompanied by an induction of GLUT4 translocation 
in cardiomyocytes [6, 32]. In agreement, in the present study dipyridamole 
stimulated glucose uptake neither in wild-type cardiomyocytes nor in 
cardiomyocytes from AMPK KD mice. In AMPK KD cardiomyocytes, 
dipyridamole retained its stimulatory action on LCFA uptake, adding further 
evidence to the notion that dipyridamole activates a protein kinase downstream of 
AMPK specifically leading to CD36 translocation. The retention of dipyridamole-
stimulated LCFA uptake in AMPK KD cardiomyocytes also illustrates that the 
subcellular translocation machinery is not negatively affected by the large reduction 
in AMPK activity. 
Besides LCFA uptake, LCFA oxidation is retained in dipyridamole-stimulated 
AMPK KD cardiomyocytes. It should be noted that the stimulation of LCFA 
oxidation by dipyridamole (5.2-fold) greatly exceeds its stimulatory action on 
LCFA uptake (1.7-fold), indicating that dipyridamole, just like 
contraction/oligomycin, redirects the incoming LCFA efficiently into mitochondrial 
E-oxidation. Unlike the non-involvement of the cyclic AMP-elevating action of 
dipyridamole in stimulation of LCFA uptake, the elevation of intracellular cyclic 
AMP levels is definitely involved in dipyridamole’s stimulation of LCFA oxidation 
in cardiomyocytes, because also other phosphodiesterase inhibitors or cell-
permeable cyclic AMP analogs were shown to redirect the incoming LCFA 
efficiently towards mitochondrial E-oxidation [41]. Hence, the combined ability of 
dipyridamole to activate a kinase downstream of AMPK and to induce cyclic AMP-
dependent signaling perfectly mimics the combined ability of 
contraction/oligomycin to increase simultaneously the activity of AMPK and ACC. 
Just like with contraction/oligomycin, the mechanism by which dipyridamole 
treatment stimulates E-oxidation may include activation of ACC. Namely, 
dipyridamole’s stimulatory action on cyclic AMP can be related to earlier 
observations that cyclic-AMP-activated protein kinase A phosphorylates purified 
ACC in in vitro kinase assays [42, 43]. However, unlike contraction/oligomycin, 
this is not associated with phosphorylation of ACC at Ser79 (see Fig. 4.1A). 
Possibly, dipyridamole treatment enhances phosphorylation of ACC at Ser77 and 
Ser1200, just like protein kinase A did in in vitro kinase assays [42]. In view that 
the combined evidence from previous work [6, 32] and the present study indicates 
that dipyridamole acts in an AMPK-independent manner to alter LCFA but not 
glucose utilization, it appears that other signaling components involved in 
stimulating LCFA uptake and oxidation remain to be identified.  
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Conclusions 
The onset of contractions results in a rapid rise in the concentration of a number of 
second messengers in cardiac myocytes, such as AMP, cyclic AMP, Ca2+ and 
reactive oxygen species [10]. Together these second messengers activate a complex 
network of signaling events. The present study demonstrates that AMP-mediated 
AMPKD2 activation in a LKB1-dependent manner is necessary for stimulating 
LCFA and glucose uptake into the heart by oligomycin and AICAR. We expect that 
the involvement of LKB1 and AMPKD2 in stimulation of substrate uptake using 
both agents can be extrapolated to contraction based on the ability of both 
oligomycin and AICAR to stimulate CD36 and GLUT4 translocation in a non-
additive manner to contraction [7]. 
However, this does not imply that the LKB1 - AMPKD2 axis is the only signaling 
pathway involved in contraction-induced substrate utilization in the heart. We have 
recently found evidence for the involvement of protein kinase D in contraction-
induced glucose uptake, a process that was shown to be completely independent of 
AMPK signaling [44]. Thus, it appears that contraction-induced GLUT4 
translocation may depend on the simultaneous input of two distinct pathways, i.e, 
the LKB1 - AMPK axis and protein kinase D signaling, similar to what has been 
shown for insulin-induced GLUT4 translocation, i.e., the insulin receptor substrate - 
phosphatidylinositol-3-kinase - protein kinase B axis and the CAP/Cbl pathway 
[45]. Likewise, contraction-induced CD36 translocation might therefore also be co-
dependent on a signaling pathway that is complementary but independent of 
AMPK. Finally, the LKB1 - AMPKĮ2 axis could be an attractive target for therapy 
in cardiac diseases with decreased energy reserves. 
 
Acknowledgements 
The authors gratefully acknowledge Ms Rogayah Carroll and Prof. dr. David 
Severson (University of Calgary, Canada) for their expert help to optimize the 
technique of isolating mouse cardiomyocytes. Prof. dr. Morris Birnbaum 
(University of Pennsylvania, USA) is thanked for providing founder AMPK KD 
mice. Founder LKB1 KO mice were kindly provide by dr. Kei Sakamoto 
(University of Dundee, UK). We gratefully thank Prof. dr. Grahame Hardie 
(University of Dundee, UK) for the AMPKĮ1 and AMPKĮ2 antibodies and the 
SAMS peptide. We also wish to thank Mr. J. Willems for helping with the 
illustrations. 
This study was supported by the Netherlands Organisation for Health Research and 
Development (ZonMw grant nr. 40-00812-98-03075), the European Community 
(Integrated Project LSHM-CT-2004-005272, Exgenesis), the Danish Medical 
Research Council, the Lundbeck Foundation, the Danish Ministry of Food, 
Thesis_Habets_v2.pdf   83 30-9-2008   13:39:36
 84 | Chapter 4 
 
Agriculture and Fisheries, the Fonds National de la Recherche Scientifique et 
Médicale (Belgium) and the Actions de Recherche Concertées (Belgium), the 
Canadian Institutes of Health Research, the Natural Sciences and Engineering 
Research Council of Canada, the Heart and Stroke Foundation of Ontario, the 
Canada Research Chair program. L. Bertrand is Research Associate of the Fonds 
National de la Recherche Scientifique, Belgium. A. Bonen is the Canada Research 
Chair in Metabolism and Health. J.F.C. Glatz is Netherlands Heart Foundation 
Professor of Cardiac Metabolism. 
Thesis_Habets_v2.pdf   84 30-9-2008   13:39:36
  Crucial role for LKB1 to AMPKĮ2 axis in transporter-mediated cardiac substrate uptake | 85 
 
References 
1 Stanley WC, Recchia FA and Lopaschuk GD 2005 Myocardial substrate metabolism in the normal and 
failing heart. Physiol Rev 85: 1093-1129 
2 Belke DD, Larsen TS, Lopaschuk GD and Severson DL 1999 Glucose and fatty acid metabolism in the 
isolated working mouse heart. Am J Physiol 277: R1210-1217 
3 Zorzano A, Sevilla L, Camps M, Becker C, Meyer J, Kammermeier H, Munoz P, Guma A, Testar X, 
Palacin M, Blasi J and Fischer Y 1997 Regulation of glucose transport, and glucose transporters 
expression and trafficking in the heart: studies in cardiac myocytes. Am J Cardiol 80: 65A-76A 
4 Bonen A, Chabowski A, Luiken JJ and Glatz JF 2007 Is membrane transport of FFA mediated by lipid, 
protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: molecular, 
biochemical, and physiological evidence. Physiology (Bethesda) 22: 15-29 
5 Luiken JJ, van Nieuwenhoven FA, America G, van der Vusse GJ and Glatz JF 1997 Uptake and 
metabolism of palmitate by isolated cardiac myocytes from adult rats: involvement of sarcolemmal 
proteins. J Lipid Res 38: 745-758 
6 Habets DD, Coumans WA, Voshol PJ, den Boer MA, Febbraio M, Bonen A, Glatz JF and Luiken JJ 
2007 AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on 
sarcolemmal CD36. Biochem Biophys Res Commun 355: 204-210 
7 Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ and Glatz JF 2003 
Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated 
through AMP-activated protein kinase signaling. Diabetes 52: 1627-1634 
8 Luiken JJ, Willems J, van der Vusse GJ and Glatz JF 2001 Electrostimulation enhances FAT/CD36-
mediated long-chain fatty acid uptake by isolated rat cardiac myocytes. Am J Physiol Endocrinol Metab 
281: E704-712 
9 Rose AJ and Richter EA 2005 Skeletal muscle glucose uptake during exercise: how is it regulated? 
Physiology (Bethesda) 20: 260-270 
10 Luiken JJ, Coort SL, Koonen DP, Bonen A and Glatz JF 2004 Signalling components involved in 
contraction-inducible substrate uptake into cardiac myocytes. Proc Nutr Soc 63: 251-258 
11 Hardie DG, Hawley SA and Scott JW 2006 AMP-activated protein kinase--development of the energy 
sensor concept. J Physiol 574: 7-15 
12 Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, 
Witters LA and Kemp BE 1996 Mammalian AMP-activated protein kinase subfamily. J Biol Chem 271: 
611-614 
13 Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, Goodyear LJ and Tian R 2003 Glucose 
metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit 
of AMP-activated protein kinase. J Biol Chem 278: 28372-28377 
14 Russell RR, 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ 
and Young LH 2004 AMP-activated protein kinase mediates ischemic glucose uptake and prevents 
postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503 
15 Carvajal K, Zarrinpashneh E, Szarszoi O, Joubert F, Athea Y, Mateo P, Gillet B, Vaulont S, Viollet B, 
Bigard X, Bertrand L, Ventura-Clapier R and Hoerter JA 2007 Dual cardiac contractile effects of the 
alpha2-AMPK deletion in low-flow ischemia and reperfusion. Am J Physiol Heart Circ Physiol 292: 
H3136-3147 
16 Mu J, Brozinick JT, Jr., Valladares O, Bucan M and Birnbaum MJ 2001 A role for AMP-activated 
protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7: 
1085-1094 
17 Fujii N, Hirshman MF, Kane EM, Ho RC, Peter LE, Seifert MM and Goodyear LJ 2005 AMP-activated 
protein kinase alpha2 activity is not essential for contraction- and hyperosmolarity-induced glucose 
transport in skeletal muscle. J Biol Chem 280: 39033-39041 
18 Jorgensen SB, Viollet B, Andreelli F, Frosig C, Birk JB, Schjerling P, Vaulont S, Richter EA and 
Wojtaszewski JF 2004 Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform 
abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose 
uptake in skeletal muscle. J Biol Chem 279: 1070-1079 
Thesis_Habets_v2.pdf   85 30-9-2008   13:39:36
 86 | Chapter 4 
 
19 Barnes BR, Marklund S, Steiler TL, Walter M, Hjalm G, Amarger V, Mahlapuu M, Leng Y, Johansson 
C, Galuska D, Lindgren K, Abrink M, Stapleton D, Zierath JR and Andersson L 2004 The 5'-AMP-
activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in 
glycolytic skeletal muscle. J Biol Chem 279: 38441-38447 
20 Jensen TE, Rose AJ, Jorgensen SB, Brandt N, Schjerling P, Wojtaszewski JF and Richter EA 2007 
Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of 
mild tetanic skeletal muscle contraction. Am J Physiol Endocrinol Metab 292: E1308-1317 
21 Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG and Hardie DG 2005 
Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated 
protein kinase. Cell Metab 2: 9-19 
22 Sakamoto K, Goransson O, Hardie DG and Alessi DR 2004 Activity of LKB1 and AMPK-related 
kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am J Physiol Endocrinol 
Metab 287: E310-317 
23 Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR and Hardie DG 2003 
Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream 
kinases in the AMP-activated protein kinase cascade. J Biol 2: 28 
24 Witczak CA, Fujii N, Hirshman MF and Goodyear LJ 2007 Ca2+/calmodulin-dependent protein kinase 
kinase-alpha regulates skeletal muscle glucose uptake independent of AMP-activated protein kinase and 
Akt activation. Diabetes 56: 1403-1409 
25 Sakamoto K, McCarthy A, Smith D, Green KA, Grahame Hardie D, Ashworth A and Alessi DR 2005 
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during 
contraction. Embo J 24: 1810-1820 
26 Thomson DM, Brown JD, Fillmore N, Condon BM, Kim HJ, Barrow JR and Winder WW 2007 LKB1 
and the Regulation of Malonyl-CoA and Fatty Acid Oxidation in Muscle. Am J Physiol Endocrinol 
Metab 
27 Russell RR, 3rd, Bergeron R, Shulman GI and Young LH 1999 Translocation of myocardial GLUT-4 
and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol 277: H643-649 
28 Hayashi T, Hirshman MF, Kurth EJ, Winder WW and Goodyear LJ 1998 Evidence for 5' AMP-
activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47: 
1369-1373 
29 Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D 
and Hue L 2000 Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation 
of glycolysis during ischaemia. Curr Biol 10: 1247-1255 
30 Chabowski A, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ and Bonen A 2005 The 
subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by 
AICAR. FEBS Lett 579: 2428-2432 
31 Bertrand L, Ginion A, Beauloye C, Hebert AD, Guigas B, Hue L and Vanoverschelde JL 2006 AMPK 
activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant 
cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 291: H239-250 
32 Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A and Glatz JF 2004 Dipyridamole alters cardiac 
substrate preference by inducing translocation of FAT/CD36, but not that of GLUT4. Mol Pharmacol 
65: 639-645 
33 Zarrinpashneh E, Carjaval K, Beauloye C, Ginion A, Mateo P, Pouleur AC, Horman S, Vaulont S, 
Hoerter J, Viollet B, Hue L, Vanoverschelde JL and Bertrand L 2006 Role of the alpha2-isoform of 
AMP-activated protein kinase in the metabolic response of the heart to no-flow ischemia. Am J Physiol 
Heart Circ Physiol 291: H2875-2883 
34 Viollet B, Andreelli F, Jorgensen SB, Perrin C, Geloen A, Flamez D, Mu J, Lenzner C, Baud O, 
Bennoun M, Gomas E, Nicolas G, Wojtaszewski JF, Kahn A, Carling D, Schuit FC, Birnbaum MJ, 
Richter EA, Burcelin R and Vaulont S 2003 The AMP-activated protein kinase alpha2 catalytic subunit 
controls whole-body insulin sensitivity. J Clin Invest 111: 91-98 
35 Carroll R, Carley AN, Dyck JR and Severson DL 2005 Metabolic effects of insulin on cardiomyocytes 
from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 288: E900-906 
Thesis_Habets_v2.pdf   86 30-9-2008   13:39:36
  Crucial role for LKB1 to AMPKĮ2 axis in transporter-mediated cardiac substrate uptake | 87 
 
36 Prinzen FW, Van der Vusse GJ, Arts T, Roemen TH, Coumans WA and Reneman RS 1984 
Accumulation of nonesterified fatty acids in ischemic canine myocardium. Am J Physiol 247: H264-272 
37 Glatz JF, Jacobs AE and Veerkamp JH 1984 Fatty acid oxidation in human and rat heart. Comparison of 
cell-free and cellular systems. Biochim Biophys Acta 794: 454-465 
38 van Oort MM, van Doorn JM, Bonen A, Glatz JF, van der Horst DJ, Rodenburg KW and Luiken JJ 2008 
Insulin-induced translocation of CD36 to the plasma membrane is reversible and shows similarity to that 
of GLUT4. Biochim Biophys Acta 1781: 61-71 
39 Sakamoto K, Zarrinpashneh E, Budas GR, Pouleur AC, Dutta A, Prescott AR, Vanoverschelde JL, 
Ashworth A, Jovanovic A, Alessi DR and Bertrand L 2006 Deficiency of LKB1 in heart prevents 
ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab 
290: E780-788 
40 Abdel-aleem S, El-Guindy N, Sallam TI, Hughes GC and Lowe JE 1999 Stimulation of long-chain fatty 
acid uptake by dipyridamole in isolated myocytes. J Cardiovasc Pharmacol 33: 43-48 
41 Luiken JJ, Willems J, Coort SL, Coumans WA, Bonen A, Van Der Vusse GJ and Glatz JF 2002 Effects 
of cAMP modulators on long-chain fatty-acid uptake and utilization by electrically stimulated rat cardiac 
myocytes. Biochem J 367: 881-887 
42 Davies SP, Sim AT and Hardie DG 1990 Location and function of three sites phosphorylated on rat 
acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 187: 183-190 
43 Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG and Lopaschuk GD 1999 Phosphorylation control of 
cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein 
kinase. Eur J Biochem 262: 184-190 
44 Luiken JJ, Vertommen D, Coort SL, Habets DD, El Hasnaoui M, Pelsers MM, Viollet B, Bonen A, Hue 
L, Rider MH and Glatz JF 2008 Identification of protein kinase D as a novel contraction-activated 
kinase linked to GLUT4-mediated glucose uptake, independent of AMPK. Cell Signal 20: 543-556 
45 Hou JC and Pessin JE 2007 Ins (endocytosis) and outs (exocytosis) of GLUT4 trafficking. Curr Opin 
Cell Biol 19: 466-473 
 
 
Thesis_Habets_v2.pdf   87 30-9-2008   13:39:36
 88 | Chapter 4 
 
Thesis_Habets_v2.pdf   88 30-9-2008   13:39:36
  AICAR stimulates LCFA uptake and oxidation in mouse heart independent of CD36 | 89 
 
CHAPTER 5 
AICAR stimulates long-chain fatty 
acid uptake and oxidation in mouse 
heart independent of CD36 
 
 
 
 
Chapter 5 
AICAR stimulates LCFA uptake and oxidation in mouse heart independent of CD36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Daphna D.J. Habets1, Arend Bonen2, Peter J. Voshol3, Jan F.C. Glatz1 and Joost J.F.P. Luiken1 
 
1 Department of Molecular Genetics, Cardiovascular Research Institute Maastricht (CARIM), Maastricht 
  University, the Netherlands 
2 Department of Human Health and Nutritional Sciences, Guelph University, Guelph, Ontario, Canada 
3 Department of Endocrinology and Diabetes, Leiden University Medical Center, Leiden, the Netherlands 
Thesis_Habets_v2.pdf   89 30-9-2008   13:39:36
 90 | Chapter 5 
 
Abstract 
Cardiac long-chain fatty acid (LCFA) uptake is facilitated by a number of 
sarcolemmal fatty acid transporters, namely fatty acid translocase/CD36 (CD36), 
plasma membrane fatty acid-binding protein (FABPpm), and two isoforms of the 
fatty acid-transport protein family (FATP1 and FATP6). 5-aminoimidazole-4-
carboxamide ribonucleoside (AICAR) is an insulin-sensitizing therapeutic agent 
through its ability to activate AMP-activated protein kinase (AMPK). In this study 
cardiomyocytes from CD36 knockout mice were used to compare the effects of 
AICAR on LCFA transporters distribution and LCFA utilization with that of 
oligomycin, another AMPK-activating agent. In CD36 knockout cardiomyocytes 
the effects of oligomycin, but not AICAR, on LCFA uptake and oxidation were 
reduced. In WT cardiomyocytes, oligomycin induced surface appearance of CD36 
but not of other LCFA transporters, whereas AICAR had no effect on any 
transporter distribution in WT or CD36 knockout cardiomyocytes. It is concluded 
by default that in CD36 knockout cardiomyocytes LCFA transporters other than 
CD36 are involved in AICAR stimulated LCFA uptake, but that in murine 
cardiomyocytes these other LCFA transporters do not mediate this event by a 
translocation mechanism. Moreover, species and tissue specific aspects of these 
observations are discussed. 
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Introduction 
Cardiac tissue acquires most of its metabolic energy from major substrates, glucose 
and long-chain fatty acids (LCFA). Compared with glucose, LCFA is the preferred 
substrate consumed by the heart, contributing ~70% of ATP when supplied at 
physiological levels [1, 2]. It is now well-documented that LCFA uptake in many 
tissues, including skeletal muscle and the heart, is facilitated by membrane-
associated LCFA transporters. Several LCFA transporters are expressed in these 
muscles, including fatty acid translocase/CD36 (CD36), plasma membrane fatty 
acid-binding protein (FABPpm), and isoforms of the fatty acid-transport protein 
family (FATP1, FATP4 and FATP6) [3, 4]. Although the mechanism of protein-
mediated LCFA transport across the plasma membrane is incompletely understood, 
there is strong evidence for the involvement of both CD36 and FABPpm in this 
process. Furthermore, LCFA uptake is regulated by the reversible translocation of 
CD36 and FABPpm from intracellular storage pools to the sarcolemma. It has been 
suggested that these LCFA transporters act in concert but the exact mechanism is 
not yet known [5]. A vesicle-mediated process has not been observed for FATP1 [6, 
7] while for FATP6 this remains unknown. 
In heart and skeletal muscle, contraction and insulin are the two main physiological 
stimuli inducing CD36-mediated LCFA uptake and glucose transporter 4 (GLUT4)-
mediated glucose uptake [6, 8, 9]. A key player in the regulation of LCFA 
metabolism [8] is AMP-activated protein kinase (AMPK) similar to that established 
for glucose metabolism [10]. Generally, AMPK activation results in activation of 
catabolic pathways (LCFA and glucose oxidation), and de-activation of anabolic 
pathways (LCFA and glucose storage) [10]. AMPK is activated in response to 
increased AMP levels during cellular contractions but also in response to different 
pharmacological agents, e.g., oligomycin and 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) [8]. Oligomycin is a F1F0-ATPase inhibitor leading to an 
increased AMP/ATP ratio and finally increased AMPK activity [11, 12]. AICAR, a 
cell-permeable analog of adenosine is taken up into cells and metabolized by 
adenosine kinase to form ZMP, the monophosphorylated derivate that mimics the 
effect of AMP on AMPK activity [13-15]. The advantage of AICAR over 
oligomycin is that ATP depletion by oligomycin could have toxic effects, 
depending on the dose and duration of treatment (see chapter 2), while AICAR has 
been used as an insulin sensitizing agent [13, 15-17]. 
Oligomycin and AICAR have been used in many studies to investigate the 
regulatory mechanism of energy metabolism in heart and skeletal muscle. Both 
agents increase LCFA uptake and oxidation in cardiomyocytes. The oligomycin-
induced increase in LCFA uptake is CD36 dependent as has been established by 
using sulfo-N-succinimidyl oleate (SSO), a specific inhibitor of CD36, in studies 
with cardiomyocytes and by using cardiomyocytes from CD36 knockout (CD36 
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KO) mice [8, 18]. AICAR increases the abundance of CD36 and FABPpm at the 
sarcolemma at the cost of its intracellular storage resulting in an increased LCFA 
uptake rate into rat cardiomyocytes [7]. The AICAR-induced increase in LCFA 
uptake was completely blocked by SSO incubations in rat cardiomyocytes [7, 8]. In 
addition, in skeletal muscle of CD36 KO mice the increase in LCFA uptake and 
oxidation by AICAR treatment is almost fully inhibited [6]. This suggests that 
either FABPpm translocation is not involved in stimulation of LCFA uptake by 
AICAR, or the contribution of FABPpm to stimulation of AICAR-induced LCFA 
uptake is CD36 dependent. Since CD36 and FABPpm co-immunoprecipitate [5] it 
could be speculated that these transporters act in concert to mediate LCFA uptake.  
We sought to investigate whether in mouse cardiomyocytes CD36 fulfills a similar 
role in AICAR-stimulated LCFA uptake as has been observed in oligomycin-
stimulated LCFA uptake. For this, cardiomyocytes from CD36 KO mice were used 
to study the role of CD36 in the stimulation of LCFA uptake and oxidation by 
AICAR.  
 
Materials and methods 
Materials  
 [1-14C]palmitic acid was obtained from GE Healthcare (Piscataway, NJ, USA). 
AICAR, BSA (fraction V, essentially fatty acid free), phloretin, DMSO and 
oligomycin were obtained from Sigma (St. Louis, MO). Liberase blendzyme 1 was 
purchased from Roche Diagnostics (Indianapolis, IN). The antibody directed 
against phosphorylated ACC was from Upstate (Dundee, UK) and anti-phospho-
AMPK from Cell Signalling (Danvers, MA). An antibody directed against CD36 
was obtained from Chemicon International Inc. (Temecula, USA) and FATP1 from 
Santa Cruz Biotechnology Inc. (Santa Cruz, USA). Anti-FABPpm was a gift from 
Dr. J. Calles-Escandon, Wake Forest University School of Medicine & Baptist 
Medical Center, Winston-Salem NC. The antibody for FATP6 was kindly provided 
by Dr. A. Stahl, Palo Alto Medical Foundation and Stanford University School of 
Medicine, Palo Alto, California.  
 
Animals 
CD36 KO mice were generated by targeted homologous recombination and crossed 
back eight times to the C57Bl/6 background. WT and CD36 KO mice were bred at 
TNO Quality of Life, Leiden, the Netherlands. The Experimental Animal 
Committee of Maastricht University gave approval for all experiments involving 
animals. 
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Isolation and pre-incubation of mouse cardiomyocytes 
Adult mouse cardiomyocytes (male mice 2-3 months of age) were isolated using a 
Langendorff perfusion system according to the procedure described by Severson et 
al. [19], which has been described previously [18]. After 30 min of recovery, 
suspensions of cardiomyocytes (2.0 ml; 5-10 mg wet mass/ml) were pre-incubated 
in capped 20-ml incubation vials either with 0.35% dimethyl sulfoxide 
(DMSO;Ctrl), 1 μmol/l oligomycin or 2 mmol/l AICAR for 20 min at 37°C under 
continuous shaking. At the applied concentrations of oligomycin and AICAR, 
LCFA uptake rates were found to be maximally stimulated (data not shown).  
 
Phosphorylation of AMPK and ACC in cardiomyocytes 
Pellets of stimulated cell suspensions were dissolved in sample buffer and subjected 
to SDS-polyacrylamide gel electrophoresis, followed by Western blotting to 
determine the phosphorylation of AMPK and ACC by applying antibodies against 
phospho-AMPKĮ (Thr172) and phospho-ACC (Ser79), respectively according to 
the manufacturer’s instructions.  
 
Palmitate uptake in cardiomyocytes 
To study palmitate uptake, 0.5 ml of [1-14C]palmitate/BSA complex  was added to 
pre-incubated cell suspensions at the start of the incubations with a final 
concentration of 100 μmol/l palmitate with a corresponding palmitate/BSA ratio of 
0.3. Cellular uptake of 14C-palmitate (3-min incubation) was determined upon 
washing the cells two times for 2 min at 45 g in an ice-cold stop solution containing 
0.2 mmol/l phloretin. The radioactivity of the cell pellets was measured by 
scintillation counting.  
 
Palmitate oxidation into cardiomyocytes 
To study palmitate oxidation, 0.5 ml of a mixture of  [1-14C]palmitate/BSA 
complex  was added to pre-incubated cell suspensions at the start of the incubations 
with a final concentration of 100 μmol/l palmitate with a corresponding 
palmitate/BSA ratio of 0.3 [20]. The oxidation of palmitate (20-min incubation) into 
CO2 was determined after addition of perchloric acid (final concentration 0.5 M) to 
cell suspensions. Production of 14CO2 was measured after base trapping. 
 
Sarcolemmal CD36, FABPpm, FATP1 and FATP6 content of 
cardiomyocytes 
Directly after isolation, cell suspensions of cardiomyocytes were plated in laminin-
coated (20 μg/ml) 35 mm culture plates. After 1 h the cells were incubated with 
0.35% DMSO (Ctrl), 1 μmol/l oligomycin or 2 mmol/l AICAR for 20 min at 37°C. 
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As previously described [21], cells were biotinylated with the cell-permeable 
reagent sulfo-NHS-LC-biotin in bicarbonate medium at a final concentration of 1 
mg/ml for 45 min at 4°C. Cells were treated with ice-cold glycine in bicarbonate 
medium (100 mM). After a brief wash with ice-cold bicarbonate medium, cells 
were lysed by scraping in 250 μl lysis buffer. The lysates were incubated on ice for 
1 h, and centrifuged for 10 min at 13,000 g at 4°C. A 15 μl supernatant sample was 
used as total lysate sample for Western Blotting, and 150 μl was then incubated 
overnight with streptavidin beads. Samples were briefly centrifuged, and the beads 
were washed twice with lysis buffer. The biotinylated proteins were eluted by 
incubation of the streptavidin beads for 5 min at 95°C in sample buffer. Samples 
were subjected to SDS-polyacrylamide gel electrophoresis, followed by Western 
Blotting for the detection of CD36, FABPpm, FATP1, FATP6 and caveolin-3 by 
applying mouse monoclonal anti-CD36 antibody 1258, a rabbit polyclonal anti-
FABPpm antiserum, a goat polyclonal anti-FATP1 antiserum and rabbit anti-
FATP6 antiserum, respectively, according to the manufacturer’s instructions.  
 
Data presentation and statistics 
All data are presented as means ± S.E.M. for the indicated number of 
cardiomyocyte preparations. Statistical difference between means was analyzed by 
the paired Student’s t test. P values  0.05 were considered significant.  
 
Results 
Effects of oligomycin and AICAR on the contraction signaling 
cascade in cardiomyocytes from WT and CD36 KO mice 
Activation of AMPK was assessed by determining phosphorylation of the specific 
threonine residue (Thr172) at the Į-subunit of this heterotrimeric enzyme, and by 
the phosphorylation of its main substrate acetyl-CoA carboxylase (ACC; Ser79). 
Oligomycin-treatment of cardiomyocytes increased the degree of phosphorylation 
of both AMPK and ACC by 4.1-fold (± 0.6; n=4, P<0.05) and 5.9-fold (± 0.6; n=4, 
P<0.05), respectively, in WT cardiomyocytes as well as in CD36 KO 
cardiomyocytes (to 3.9-fold ± 0.2 and 5.5-fold ± 0.4; n=4, P<0.05, respectively; 
Fig. 5.1). Although, AMPK was modestly phosphorylated by 1.2-fold (± 0.2; n=4, 
P<0.05) in WT and by 1.3-fold (± 0.2; n=4, P<0.05) in CD36 KO cardiomyocytes 
after AICAR treatment, phosphorylation of ACC was elevated by 4.4-fold (± 0.5; 
n=4, P<0.05) and 4.2-fold (± 0.4; n=4, P<0.05) in WT cardiomyocytes and in CD36 
KO cardiomyocytes (Fig. 5.1), respectively. This indicates that AMPK signalling is 
markedly activated during AICAR-treatment. Taken together, in CD36 KO 
cardiomyocytes AMPK signaling is not impaired. 
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Figure 5.1 Effect of oligomycin and AICAR stimulation on the contraction signaling cascade in 
cardiomyocytes from WT and CD36 KO mice 
Cardiomyocytes from WT mice and CD36 KO mice were incubated for 20 min in the absence (Ctrl) or 
presence of 15 ȝmol/l oligomycin (Oli) or 2 mmol/l 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR). Phosphorylation of AMP-activated protein kinase (AMPK)-Thr172 and of acetyl-CoA 
carboxylase (ACC)-Ser79 was determined by Western Blotting. From each sample, 20 μg of myocytes 
wet mass was taken for electrophoresis. Western Blotting with antibodies against caveolin-3 and ȕ-actin 
further confirmed no differences in protein amount per lane (data not shown). A representative Western 
Blot is presented out of 4 experiments with different cardiomyocyte preparations. 
 
 
Effects of oligomycin and AICAR on palmitate uptake into 
cardiomyocytes from WT and CD36 KO mice 
Palmitate uptake in quiescent cardiomyocytes (referred to as basal/control uptake) 
was not significantly different between WT and CD36 KO cardiomyocytes (Fig. 
5.2A). Stimulation of WT cardiomyocytes with oligomycin markedly enhanced 
palmitate uptake by 2.5-fold, but caused a merely modest increase in palmitate 
uptake (1.3-fold) in CD36 KO cardiomyocytes (Fig. 5.2A). In contrast, stimulation 
of palmitate uptake in cardiomyocytes by AICAR was not significantly different in 
WT cardiomyocytes (1.9-fold) compared to CD36 KO cardiomyocytes (2.1-fold; 
Fig. 5.2A). Thus, it appears that AICAR-stimulated LCFA uptake in 
cardiomyocytes was not changed due to knockout of CD36, while oligomycin 
stimulated LCFA uptake was largely reduced.  
 
Effects of oligomycin and AICAR on palmitate oxidation in 
cardiomyocytes from WT and CD36 KO mice 
Under basal conditions, palmitate oxidation in cardiomyocytes was not significantly 
different between WT and CD36 KO cardiomyocytes (Fig. 5.2B). Oligomycin 
significantly stimulated palmitate oxidation in WT cardiomyocytes by 3.6-fold, also 
the 2.5-fold stimulation in CD36 KO cardiomyocytes was found to be significant, 
although, this increase was significantly lower compared to WT cardiomyocytes 
(Fig. 5.2B). However, AICAR-stimulated palmitate oxidation was not changed in 
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WT (1.7-fold increase) compared to CD36 KO cardiomyocytes (1.8-fold increase; 
Fig. 5.2B). Thus, cardiomyocyte CD36 ablation does not alter AICAR-stimulated 
LCFA oxidation while oligomycin stimulated LCFA oxidation was reduced.  
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Figure 5.2 Effect of oligomycin and AICAR stimulation on LCFA uptake and oxidation in 
cardiomyocytes from WT and CD36 KO mice 
Cardiomyocytes from WT mice (Ƒ) and CD36 KO mice (Ŷ) were incubated for 20 min in the absence 
(Ctrl) or presence of 15 μmol/l oligomycin (Oli) or 2 mmol/l 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) where after uptake rates (panel A) and oxidation rates (panel B) of palmitate 
were measured. Values are means ± S.E.M. for 5-7 animals per group. *Significantly different from 
Ctrl (P<0.05); ^significantly different from WT (P<0.05). 
 
 
Sarcolemmal content of fatty acid transporters after oligomycin 
and AICAR stimulation of cardiomyocytes from WT and CD36 KO 
mice 
We explored the possible translocation of all LCFA transporters upon oligomycin 
and AICAR treatment by using cell surface biotinylation assay. First, we confirmed 
the phenotype of the CD36 KO cardiomyocytes: expression of CD36 was not 
detectable in these cardiomyocytes. Then, we confirmed that oligomycin treatment 
of WT cardiomyocytes resulted in an increase in the sarcolemmal content of CD36, 
amounting to 1.9-fold (± 0.3; n=5, P<0.05; Fig. 5.3A). We made the surprising 
observation that AICAR treatment did not increase CD36 present at the sarcolemma 
in WT cardiomyocytes (1.1 ± 0.3; n=5, P>0.05; Fig. 5.3A). The total protein 
expression of FABPpm (Fig. 5.3B) and FATP6 (Fig. 5.3D) was similar in WT and 
CD36 KO cardiomyocytes, while FATP1 (Fig. 5.3C) total protein expression was 
greater in CD36 KO cardiomyocytes (to 1.5-fold ± 0.2; n=5, P<0.05) compared to 
WT mice, in agreement with earlier studies in heart and muscle of CD36 KO mice 
[6, 18, 22]. However, oligomycin and AICAR did not change the sarcolemmal 
content of FATP1 in WT nor in CD36 KO cardiomyocytes (Fig. 5.3C). The 
contents of FABPpm and FATP6 at the sarcolemmal were not changed, in WT and 
CD36 KO cardiomyocytes, under basal conditions or when stimulated with 
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oligomycin or AICAR (Fig. 5.3B and 5.3D). This indicates that both stimuli did not 
alter the subcellular distribution of FABPpm, FATP1 and FATP6 in mouse heart.  
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Figure 5.3 Effect of oligomycin and AICAR stimulation on sarcolemmal and total contents of 
LCFA transporters in cardiomyocytes from WT and CD36 KO mice 
Cardiomyocytes from WT mice (Ƒ) and CD36 KO mice (Ŷ) were incubated for 20 min in the absence 
(Ctrl) or presence of 1 μmol/l oligomycin (Oli) or 2 mmol/l 5-aminoimidazole-4-carboxamide 
ribonucleoside (AIC), whereafter biotin-labeled (cell surface) fatty acid translocase/ CD36 (CD36), 
plasma membrane fatty acid-binding protein (FABPpm), fatty acid-transport protein 1 and 6 (FATP1 
and FATP6), and total cellular CD36, FABPpm, FATP1 and FATP6 were determined by Western 
Blotting followed by densitometry (relative abundance Ctrl set at 1). Representative Western Blots are 
presented out of 5 experiments with different cardiomyocyte preparations. *Significantly different from 
Ctrl (P<0.05) 
 
 
Discussion 
In this study we observed for the first time that short-term, i.e., within minutes, 
stimulated LCFA uptake does not always correlate with increased CD36 and/or 
other LCFA transporter abundance at the sarcolemma. Oligomycin (15 min 
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incubations) elevates sarcolemmal CD36 content concomitant with LCFA uptake 
and oxidation rates. However, in response to AICAR (15 minutes incubations) the 
abundance of CD36 at the sarcolemma was not changed while LCFA uptake and 
oxidation rates were increased. Direct evidence that CD36 is not involved in 
AICAR-stimulated LCFA uptake and oxidation was provided by using CD36 KO 
mice in this study. We attempted to unravel the mechanism as a result of which 
AICAR was able to induce LCFA uptake by determining whether the sarcolemmal 
presence of other LCFA transporters is altered during AICAR stimulation. In the 
present study, FABPpm, FATP1 and FATP6 were expressed at the sarcolemma of 
cardiomyocytes. However, the sarcolemmal expression was not altered after 
AICAR treatment neither in WT nor in CD36 KO cardiomyocytes. These current 
observations are in contrast with earlier studies in rat cardiomyocytes and mouse 
skeletal muscle in which we have demonstrated that AICAR induces the 
translocation of CD36 and FABPpm to the sarcolemma concomitant with elevated 
LCFA metabolism [6, 7]. This leads us to speculate about the possible mechanisms 
explaining redundancy of AICAR-stimulated LCFA uptake and oxidation rates in 
isolated cardiomyocytes from CD36 KO mice.  
It is possible that LCFA uptake is not only regulated by translocation of LCFA 
transporters from intracellular compartments to the sarcolemmal, but also by 
stimulation of the intrinsic activity of these transporters at the sarcolemma. The 
increase in intrinsic activity could be due to post-translational modifications and 
possibly by phosphorylation of LCFA transporters at the sarcolemma. In CD36 KO 
cardiomyocytes the AICAR-mediated transporter activation event then must include 
modifications of either FABPpm, FATP1 and/or FATP6. However, while post-
translational modifications and phosphorylation of CD36 have been described in the 
literature  [23-25] this is presently unknown for the other LCFA transporters.  
Another possibility is that LCFA transporters reposition to specialized regions of 
the sacrolemma to be able to increase the uptake rates of LCFA. It has been shown 
in cell lines that CD36 is not homogenous distributed over the sarcolemma but that 
it is clustered in specific regions of the sarcolemma. Examples of these specialized 
regions at the sarcolemma are caveolae. Caveolae are invaginations of the 
sarcolemma consisting of caveolin, cholesterol, and glycosphingolipids, and are 
enriched with membrane receptors and signaling molecules [26].  It has been 
observed that caveolae are involved in the CD36-mediated LCFA uptake process in 
adipocytes [27, 28]. In addition, it has been shown that the major component 
caveolae in muscle, namely caveolin-3, colocalizes with CD36 in human skeletal 
muscle [29]. This suggests that the translocation of LCFA transporters to the 
sarcolemma is not the only regulatory step in LCFA uptake and that their targeting 
to caveolae could provide another level of regulation for LCFA transport. However, 
it has not been investigated yet whether FABPpm, FATP1 and FATP6 are located 
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in caveolae of cardiomyocytes and whether AICAR can influence their shuttling 
between caveolae and non-caveolae plasma membrane regions.  
Furthermore, this study shows that the regulation of LCFA uptake is not only 
different between species, i.e., rat and mouse, but also between muscles, i.e., heart 
and skeletal muscle. Earlier studies showed that the effect of AICAR on LCFA 
uptake rate was dependent on CD36, because of the sensitivity to inhibition by the 
specific CD36 inhibitor, SSO in rat cardiomyocytes [7, 8]. Furthermore, in rat 
cardiomyocytes AICAR induced the translocation of CD36 from the intracellular 
storage pool to the plasma membrane [7]. In these studies the incubation conditions 
were exactly the same. Thus, AICAR-stimulated LCFA uptake appears differently 
regulated in rat and mouse hearts. Even comparing LCFA uptake in mouse tissues 
showed different results. In skeletal muscle of CD36 KO mice the effect of AICAR 
on LCFA uptake was almost fully prevented [6], while in the present study CD36 
knockout in cardiomyocytes did not inhibit LCFA uptake and oxidation. This 
indicates that information about the regulation of substrate utilization can not 
always be extrapolated from one tissue to another and not from one species to 
another.  
To conclude, not only translocation but also activity and localization of transporters 
on the sarcolemma could be involved in the regulation of LCFA uptake and 
oxidation. The present study illustrates that unraveling the activation, interactions, 
and localization of LCFA transporters on the sarcolemma is of interest in the 
perspective to regulate LCFA metabolism.  
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Abstract 
The role of soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE)- and SNARE-associated proteins have not yet been assessed in regulation 
of cardiac glucose uptake, nor in the regulation of long-chain fatty acid (LCFA) 
uptake in any tissue. Munc18c is a SNARE-associated protein that regulates 
glucose transporter translocation in skeletal muscle and adipose tissue. Using 
cardiomyocytes from Munc18c-/+ mice (with 56% reduction of Munc18c protein 
expression), we investigated whether this syntaxin4-associated protein is involved 
in regulation of cardiac substrate uptake. Basal, insulin- and oligomycin (an AMP-
activated protein kinase-activating agent)-stimulated glucose and LCFA uptake was 
not altered significantly in Munc18c-/+ cardiomyocytes compared to wild-type cells. 
We conclude, therefore, that Munc18c is not rate-limiting for cardiac substrate 
uptake, neither under basal conditions nor when maximal stimulated metabolically.  
 
Thesis_Habets_v2.pdf   104 30-9-2008   13:39:37
  Munc18c is not rate-limiting for glucose and LCFA uptake in the heart | 105 
 
Introduction 
In the heart, long-chain fatty acids (LCFA) and glucose are the predominant 
substrates. Glucose is mainly taken up into cardiomyocytes via glucose transporter 
4 (GLUT4), and LCFA largely via fatty acid translocase/CD36 (CD36) [1]. Both 
transporters recycle between intracellular stores and the sarcolemma, and can be 
induced to translocate to the sarcolemma by several physiological stimuli, such as 
an increase in circulating concentrations of insulin [2], and an increase in contractile 
activity [3]. Hence, both the translocation of GLUT4 and CD36 appear to be 
similarly regulated. This similarity also applies to the signaling components 
activated by each of these stimuli. Insulin recruits both GLUT4 and CD36 via 
activation of the phosphatidylinositol-3-kinase - protein kinase B (PKB)/Akt axis, 
and contraction recruits these transporters via activation of the LKB1 - AMP-
activated protein kinase (AMPK) axis [2, 3].  
The translocation of GLUT4 and CD36 to the sarcolemma in response to 
physiological stimuli occurs by vesicular trafficking [2, 3], but for the heart there is 
little information on the routes involved. However, much more information is 
available for GLUT4 translocation in adipocytes [4], and to a lesser extent in 
skeletal muscle [5], upon insulin stimulation. This work revealed that GLUT4 
translocation is a vesicle-mediated exocytotic process, obeying principles of the 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
hypothesis. Accordingly, in vesicular trafficking events a unique vesicle SNARE 
(vSNARE) specifically recognizes and interacts with a cognate target SNARE 
(tSNARE) localized at the target membrane. This specific vSNARE – tSNARE 
recognition ensures that transport vesicles do not fuse randomly with subcellular 
membrane compartments, but deliver their cargo at the appropriate intracellular 
address. Cardiomyocytes contain multiple types of SNARE proteins [6], which 
include the vSNARE vesicle-associated membrane protein-2 (VAMP2) and the 
tSNAREs soluble NSF-attachment protein-23 (SNAP23) and syntaxin4, which were 
found to be involved in insulin-induced GLUT4 translocation in adipocytes and 
skeletal muscle [7]. 
Besides SNARE proteins, a number of accessory proteins have been shown to be 
important in formation of the SNARE complex [7]. One of these accessory proteins 
is Munc18c, which belongs to a family of Sec1p-like/Munc18 proteins. Munc18c 
forms a complex with syntaxin4 [8], and is known to be involved in several 
trafficking processes including GLUT4 translocation, as has been shown in cell 
lines [9] and in skeletal muscle from heterozygous Munc18c mice [10]. Driven by 
the lack of information about the role of SNAREs and accessory proteins in GLUT4 
translocation in the heart and in CD36 translocation in any tissue, we sought to 
investigate (i) whether in the heart Munc18c fulfills a similar role in insulin-
stimulated GLUT4 translocation, as has been observed in adipose tissue and in 
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skeletal muscle, and (ii) whether this role can be extended to AMPK-stimulated 
GLUT4 translocation, and/or to (iii) insulin- and contraction-induced CD36 
translocation. Because homozygous Munc18c mice are not viable [10, 11], we used 
heterozygous Munc18c mice to study the potential effects of partial ablation of this 
protein in the stimulation of glucose and LCFA uptake into cardiomyocytes by 
insulin and by oligomycin, an AMPK-activating contraction-mimetic agent. 
 
Materials and methods 
Materials  
[1-14C]palmitic acid and 2-deoxy-D-[1-3H]glucose were obtained from GE 
Healthcare (Piscataway, NJ, USA). BSA (fraction V, essentially fatty acid free), 
phloretin, oligomycin, insulin and DMSO were obtained from Sigma (St. Louis, 
MO). Liberase blendzyme 1 was purchased from Roche Diagnostics (Indianapolis, 
IN). The rabbit anti-Munc18c antibody was generated as previously described [9]. 
The antibody directed against phosphorylated ACC was obtained from Upstate 
(Dundee, UK), anti-GAPDH, anti-phospho-PKB and anti-phospho-AMPK from 
Cell Signalling (Danvers, MA). Antibodies directed against CD36 and GLUT4 
were obtained from Chemicon International Inc. (Temecula, USA). 
 
Animals 
Munc18c-/+ mice on the C57Bl/6 background were generated as previously 
described [10]. The Experimental Animal Committee of Maastricht University gave 
approval for all experiments involving animals. 
 
Isolation and pre-incubation of mouse cardiomyocytes 
Adult mouse cardiomyocytes (male mice 2-3 months of age) were isolated using a 
Langendorff perfusion system as described previously [12]. Suspensions of 
cardiomyocytes (2.0 ml; 5-10 mg wet mass/ml; viability 60-80%) were pre-
incubated in capped 20-ml incubation vials either with 0.35% dimethyl sulfoxide 
(DMSO; Ctrl), 1 μmol/l oligomycin or 100 nmol/l insulin for 20 min at 37°C under 
continuous shaking. Previously we have shown that oligomycin, a mitochondrial 
F1F0-ATPase inhibitor, stimulates LCFA uptake in a non-additive manner to 
contractions, indicating that oligomycin activates the same signaling cascade as 
contractions [3]. 
 
Phosphorylation of AMPK, ACC, PKB and total expression of 
Munc18c, GADPH, CD36 and GLUT4 in cardiomyocytes 
Pellets of stimulated cell suspensions were dissolved in sample buffer, as previously 
described [12],  and subjected to SDS-polyacrylamide gel electrophoresis, followed 
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by Western Blotting for the detection of Munc18c [9], GAPDH, of phospho-
AMPKĮ (Thr172), phospho-ACC (Ser79), phospho-PKB (Ser473), and of total 
GLUT4 and CD36 expression levels by applying the antibodies according to the 
manufacturer’s instructions.  
 
Deoxyglucose and palmitate uptake into cardiomyocytes 
To study the rate of deoxyglucose and palmitate uptake, 0.5 ml of a mixture of [1-
3H]deoxyglucose and [1-14C]palmitate/BSA complex  was added to pre-incubated 
cell suspensions at the start of the incubations with a final concentration of 100 
μmol/l deoxyglucose and 100 μmol/l palmitate with a corresponding 
palmitate/bovine serum albumin (BSA) ratio of 0.3. Cellular uptake of 3H-
deoxyglucose (3-min incubation) and 14C-palmitate (3-min incubation) was 
determined upon washing the cells, and measuring the radioactivity of the cell 
pellets [13]. 
 
Data presentation and statistics 
All data are presented as means ± S.E.M. for the indicated number of 
cardiomyocyte preparations. Statistical difference between means was analyzed by 
the paired Student’s t test. P values  0.05 were considered significant.  
 
Results 
Munc18c expression in WT and Munc18c-/+ cardiomyocytes 
Quantification of Western Blots showed Munc18c to be reduced in Munc18c-/+ 
cardiomyocytes by 56% (± 0.6; n=5, P<0.05; Fig. 6.1A), in agreement with the 
previously observed 50% reduction in heart homogenates of these mice [10]. The 
loading control; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression 
was similar in WT and Munc18c-/+ cardiomyocytes (Fig. 6.1A). 
 
Effects of oligomycin and insulin on signal transduction pathways 
in WT and Munc18c-/+ cardiomyocytes 
Activation of AMPK was assessed by determining phosphorylation of the specific 
threonine residue (Thr172) at the Į-subunit of this heterotrimeric enzyme, and by 
the phosphorylation of its main substrate acetyl-CoA carboxylase (ACC; Ser79). 
AMPK-Thr172 and ACC-Ser79 phosphorylation in quiescent cardiomyocytes 
(referred to as Ctrl) was similar in WT and Munc18c-/+ cardiomyocytes. 
Oligomycin-treatment of cardiomyocytes increased the degree of phosphorylation 
of both AMPK by 5.9-fold (± 0.5; n=4, P<0.05) and ACC by 7.5-fold (± 0.5; n=4, 
P<0.05), respectively, in WT cardiomyocytes as well as in Munc18c-/+  
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Fig. 6.1 Munc18c expression in cardiomyocytes from WT and Munc18c-/+ mice and the effects 
of oligomycin and insulin treatment on phosphorylation of AMPK, ACC, PKB, and on total 
expression of CD36 and GLUT4  
WT and Munc18c-/+ cardiomyocytes were used to determine Munc18c and glyceraldehydes-3-
phosphate dehydrogenase (GAPDH; loading control) expression (panel A), and after incubation for 20 
min in the absence (Ctrl) or presence of 1 μmol/l oligomycin (Oli) or 100 nmol/l insulin (Ins) phospho-
AMP-activated protein kinase (AMPK;Thr172), phospho-acetyl-CoA carboxylase (ACC;Ser79), 
phospho-protein kinase B (PKB; Ser473; panel B), and total expression of glucose transporter 4 
(GLUT4) and fatty acid translocase/CD36 (CD36; panel  C) were determined by Western Blotting. A 
representative Western Blot is presented out of 5 experiments with different cardiomyocyte 
preparations. 
 
 
cardiomyocytes (to 5.3-fold ± 0.4 and 7.9-fold ± 0.6; n=4, P<0.05, respectively) 
(Fig. 6.1B). Stimulation of cardiomyocytes with insulin did not alter the 
phosphorylation state of AMPK and ACC, neither in WT cardiomyocytes nor in 
Munc18c-/+ cardiomyocytes (Fig. 6.1B).  
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Activation of the insulin signaling pathway was determined by phosphorylation of 
PKB (Ser473). In quiescent cardiomyocytes, phosphorylation of PKB was similar 
in WT and Munc18c-/+ cardiomyocytes. Treatment of WT cardiomyocytes with 
insulin (4.3-fold ± 0.5; n=5, P<0.05) but not oligomycin, increased the 
phosphorylation of PKB (Fig. 6.1B). This increase after insulin treatment was 
similar in Munc18c-/+ cardiomyocytes (4.1-fold ± 0.4; n=5, P<0.05). Hence, 
activation of signal transduction pathways normally leading to increased myocardial 
substrate uptake are not disrupted in Munc18c-/+ cardiomyocytes. 
 
Expression of GLUT4 and CD36 in WT and Munc18c-/+ 
cardiomyocytes 
Total expression of GLUT4 and CD36 was not significantly different between WT 
and Munc18c-/+ cardiomyocytes (Fig. 6.1C), nor after incubation with oligomycin 
or insulin. This indicates that the cardiac transport capacity for LCFA and glucose 
is not altered due to heterozygous knockout of Munc18c.  
 
Oligomycin- and insulin-stimulated deoxyglucose and palmitate 
uptake into WT and Munc18c-/+ cardiomyocytes 
Deoxyglucose uptake into quiescent cardiomyocytes was similar between WT and 
Munc18c-/+ cardiomyocytes (Fig. 6.2A). Oligomycin treatment increased 
deoxyglucose by 3.4-fold in WT and by 2.9-fold in Munc18c-/+ cardiomyocytes. 
Insulin enhanced the deoxyglucose uptake by 5.8-fold and 6.1-fold into WT and 
Munc18c-/+ cardiomyocytes, respectively. 
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Fig. 6.2 Effects of oligomycin and insulin stimulation on deoxyglucose and palmitate uptake 
into cardiomyocytes from WT and Munc18c-/+ mice  
WT (Ƒ) and Munc18c-/+ cardiomyocytes (Ŷ) were incubated for 20 min in the absence (Ctrl) or presence 
of 1 μmol/l oligomycin (Oli) or 100 nmol/l insulin (Ins) whereafter uptake rates of 3H-deoxyglucose 
(panel A) and 14C-palmitate (panel B) were measured. Data are means ± S.E.M. for 10 experiments 
carried out with different cardiomyocyte preparations. *Significantly different from Ctrl (P<0.05). 
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Palmitate uptake into quiescent cardiomyocytes was not significantly different 
between WT and Munc18c-/+ cardiomyocytes (Fig. 6.2B). Treatment of WT and 
Munc18c-/+ cardiomyocytes with oligomycin increased palmitate uptake by 1.9-fold 
and 1.7-fold, respectively. In addition, there was no significant difference in insulin-
induced palmitate uptake into WT (1.2-fold increase) and Munc18c-/+ 
cardiomyocytes (1.2-fold increase). Taken together, WT and Munc18c-/+ 
cardiomyocytes, in the absence or presence of a stimulus, showed no significant 
differences in deoxyglucose and palmitate uptake rates.  
 
Discussion 
The SNARE-associated protein Munc18c is on the steadily growing list of proteins 
found to be involved in insulin-stimulated GLUT4 translocation, as established in 
adipocytes and skeletal muscle [14]. Whether Munc18c fulfils a similar role in 
insulin-induced GLUT4 translocation in the heart is not known. It is also of interest 
to study whether Munc18c is involved in CD36 translocation, because differences 
in the regulation of the translocation of CD36 relative to GLUT4 would disclose 
targets for modulation of the substrate preference of the heart [1]. Using 
cardiomyocytes from heterozygous Munc18c knockout mice, we made the 
following observations: (i) basal, oligomycin- or insulin-induced glucose uptake 
rates were not altered by partial Munc18c deletion, nor were (ii) basal, oligomycin- 
or insulin-induced LCFA uptake rates. Together, these findings suggest that 
Munc18c is not rate-limiting for basal and stimulus-induced cardiac substrate 
uptake. 
The lack of effect upon insulin signaling (PKB-Ser473 phosphorylation) in 
cardiomyocytes here in heterozygous Munc18c mice is consistent with that lack of 
effect in skeletal muscle, supporting the concept that Munc18c plays a more direct 
role in modulating SNARE protein machinery at the plasma membrane in 
exocytosis events. With respect to the regulation of glucose uptake through GLUT4 
translocation, the heterozygous Munc18c mice display significantly impaired 
skeletal muscle insulin-stimulated GLUT4 translocation [10]. Obviously, the 
unimpaired glucose uptake rate into insulin-treated cardiomyocytes with 56% 
reduced Munc18c content, as obtained in this study, contrasts markedly with the 
effects in skeletal muscle. There are two explanations for this discrepancy: (i) 
Munc18c is obligatorily involved in insulin-stimulated GLUT4 translocation in 
muscle, but not in heart, or (ii) Munc18c is redundantly present in heart, but not in 
skeletal muscle, so that a partial reduction in its content is not rate-limiting for 
glucose flux under maximal conditions. We speculate that the latter option is more 
likely. Notably, in heart and muscle glucose uptake is similarly regulated by 
signaling cascades inducing GLUT4 translocation from endosomal and pre-
endosomal stores to the sarcolemma [15, 16]. Moreover, besides Munc18c, 
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components of the SNARE complex involved in insulin-induced fusion of GLUT4-
containing transport vesicles with the sarcolemma, as found in muscle [17], 
including VAMP2, syntaxin4 and SNAP23, are also present in heart [6]. When 
taken in consideration that this redundancy hypothesis cannot be explained by the 
degree of Munc18c expression in heart versus muscle, being of similar magnitude 
[6, 17], a higher activation state of Munc18c in heart versus muscle may be 
compatible with a functional redundancy in the heart. This might be related to the 
permanent contractile state of the heart resulting in the permanent elevation of 
second messengers which could be involved in Munc18c activation. The recent 
finding that tyrosine phosphorylation of Munc18c facilitates vesicle exocytosis 
[18], might elude to the notion that in the heart tyrosine phosphorylation of 
Munc18c is chronically upregulated. Alternatively, the ratio of Munc18c expression 
to expression of the other components of the SNARE complex could be different in 
heart versus muscle. In this instance, either one of the proteins VAMP2, syntaxin4 
or SNAP23 could display a lower expression level in heart compared to muscle, so 
that these proteins, and thus not Munc18c, are rate-limiting for SNARE complex 
formation in heart. 
Concerning regulation of LCFA uptake via CD36 translocation, no studies have yet 
been undertaken to examine the involvement of SNARE- or SNARE-associated 
proteins in this process. The inability of partial Munc18c deletion to alter LCFA 
uptake into quiescent and stimulated cardiomyocytes leads us to speculate that (i) 
Munc18c is not involved in the regulation of LCFA uptake, or (ii) Munc18c is not 
rate-limiting for LCFA uptake. As above we propose that the latter possibility is 
more likely, since the regulation of glucose uptake and LCFA uptake are very 
similar with respect to localization of intracellular compartments and involvement 
of signaling cascades. Taken together, Munc18c is not rate-limiting for uptake of 
both glucose and LCFA into cardiomyocytes, neither under basal nor under 
maximal metabolic demands. 
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Introduction 
In this chapter the most important findings of this thesis will be discussed in a 
broader perspective and in relation to the newest literature. Next to the studies 
described in this thesis I have also contributed to other investigations. The 
conclusions of these studies will also be discussed in this chapter.  
In the heart there is a very finely tuned balance between long-chain fatty acid 
(LCFA) and glucose utilization, of which LCFA is the predominant substrate for 
ATP production necessary to sustain mechanical performance [2]. In many 
conditions, e.g., fasted state, fed state or during increased workload, the heart is a 
highly flexible metabolic organ in which many regulatory processes are involved to 
maintain energy homeostasis. In general, the aim of this thesis was to further 
unravel the regulation of cellular substrate utilization in the healthy heart. In the 
studies described in this thesis we used isolated cardiomyocytes from various 
genetically manipulated mouse models. Isolated cells from mice with altered 
expression of relevant signaling and trafficking genes involved in stimulus-induced 
translocation of LCFA and glucose transporters provide direct evidence for their 
role in cardiac substrate regulation under healthy conditions. Subsequently, the role 
of these regulatory signaling and trafficking pathways was studied in pathological 
conditions, as in cardiomyocytes from rats on a high-fat diet. Understanding the 
regulation of cardiac substrate utilization under healthy and pathological conditions 
could be promising to identify novel therapies aimed at restoring cardiac substrate 
balance of the diseased heart [84], e.g., diabetic cardiomyopathy, in which the 
substrate balance is disrupted as observed in cardiomyocytes from rats on a high-fat 
diet [85].  
 
Lessons from cardiac metabolism in the healthy heart  
The uptake of both LCFA and glucose is regulated by the sarcolemmal content of 
specific transport proteins, e.g., fatty acid translocase/CD36 (CD36) (see chapter 3) 
and GLUT4, respectively. These transporters are not only present at the 
sarcolemma, but also in intracellular storage compartments [14]. The recruitment of 
these transporters to the sarcolemma is regulated by signal transduction cascades. 
Regulatory key players in stimulated cardiac energy metabolism have been  
unraveled in the last few years [6]. Others have explored the role of AMP-activated 
protein kinase (AMPK), calmodulin-dependent protein kinase kinase (CaMKK), 
AS160, and protein kinase C (PKC) isoforms but only in contraction-stimulated 
GLUT4-mediated glucose uptake in skeletal muscle [86]. During my thesis work, 
the roles of most of these metabolic regulatory proteins have been examined in the 
heart and also in contraction-stimulated CD36-mediated LCFA uptake. 
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Fig. 7.1 Hypothetical scheme of the involvement of contraction signal transduction pathways 
in stimulation of cardiac substrate utilization 
Under basal conditions, the majority of the glucose transporter 4 (GLUT4), fatty acid translocase/CD36 
(CD36), and plasma membrane fatty acid-binding protein (FABPpm) are present in both intracellular 
storage compartments (recycling endosomes) and at the sarcolemma. For fatty acid transporter 1 and 6 
(FATP1 and FATP6) the subcellular distribution is largely unknown. The onset of contraction results in 
elevation of the intracellular AMP/ATP ratio. Elevation of AMP stimulates LKB1-mediated activation 
of the AMP-activated protein kinase (AMPK) subunits Į1 and Į2. Activated AMPKĮ1/Į2 directly 
phosphorylates acetyl-CoA carboxylase (ACC), resulting in increased mitochondrial ȕ-oxidation (ȕ-ox) 
of long-chain fatty acids (LCFA). AMPKĮ2, but not Į1, is also involved in contraction-induced uptake 
of LCFA and glucose. Specifically, AMP-induced LKB1-mediated activation of AMPKĮ2 results in 
vesicle-mediated translocation of CD36 and GLUT4 from the recycling endosomes to the sarcolemma. 
As during contractions, oligomycin (Oli) results in elevation of AMP and subsequent AMPKĮ1/Į2 
activation, and finally stimulates LCFA and glucose uptake by CD36 and GLUT4 translocation from 
contraction-responsive recycling endosomes, respectively, as well as stimulation of ȕ-ox. Independent 
of AMPK, activation of protein kinase D (PKD) by contraction and oligomycin results in GLUT4-
mediated glucose uptake. Treatment of cardiomyocytes with 5-aminoimidazole-4-carboxamide 
ribonucleoside (AICAR) results in activation of AMPKĮ2, whereafter LCFA and glucose uptake are 
stimulated, as well as stimulation of LCFA ȕ-ox.  AICAR stimulates GLUT4-mediated glucose uptake 
although the regulation for the stimulated LCFA uptake is independent of CD36 and is possibly 
regulated via other LCFA transporters, i.e., FABPpm and/or FATP1/6. Treatment of cardiomyocytes 
with dipyridamole (DPY) results in activation of ACC, and finally in increased ȕ-ox. Dipyridamole 
stimulates LCFA uptake by an unknown protein kinase downstream of AMPKĮ2 at the signaling 
branch specifically leading to CD36 translocation from contraction-responsive recycling endosomes. 
On the other hand, arsenite treatment selectively elevates GLUT4-mediated glucose uptake, but not 
LCFA uptake. 
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AMPK and upstream kinases; LBK1 and CaMKK 
The critical role of AMPK as an energy sensor in the heart and other tissues has 
been extensively reviewed [87]. The AMPK signaling cascade has been highly 
conserved through evolution, to turn off ATP-consuming processes whilst 
activating ATP-generating pathways. Although activation of AMPK by the binding 
of AMP to its regulatory Ȗ subunit represents the classical mode of regulation, it is 
becoming clear that also several potential upstream kinases of AMPK are involved. 
The first identified upstream kinase was the tumor suppressor LKB1. AMP binding 
to AMPK promotes phosphorylation by LKB1 [65] as LKB1 activity is not 
increased during contraction [71]. Furthermore, evidence is provided that CaMKK-
Į and -ȕ, especially the latter, also activates AMPK [88]. Thus, calcium signaling 
may also have a role in activating AMPK in muscle during contractions. A last 
potential upstream kinase is transforming growth factor-ȕ-activated kinase-1 
(Tak1), which activates the SNF1 complex (the yeast orthologue of AMPK) when 
expressed in S. cerevisiae, and also activates AMPK in cell free assays [89]. The 
physiologically relevance of this kinase remains unclear at present.  
Previously, the importance of AMPK activity and upstream kinases in the 
maintenance of energy levels in skeletal muscle was explored in different AMPK 
transgenic and knockout mouse models. In skeletal muscle of these mice 5-
aminoimidazole-4-carboxamide ribonucleoside (AICAR)-induced increase in 
glucose uptake was completely blocked, however, stimulated glucose uptake by 
contraction was not affected [90, 91] or partly reduced [92] in these mice. Whether 
CaMKK regulates contraction-stimulated glucose uptake in muscle via AMPK 
activation mains controversial [69, 93]. In LKB1 null mice, contraction and 
AICAR-stimulated glucose uptake by muscle were reduced [72], as was LCFA 
oxidation [94]. Hence, these conflicting results cast doubt on the role of AMPK and 
upstream kinases in contraction-induced glucose uptake in skeletal muscle. In 
chapter 4 it has been shown that AMPK is a regulatory kinase for cardiac substrate 
uptake. Chapter 4 describes a study with different genetically manipulated mouse 
models to investigate the regulatory role of AMPK in cardiac energy metabolism 
stimulated by contraction-mimetic agents (see chapter 2). In the heart of AMPK 
kinase-dead, AMPKĮ2 knockout, and LKB1 knockout mice, in which AMPKĮ1 
activity was still present or compensated, both the contraction-induced increase in 
LCFA and glucose uptake were completely blocked. This indicates that AMPK has 
a more important role in the regulation of substrate uptake in the heart than in 
skeletal muscle. Since cardiac LCFA oxidation was only partly reduced it appears 
that the regulation of LCFA uptake and oxidation are not entirely similar. The 
results from this study suggest that AMPKĮ1 and AMPKĮ2 activity is involved in 
the upregulation of LCFA oxidation while a change in LCFA uptake is only 
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regulated by AMPKĮ2 activity (Fig. 7.1). Whether CaMKKs are responsible for the 
residual, LKB1-independent activity of AMPKĮ1 is not completely resolved.  
 
Downstream targets of AMPK; AS160 and PKC  
AS160   
An interesting novel target of AMPK is the rab GTPase-activating protein AS160, 
which is involved in contraction-stimulated glucose uptake in skeletal muscle [95]. 
Phosphorylated AS160 inhibits its ability to activate GTPase and therefore results in 
GTP loading of its cognate Rab protein. GTP-loaded Rab may subsequently allow 
GLUT4 storage vesicles to dock and fuse with the plasma membrane [96]. Recently 
it has been shown that insulin-stimulated glucose uptake requires the 
phosphorylation of AS160 in cardiomyocytes [97] as has previously been shown in 
skeletal muscle [98]. Moreover, insulin-induced AS160 phosphorylation is additive 
to contraction-induced AS160 phosphorylation. These observations indicate that 
insulin signaling and contraction pathways meet at the level of AS160. The role of 
AS160 in contraction-induced CD36 translocation has not been investigated yet.  
 
PKC 
Another kinase that is activated by both insulin and contraction is PKC-ȗ. It is 
firmly established that, at least in skeletal muscle, phosphatidylinositol-3-kinase-
mediated PKC-ȗ activation is necessary for insulin-induced GLUT4 translocation 
[99-101]. Subsequently, we have shown that PKC-ȗ is also important in insulin-
induced glucose uptake (Fig. 7.2A) and LCFA uptake in the heart (Fig. 7.2B). 
Moreover, in the heart PKC-ȗ is already fully active under basal conditions and not 
further stimulated by insulin (Fig. 7.2C), indicating that its role in insulin-
stimulated uptake of both LCFA and glucose is permissive rather than regulatory 
(Luiken et al. submitted). With respect to the role of PKC-ȗ in contraction-induced 
AMPK-mediated substrate uptake the stimulatory effect of the AMPK activating 
agent AICAR on GLUT4 translocation and glucose uptake were blocked by pre-
treatment of muscle cells with myristoylated PKC-ȗ pseudosubstrate [99]. The role 
of PKC-ȗ in insulin-induced substrate uptake converges with that in contraction-
induced substrate uptake, namely treadmill exercise activates PKC-ȗ in skeletal 
muscle, and insulin even increases this effect [99]. It remains to be established 
whether PKC is involved in contraction-induced CD36 translocation in muscle 
tissues.  
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Fig. 7.2 Influence of a PKC-ȗ inhibitors on insulin-induced deoxyglucose and palmitate uptake, 
and PKC-ȗ activity in rat cardiomyocytes   
Isolated rat cardiomyocytes were pre-incubated for 60 min at 37°C without additions (Ctrl) or with 50 
μmol/l myristoylated PKC-ȗ pseudosubstrate (ȗPS). Thereafter, cardiomyocytes were treated without or 
with 100 nmol/l insulin (Ins) for 15 min at 37°C. Finally, initial uptake rates of 3H-deoxyglucose (panel 
A) and 14C-palmitate (panel B) were measured. For the assessment of PKC-ȗ activity, pre-incubated 
cardiomyocytes, as described above, were lysed and used for immunoprecipitations, whereafter PKC-ȗ 
activity was measured by incorporation of [Ȗ-32P]-ATP into a PKC-target peptide (panel C). Data are 
means ± S.E.M. for 4-5 experiments carried out with different cardiomyocyte preparations.  
*Significantly different from Ctrl (P<0.05). Submitted by Luiken et al.  
 
 
AMPK independent signaling; PKD 
Independent of AMPK, we recently showed that another pathway is involved in 
cardiac substrate metabolism, i.e., contraction-activated protein kinase D (PKD) 
[70]. A pharmacological blockade of PKD is associated with inhibition of 
contraction-stimulated GLUT4 translocation and glucose uptake (Fig. 7.3A), 
suggesting that PKD could also be involved in stimulation of cardiac substrate 
uptake upon an increase in contractile activity. This finding is only based on a 
pharmacological approach by using rather non-specific PKC/PKD inhibitors. We 
will investigate PKD knockout mice from Fielitz et al. [102] to verify these 
pharmacological findings, namely that the use of isolated cardiomyocytes from 
these mice could provide direct evidence for the regulatory role of PKD in cardiac 
substrate uptake. Because contraction activates both AMPK and PKD 
simultaneously, we have investigated isolated cardiomyocytes from AMPKĮ2 
knockout mice whether or not these enzymes operate within the same signal 
cascade (Fig. 7.3B) [70]. Since both AMPK ablation and blockade of PKD inhibits 
contraction-induced glucose uptake, this indicates that contraction-induced GLUT4 
translocation would require the input of two parallel pathways, i.e., AMPK 
signaling and PKD signaling, either of which is necessary to move GLUT4 to the 
sarcolemma in the contracting heart. This dual signaling input is not a novel 
concept in the regulation of cellular glucose uptake, because also insulin-induced 
GLUT4 translocation has been established to depend on simultaneous and parallel 
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activation of phosphatidylinositol-3-kinase, and of subsequent protein kinase B/Akt 
signaling axis, and a pathway beginning with the phosphorylation of the adaptor 
protein Cbl by the insulin receptor and resulting in activation of a small GTP-
binding protein TC10 (as described in chapter 1; insulin signaling pathway) [103]. 
It is currently unknown, whether PKD is also involved in contraction-induced CD36 
translocation and subsequent LCFA uptake. Furthermore, upstream and 
downstream components in PKD signaling involved in contraction-induced 
transporter translocation have not yet been identified. One possibility to explain 
contraction-induced PKD activation could be via reactive oxygen species (ROS). 
ROS is a by-product of oxidative phosphorylation, and ROS levels increase upon 
increased contractile activity. Moreover, radical-induced ROS production has been 
shown to increase glucose uptake in muscle [77-79]. A likely downstream kinase of 
PKD in the regulation of cardiac energy metabolism is phosphatidylinositol-4-
kinase since it is a physiological substrate of PKD and it is present in GLUT4-
containing vesicles [104, 105] in which it regulates vesicle transport [106].  
 
- CC St - CC St - CC St
0.0
2.5
5.0
7.5 *
A
Ctrl   Oligomycin     Contraction
*
D
eo
xy
gl
uc
os
e 
up
ta
ke
(n
m
ol
/g
 w
w
 p
er
 m
in
)
 
 
Fig. 7.3 Effect of PKC/PKD inhibitors on oligomycin/contraction-stimulated deoxyglucose 
uptake, and the effect of oligomycin on PKD activity in cardiomyocytes  
Isolated rat cardiomyocytes were pre-incubated for 15 min at 37°C without additions (-) or with protein 
kinase C/D (PKC/PKD) inhibitors, i.e., 2 μmol/l calphostin-C (CC) or 1 μmol/l staurosporine (St). 
Thereafter, cardiomyocytes were incubated in the absence (Ctrl) or presence of 1 μmol/l oligomycin 
stimulation or electrical stimulation at 200V/4Hz (Contraction) for 15 min at 37°C. Finally, initial rates 
of 3H-deoxyglucose were measured (panel A). Isolated cardiomyocytes from WT (Ƒ) and AMP-
activated protein kinaseĮ2 (AMPKĮ2) KO mice (Ŷ) were treated for 20 min at 37°C without (Ctrl) or 
with 1 μmol/l oligomycin (Oli). Upon PKD immunoprecipitations of lysed cardiomyocytes, PKD 
activity was measured by incorporation of [Ȗ-32P]-ATP into syntide-2 (panel B). PKD activity in non-
stimulated cardiomyocytes from AMPKĮ2 KO mice was not significantly different from that in non-
stimulated cardiomyocytes in WT mice. Data are means ± S.E.M. (panel A) or expressed relative to 
Ctrl ± S.E.M. (panel B) for 4-5 experiments carried out with different cardiomyocyte preparations. 
*Significantly different from Ctrl (P<0.05). Taken from [70]. 
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Merging of signaling pathways 
Taken together, the proteins involved in the insulin-induced transporter 
translocation machinery and in the contraction-induced transporter translocation 
machinery can be divided into two classes: (i) proteins that are specific to either 
machinery so as to ensure that insulin-responsive compartments are activated to 
mobilize transporter-containing vesicles in response to insulin (e.g., protein kinase 
B/Akt) and contraction-responsive compartments in response to contraction (e.g., 
AMPK and/or PKD), and (ii) proteins that are common to both machineries, likely 
because of their general involvement in vesicle budding and translocation. In this 
respect, inhibition of AS160 appears necessary for activation of GLUT4 vesicles to 
translocate to the plasma membrane, and the function of PKC-ȗ appears to be 
remodeling of the actin cytoskeleton, which is the transport route for the GLUT4-
containing vesicles. Both, the activation of GLUT4 vesicles and their transport 
along the actin cytoskeleton are general preconditions to increase sarcolemmal 
GLUT4 and glucose uptake in response to insulin or increased workload. Therefore, 
both signaling pathways might converge at the level of GLUT4 translocation and 
interact with the same regulatory elements. Future studies should investigate 
whether this trafficking machinery is also involved in CD36 translocation.  
 
AMPK in diabetic cardiomyopathy 
Because the AMPK system is a major regulator of energy balance at both cellular 
and whole body level, its role in metabolic disorders needs to be considered. The 
role of AMPK in the etiology of these diseases is currently unclear. Interestingly, it 
has recently been reported that the activation of AMPK during exercise is reduced 
in obese and type 2 diabetic humans [107]. In contrast, the role of AMPK activation 
in the treatment of metabolic disorders is well established. Drugs that activate 
AMPK (metformin and thiazolidinediones) are now commonly used for the 
treatment of type 2 diabetes [108, 109]. These drugs improve the glucose disposal 
rate which is the main defect in type 2 diabetes. Also LCFA metabolism is altered 
in type 2 diabetes and there is a tight association between excessive LCFA uptake 
and the development of cardiomyopathy [110]. A possible mechanism is that 
triacylglycerol (TAG) accumulation as occurs in the diabetic heart interferes with 
the insulin signaling pathway, finally leading to the inhibition of GLUT4 
translocation. This suggests that inhibition of TAG storage could restore the insulin-
induced GLUT4-mediated glucose uptake. Therefore, the stimulatory effect on 
LCFA utilization by AMPK activation could be effective in the treatment of 
cardiomyopathy. 
Recent studies support that AMPK activation can restore glucose uptake in insulin 
resistance [54, 111, 112]. A possible explanation is that lipid storage is decreased 
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by elevating AMPK-mediated LCFA oxidation. This then shuttles LCFA away 
from the TAG pool towards LCFA oxidation and prevents the formation of toxic 
LCFA metabolites which are in dynamic equilibrium with this TAG pool. This 
approach, however, has some disadvantage because LCFA present a less efficient 
substrate for ATP production as they require more oxygen for their oxidation 
compared to glucose. Moreover, AMPK not only enhances LCFA oxidation but 
also appears to act on LCFA uptake. Because in the diabetic heart LCFA uptake 
rates exceed  LCFA oxidation rates [2, 113], AMPK activation may exert less 
therapeutic benefits. Moreover, because in diabetes and obesity the circulating 
serum lipid levels are increased, this could further worsen lipid accumulation. 
Remarkably, in chapter 4 distinctive roles of the AMPKĮ1 and AMPKĮ2 subunits 
in LCFA uptake and oxidation have been described. AMPKĮ2 has been suggested 
to be involved in LCFA uptake and oxidation while AMPKĮ1 seems only involved 
in LCFA oxidation (Fig. 7.1). Therefore, identifying targets that lead to activation 
of AMPKĮ1 but not of AMPKĮ2 could be of therapeutical interest. Different 
physiological, pathophysiological and pharmacological activators of AMPK are 
known although till now no specific target for one of the two AMPK isoforms has 
been identified. Recently a new compound, A-769662 has been shown to activate 
both AMPKĮ1 and Į2 [114, 115]. Furthermore, A-769662 was found to elicit an 
increase on whole-body fatty acid oxidation, and simultaneously a decrease in the 
plasma TAG concentration [116], suggesting that this compound, and possibly also 
other AMPK activators, may be useful for the treatment of diabetes.  However, the 
therapeutic value of A-769662 to restore cardiac LCFA utilization in metabolic 
diseases is expected to be limited since it activates both Į-subunits of AMPK.  
 
CD36 in diabetic cardiomyopathy  
In case of diabetes the heart suffers from impaired glucose uptake and relies almost 
completely on LCFA [113, 117, 118]. CD36 is the main LCFA transporter 
responsible for LCFA influx, and in different animal models, the involvement of 
CD36 in cardiomyopathy has been described. Therefore, different strategies are 
discussed to normalize increased CD36-mediated LCFA uptake.  
Sarcolemmal abundance of CD36 has been found to be involved in the changes of 
cardiac metabolism in the diabetic heart, as observed in obese Zucker rats [119]. A 
different rat model for obesity and insulin resistance that is more comparable with 
the human life-style is high-fat diet-fed rats. In a study with rats fed a high-fat diet 
we have shown that elevated LCFA uptake was CD36 dependent because: (i) the 
content of CD36 at the sarcolemma was increased already under basal conditions 
(Fig. 7.4A), and (ii) in the presence of sulfo-N-succinimidyl oleate (SSO), a specific 
inhibitor of CD36 (see chapter 3), LCFA uptake was reduced to a similar rate as 
observed in cardiomyocytes from rats fed a low-fat diet (Fig. 7.4E) [85]. 
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Furthermore, these rats developed cardiac contractile dysfunction associated with 
increased abundance of CD36 at the sarcolemma. Thus, the permanent presence of 
CD36 at the sarcolemma resulted in enhanced rates of LCFA uptake and 
myocardial TAG accumulation, and this contributes to the development of diabetic 
cardiomyopathy. This suggests that CD36 is involved in the development of 
cardiomyopathy and that novel therapeutic strategies aimed at reducing CD36-
mediated LCFA uptake show promise for the prevention or treatment of cardiac 
dysfunction related to metabolic diseases such as obesity and diabetes. 
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Fig. 7.4 Subcellular localization of fatty acid translocase/CD36, and palmitate uptake in 
cardiomyocytes from LFD-fed rats and HFD-fed rats  
Immunohistochemical staining for fatty acid translocase/CD36 localization of left ventricle tissue 
sections from rats fed a low-fat diet (LFD; panel A an C) or high-fat diet (HFD; panel B and D) for 8 
weeks. Rats received an intraperitoneal injection of saline (panel A and B) or insulin (panel C and D) 
30 min before sacrifice. Photographs are representative of two independent experiments performed on 
three rats per experimental group. Arrows indicate intercalated discs. Scale bar indicates 25 μm. 
Isolated cardiomyocytes from LFD-fed (Ƒ) and HFD-fed (Ŷ) rats were pre-incubated for 30 min at 
room temperature without (Ctrl) or with 0.4 mmol/l sulfo-N-succinimidyl oleate (SSO), thereafter 14C-
palmitate uptake rates were measured (panel E).  Data are means ± S.E.M. for 8 experiments carried out 
with different cardiomyocyte preparations. *Significantly different from Ctrl (P<0.05). Taken from 
[85]. 
 
 
In hearts from diabetic mice, the elevated LCFA influx is also accompanied by a 
relocation of CD36 to the sarcolemma [120]. Also in skeletal muscle biopsies from 
obese and type-2 diabetic subjects CD36 was found to be relocated to the 
sarcolemma [121]. All these studies show that the increase in the CD36 functional 
pool is not due to increased total expression, but rather to a permanent relocation of 
CD36 to the sarcolemma. This then suggests that not only CD36 but also the 
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machinery regulating its translocation most likely is a common critical factor in the 
etiology of diabetic cardiomyopathy, and therefore not only CD36 but also its 
trafficking machinery are important targets in restoring substrate balance. Future 
investigations aimed at disclosing the mechanism underlying the permanent 
relocation of CD36 to the sarcolemma could reveal novel therapeutic targets in this 
trafficking machinery. 
Proof-of-principle studies have started in which CD36 ablation reverses myocardial 
lipid accumulation and thereby improves cardiac function. In hearts from CD36 
knockout mice [122] and in hearts from aged CD36-deficient mice [123] changes in 
LCFA metabolism, i.e., decrease in TAG storage, have been shown to restore 
cardiac performance. Therefore, a possible mechanism to rescue cardiac 
dysfunction observed in cardiomyopathy is inhibition of CD36. CD36-mediated 
cellular LCFA influx can be specifically inhibited with sulfo-N-succinimidyl esters 
of LCFA, e.g., SSO, which covalently binds to CD36 (see chapter 3). Although for 
in vivo administration SSO is not yet appropriate. The most important reason for 
this is that it does not only inhibit CD36 in the heart but also in other cell types, 
where CD36 performs a function unrelated to LCFA uptake (e.g., uptake of 
oxidized low-density lipoproteins in macrophages and trombospondin binding in 
platelets) [124]. Therefore, a cardiospecific strategy to inhibit CD36 could be a 
more effective approach. Studies in cells from various mammalian tissues yielded 
differential expression of proteins involved in trafficking, i.e., Rab and soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE), among the 
cell types studied, indicating tissue-specificity of the subcellular trafficking 
machinery [125, 126]. Accordingly, a therapy aimed at the CD36-associated 
trafficking proteins in cardiomyocytes is expected to be cardiospecific and could be 
a more valuable therapeutic approach to inhibit CD36. We recently started to 
investigate the role of proteins involved in the trafficking machinery in the 
regulation of cardiac LCFA uptake (see chapter 6), and in the near future other 
SNARE proteins [like vesicle-associated membrane proteins (VAMPs)] are 
interesting to investigate in regard to CD36 internalization and externalization.  
 
Future perspectives 
The majority of cardiac LCFA uptake is CD36-dependent. However, the potential 
importance of other cardiac LCFA transporters has not been excluded (see chapter 
5). CD36 could function in series or in parallel with the other proteins implicated in 
the LCFA transport process, especially since CD36 colocalizes with plasma 
membrane fatty acid-binding protein (FABPpm) [127], fatty acid-transport protein 
(FATP)1 [128] and FATP6 [129] at the sarcolemma. Future gain-of function and 
loss-of function studies aimed at each of the other cellular transport proteins alone 
and in combination with CD36 deficiency or overexpression will be helpful to 
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further define the physiological roles and relevant interactions among the LCFA 
transporters. CD36 not only colocalizes with other LCFA transporters but also with 
caveolin-3, the major component of caveolae in muscle [130]. Caveolae are 
invaginations of the sarcolemma consisting of caveolin, cholesterol, and 
glycosphingolipids, and are enriched membrane receptors and signaling molecules 
[131].  It has been observed that caveolae are involved in the CD36-mediated 
LCFA uptake process in adipocytes [132, 133]. These findings have not yet been 
extended to muscle tissue. Together, these findings suggest that the translocation of 
LCFA transporters to the sarcolemma is not the only regulatory step in LCFA 
uptake and that possibly also their interaction with other LCFA transporters and 
their targeting to caveolae could provide additional levels of regulation for LCFA 
transport. The molecular mechanism involved in the lateral movement of CD36 in 
and out of caveolae is not completely known. It appears that a dual palmitoylation 
of proteins is a targeting signal to caveolae [134]. CD36 contains at least four 
palmitoylation sites, two near the C-terminus and two close to the N-terminus 
[135]. It is interesting for future studies to investigate whether palmitoylation sites 
are involved in the movement of CD36 in and out of caveolae and whether this 
subsequently influences LCFA uptake. 
Another interesting finding in regard to the homeostasis of cardiac energy 
metabolism is that LCFA and glucose uptake can be selectively increased. These 
changes in substrate uptake are paralleled by concomitant changes in sarcolemmal 
abundance of substrate transporters. While insulin and contraction lead to the 
simultaneous recruitment of CD36 and GLUT4, treatment of cardiomyocytes with 
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Fig. 7.5 Effect of arsenite on deoxyglucose and palmitate uptake into cardiomyocytes 
Isolated rat cardiomyocytes were pre-incubated for 20 min at 37°C without additions (Ctrl) or with 200 
nmol/l wortmannin (W), which inhibits phosphatidylinositol-3-kinase of the insulin signaling cascade. 
Thereafter, cardiomyocytes were treated for 20 min at 37°C without or with 100 μmol/l arsenite (Ars). 
Finally, initial uptake rates of 3H-deoxyglucose (panel A) and 14C-palmitate (panel B) were measured.  
Data are means ± S.E.M. for 4-6 experiments carried out with different cardiomyocyte preparations.  
*Significantly different from Ctrl (P<0.05). Taken from [136].  
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dipyridamole (see chapter 3) and arsenite (see Fig. 7.5) [136] specifically recruit 
one of these transporters leading to selectively increased LCFA and glucose uptake, 
respectively. The stimulatory action of dipyridamole activation is due to a yet 
unidentified protein kinase but it has been established to be situated in the 
contraction signaling cascade downstream of AMPK beyond the signaling branch 
between separate CD36 and GLUT4 translocation, specifically leading to CD36 
translocation. The molecular mechanism behind the selective action on GLUT4 
translocation by arsenite appears unrelated to its insulin signaling action (Fig. 
7.5A), and might occur via a specific protein target of arsenite within insulin-
responsive GLUT4-containing stores. In general, the possibility to translocate 
selectively either one transporter suggests that CD36 and GLUT4 are recruited by 
distinct signaling and/or trafficking mechanisms. These targets could be of interest 
in metabolic diseases in which a shift in substrate balance in the use of either 
glucose or LCFA elicits cardiac malfunctioning. Further unraveling downstream 
targets either involved in CD36 or GLUT4 trafficking are of interest for novel 
therapies in metabolic diseases.  
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